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ABSTRACT 
 
Acute exacerbations are the major cause of morbidity and mortality in COPD and 
respiratory virus infection is believed to be a leading aetiology.  However 
mechanisms by which viruses induce acute exacerbations are poorly understood. 
 
This study reports the experimental inoculation with rhinovirus (RV) of COPD and 
non-obstructed smoking and non-smoking control subjects, of whom 9 COPD, 10 
smoking and 11 non-smoking controls were later judged to have been successfully 
infected.   
 
The hypothesis tested was that RV infection led to the induction of oxidative and 
nitrative stress which resulted in degradation of histone deacetylase (HDAC) 
enzymes in COPD subjects but not controls.  Subsequent histone hyperacetylation 
would then result in prolonged inflammatory gene transcription and therefore 
generate clinical features of an acute exacerbation. 
 
Following experimental RV inoculation the COPD subjects experienced excess lower 
respiratory tract symptoms and elevated virus load compared to the control groups.  
There was an associated acute inflammatory response and a greater burden of redox 
stress measured using the Griess and Potential of Antioxidant assays.  HDAC2 
activity was found to be reduced only in the COPD subjects following experimental 
RV infection. 
  
These findings would suggest that RV induced oxidative and nitrative stress results in 
reduced HDAC2 activity in COPD subjects leading to increased inflammation and 
symptoms consistent with the clinical phenotype of a COPD exacerbation. 
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Chapter 1: Background and statement of hypotheses 
 
1.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is a disease with a global burden 
and the only common cause of death increasing in frequency, predicted to be the 
fourth leading cause of death worldwide by 2030.  In 2005 3 million deaths (5% of 
total) worldwide were attributed to COPD.  Cigarette smoke is a major aetiological 
factor; however in the developing world organic smoke and pollution contribute 
heavily to disease aetiology.  The clinical phenotype is characterised by progressive 
airflow limitation with incomplete reversibility and pathological findings demonstrates 
airway inflammation predominantly with excess neutrophils, macrophages and CD8+ 
T cells. 
 
Acute exacerbations of COPD (AECOPD) are the major unmet health need and are 
responsible for most morbidity, mortality and health care costs associated with 
COPD.  Of the £1bn annual expenditure on COPD in the UK, 70% is consumed 
treating exacerbations.  These are now the most common cause of UK hospital 
admissions, where overall 1 in 8 inpatient visits are attributed to COPD.  There are 
great variations in rates across the UK, and these correlate with areas of most 
socioeconomic need.  Respiratory infections are the leading cause of AECOPD; and 
viruses, particularly rhinoviruses, are detected in two thirds of these.  An 
experimental model of rhinovirus 16 (RV16) induced COPD exacerbations has been 
established and is used in this study with the addition of a non-smoking control group 
in addition to the smoking controls.   
 
The understanding of cellular mechanisms involved in AECOPD is poor, in part due 
to the difficulty in studying the condition.  Here the experimental challenge model is 
used to study the role of oxidative and nitrative stress and the involvement of histone 
deacetylase (HDAC) enzymes in exacerbations.  I have performed experimental 
RV16 infection by inoculating COPD subjects and control groups of both smokers 
and non-smokers without airflow obstruction.  Samples were collected from the upper 
and lower respiratory tract using nasal lavage (NL), exhaled breath condensate 
(EBC), induced sputum (IS) and bronchoscopy. 
 
Exacerbations of COPD due to virus infection last longer and are more severe that 
those without, they also lead to increased airway and systemic inflammation[1].  
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These differences cannot be attributed solely to the structural alterations in the lungs 
of patients with COPD because healthy smokers also experience exaggerated 
symptomatic responses after virus infection, with excess susceptibility and health 
care utilisation compared to non-smokers[2-4]. 
 
Chronic Obstructive Pulmonary Disease 
1.2 Epidemiology 
The World Health Organisation (WHO) estimates that globally there are 80 million 
sufferers of moderate to severe COPD.  It is the only common cause of death 
increasing in frequency and predicted to be the fourth leading cause of death 
worldwide by 2030[5], with the number of deaths due to COPD increasing by 30% in 
the next 10 years.  Despite a higher prevalence in men during the past five decades, 
COPD rates are now almost equal between genders - mainly due to increasing 
female smoking rates in high income countries and exposure to indoor smoke and air 
pollution in low income countries[6].  Disability from COPD is difficult to quantify and 
studies may be subject to bias but Murray and Lopez predict a global increase with 
COPD becoming the fifth leading cause of disability adjusted life years lost in 
2020[7].   
 
COPD is a disease of increasing age with relatively few cases diagnosed before the 
age of 40, however many cases in the population remain unidentified with sufferers 
not seeking medical attention despite persistent respiratory symptoms.  The British 
Lung Foundation (BLF) report „Invisible Lives‟[8] estimates that there are 2.8 million 
sufferers in the UK who have yet to be diagnosed with COPD (described as the 
missing millions) and a study using survey data described COPD as „predominantly 
undiagnosed‟ in adults in England[9].  Significant variations in prevalence exist both 
within and between countries which reflects a host of geographical and social factors 
and other complexities such as differences in smoking habits, medical diagnosis and 
resources between countries[10, 11].  Although an incurable disease treatment can 
slow progression and screening high risk populations is likely to be justified. 
 
Although the Global initiative for Obstructive Lung Disease (GOLD) guidelines are 
widely accepted criteria for diagnosing COPD[12] these can lead to inaccuracies.  
The spirometric definition of obstruction is an FEV1/FVC < 0.7 however use of this 
fixed ratio may lead to an over diagnosis of obstruction in elderly subjects[13] and an 
underestimate in younger subjects[14, 15].  These findings occur due to normal aging 
of the lung, predominantly the loss of elastic recoil resulting in a lower FEV1.  They 
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serve to emphasise the importance of the medical history and examination in making 
an accurate diagnosis of COPD. 
 
1.3 Aetiology 
Development of COPD 
COPD typically develops insidiously over decades and results from a combination of 
genetic and environmental factors.  The exposure of the lungs to noxious 
substances; chiefly smoke, dust and chemicals are the principle environmental 
cause.  In high income countries tobacco smoke is the most frequently identified 
environmental risk factor, leading to 85-90% cases of COPD diagnosed.  Many 
factors influence the effects of tobacco smoke including the age of smoking onset, 
the total exposure (pack year history) and the current smoking status.  Second hand 
smoke is also a risk factor for disease development.  In the UK a link to occupational 
and socioeconomic factors and the risk of disease development have been 
identified[16] but the mechanisms have not been fully elucidated.  In developing 
countries indoor smoke exposure from cooking and heating with organic fuels; chiefly 
coal, straw, animal dung and crop residues are a major contributor to COPD[17, 18]. 
 
A recent review of COPD prevalence in non-smokers identified rates between 25-
45%[19], which is considerably higher than previous studies.  Risk factors and 
aetiological agents proposed include perinatal events and childhood illness, diet, 
fixed airway obstruction resulting from chronic asthma, human immunodeficiency 
virus (HIV) and recurrent pulmonary infections including tuberculosis (TB).  Further 
research in this area is warranted as the presence of tobacco smoke exposure has 
become central to the diagnosis of COPD and a criteria for entry to most research 
studies; which may be leading to a selection bias against non-tobacco induced 
COPD. 
 
1.4 Genetic influences 
Alpha-1 antitrypsin (1-AT) deficiency was first described in a group of patients with 
severe early onset emphysema in the 1960s[20] and it has now become the most 
widely recognised genetic abnormality leading to development of COPD.  However 
the most common homozygous deficiency (PiZZ) for this anti-proteinase enzyme still 
only accounts for 1-2% of the total cases of COPD, emphasising the importance of 
environmental factors in disease aetiology.  Given this fact it is perhaps surprising 
only a minority of smokers develop COPD.  The fraction remains debated with 
original studies identifying 15%[21] but more recent longitudinal data suggests 
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between 20-50% of smokers will develop airway obstruction given sufficient follow 
up[22, 23]. 
 
Following the identification of 1-AT deficiency, twin studies demonstrated a familial 
link with the development of airway obstruction[24], however unfortunately 
subsequent larger genetic linkage studies have proved disappointing[25], failing to 
identity robust genetic risks for COPD.  This is likely to reflect the multiple genetic 
influences responsible for the susceptibility to COPD – itself a complex and 
heterogeneous disease. 
 
1.5 Diagnosis 
The diagnosis of COPD depends on an appropriate medical history and examination 
followed by confirmation of an obstructed ratio FEV1/FVC < 0.7 on spirometry, which 
is poorly reversible after bronchodilation.  Dyspnoea, chronic cough and excessive 
sputum production with or without risk factors should prompt consideration of the 
diagnosis and severity of the disease is graded mild, moderate and severe according 
to the FEV1[12].  Although spirometry forms the mainstay of diagnosis data from the 
USA suggests that this investigation is omitted in a large number of patients.  
However another study demonstrated that smoking rates act as a useful surrogate 
marker for spirometry in high risk populations and maybe used to in parts of the world 
where access to spirometry is limited[26-28]. 
 
1.6 Pathophysiology 
COPD is an umbrella term for emphysema and chronic bronchitis, but the underlying 
disease mechanisms are diverse and complex leading to phenotypic heterogeneity.  
Pathologically loss of elastic recoil and lung tissue destruction (emphysema) 
combined with airway inflammation and mucus hypersecretion (chronic bronchitis) 
lead to ventilation perfusion (V/Q) mismatch and clinical symptoms. 
 
1.7 Chronic bronchitis 
Chronic bronchitis is defined clinically as the persistence of cough with sputum 
production for 3 months in at least two consecutive years; pathologically it consists of 
excessive mucus production and cellular inflammation of the bronchial walls.  Both 
the larger (bronchial) and smaller (bronchiolar) airways can be affected to varying 
degrees in individuals, however an interesting autopsy study of young smokers who 
died outside hospital identified small airway disease before the development of 
clinically detectable lung disease[29].  An assessment of airways disease severity 
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using 3D computed tomography (CT) in COPD demonstrated that the FEV1 
correlated more strongly with reduced luminal area in the smaller airways than the 
larger airways; suggesting that distal disease contributes most to airway obstruction 
in COPD[30].  The chronic inflammation leads to a repair and remodelling process 
that thickens airway walls and leads to the irreversible bronchoconstriction which is 
pathognomonic of COPD[31]. 
 
1.8 Mucus hypersecretion 
Under physiological conditions a thin layer of mucus lines the airways, acting as a 
primary defence to microbial infection, neutralising endogenous toxins (for example 
immune meditated cytokines) and facilitating removal of particulate matter through 
the mucociliary escalator.  In disease excessive respiratory tract mucus production 
leads to airway obstruction, inflammation and increased susceptibility to infection. 
 
In COPD both the quality and quantity of mucin production is altered; hypersecretion 
occurs through a combination of large airway mucous gland hyperplasia[32] and 
goblet cell metaplasia in the small airways[33].  Additionally levels of neutrophil 
elastase (NE) are elevated in chronic bronchitis and this proteolytic enzyme induces 
mucin production through direct inflammation and intracellular signalling via the 
protein kinase C (PKC) pathway[34].  Expression of the mucin genes MUC5AC and 
MUC5B are increased in COPD and the ratio between these is altered when 
compared to normal subjects with an excess of the negatively changed form of 
MUC5B[35] which may contribute to increased mucus viscosity. 
 
1.9 Airway inflammation 
Airway inflammation in chronic bronchitis is characterised by an increase in a wide 
range of cells types; including neutrophils, eosinophils and macrophages.  The role of 
these cell types is discussed later.  Cytotoxic T cells (CD8+) are found to be elevated 
in sputum[36], airway epithelium[33], submucosa[37] and the smooth muscle 
layer[38] of chronic bronchitis patients.  Additionally studies of bronchial biopsies 
have identified an increased ratio of CD8+ to T helper cells (CD4+) cells in patients 
with chronic bronchitis[39]. 
 
Small airway remodelling is driven by a progressive increase in connective tissue and 
fibrous thickening of the airways[40] which has been shown to be proportional to the 
severity of airway obstruction.  An inflammatory infiltrate formed from a broad range 
of cell types including neutrophils, macrophages and T and B lymphocytes are 
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thought to be responsible.  A rodent model of airway inflammation utilising transgenic 
overexpression of the Th2 cytokine IL-10 demonstrated that several mechanisms 
were responsible[41] including enhanced fibrosis, mucus production and increased 
IL-13 release, but other studies have associated airways disease with IL-10 
deficiency[42] care is therefore needed in interpreting this data.  A bronchial biopsy 
study in small airway remodelling found over expression of vascular endothelial 
growth factor (VEGF), leading to enhanced vascularity and hypercellularity and 
providing evidence of another mechanism for disease development[43]. 
 
1.10 Emphysema 
Emphysema is defined at an abnormal enlargement of airspaces distal to the 
terminal bronchiole accompanied by destruction of their walls with an absence of 
fibrosis.  The exact mechanisms for this destruction remain unclear, it is known that 
emphysema occurs as a normal process of the aging lung[44], but the precise 
pathways by which environmental toxins induce lung destruction are unclear.  Loss of 
physiological lung elastic recoil, small airway inflammation and destruction of lung 
vasculature are all considered important. 
 
1.11 Proteolysis 
The balance between proteases and antiproteases is essential for maintaining lung 
health and an excess of proteases was an early mechanism postulated for the 
development of emphysema.  This hypothesis was supported by studies in hamsters 
where emphysematous changes were induced by neutrophil elastin and radiolabeled 
elastin was shown to be readily dissolved[45].  The premature development of 
emphysema in 1-AT deficiency also provides further evidence for the role of 
unchecked proteolysis in the development of emphysema where the increased 
cellularity with an excess of neutrophils and macrophages are associated with 
heightened neutrophil elastase and MMP release. 
 
1.12 Loss of elastic recoil 
As emphysema develops the elastin fibres in lung parenchyma are damaged, this 
results in a loss of the lungs physiological elastic recoil – a phenomenon of normal 
lung tissue to deflate after it has been inflated.  Loss of elastic recoil occurs with 
ageing; in fact the process is predictable enough for age to be estimated from the 
pressure volume characteristics of a post-mortem lung[46].  This is a pertinent finding 
as one current hypothesis is to regard COPD as a disease of abnormal or premature 
lung ageing[47, 48], and an interesting study of facial skin wrinkles found this was a 
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risk factor for developing COPD and correlated with a reduced FEV1[49].  The air 
liquid interface at the alveolar surface also has an influence on elastic recoil, where 
the normal tendency of alveolar sacs to collapse encourages lung deflation.  
Emphysema leads to a loss of alveolar surface area and in this way also reduces 
elastic recoil[50, 51].  So through these two separate mechanisms emphysematous 
processes reduce elastic recoil and contribute to airway obstruction. 
 
1.13 Dynamic airway collapse 
The peripheral bronchioles differ from larger airways, particularly as they lack internal 
rigidity and without cartilage in the walls rely on alveolar wall tethering to maintain 
patency.  As alveolar units are destroyed by emphysematous processes, this support 
is lost and airways collapse more readily and at an earlier point in the cycle of 
expiration.  This phenomenon of dynamic airway collapse is part of the process 
leading to fixed airways obstruction and air trapping characteristic of COPD. 
 
1.14 COPD exacerbations 
Exacerbations of COPD are responsible for the majority of morbidity and mortality in 
the disease and represent a major unmet health need.  In the UK direct healthcare 
expenditure on COPD is £1bn but 70% of this is consumed by the management of 
exacerbations with unplanned acute care and hospital admission being the biggest 
draw on resources[52].  AECOPD are the most common cause of unplanned UK 
hospital admission, accounting for 1 in 8 episodes[53].  Exacerbations are associated 
with functional and physiological decline and are strong predictors of poor health 
status.  They are feared by patients and carers and provide management challenges 
for healthcare providers.  Additionally inequalities and variations exist in the provision 
of care for acutely ill COPD patients[54]; predicting prognosis is difficult and there is 
evidence of excess prognostic pessimism amongst doctors managing AECOPD[55].  
There is evidence that exacerbations are associated with an accelerated loss of lung 
function, leading to a vicious cycle of increasing frequency of exacerbations and 
further pulmonary decline[56, 57].  In a longitudinal study assessing emphysema 
severity by CT, subjects who experienced exacerbations had increased emphysema 
progression compared to those who did not experience exacerbations[58].  Patients 
who experience frequent exacerbations have also been found to have reductions in 
health related quality of life scores when compared to in-frequent exacerbators, 
despite similar acute falls in lung function[59]. 
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1.15 Diagnosis of exacerbations 
Although usually readily diagnosed in clinical practice; exacerbations have been 
difficult to define in research practice and medical literature.  Anthonisen et al 
established a definition of exacerbations in the mid 1980s based on the triad of 
increased dyspnoea, sputum volume and sputum purulence[60], this has been used 
extensively in research practice albeit with modifications.  The GOLD and American 
Thoracic Society/European Respiratory Society (ATS/ERS) consensus statement is 
now widely accepted as the standard definition; where an exacerbation is “an event 
in the natural course of the disease characterised by a change in the patient’s 
baseline dyspnoea, cough and/or sputum that is beyond normal day-to-day 
variations, is acute on onset, and may warrant a change in regular medication in a 
patient with underlying COPD”[12, 61].  The strength of this version is the emphasis 
that is placed upon a change in individual symptoms combined with the possible 
need for healthcare utilisation.  The importance of a standardised definition is 
illustrated by a recent review article, where 51 studies of exacerbations were 
examined and 14 different definitions identified[62].  The effect of this redundancy 
between studies has been shown to change the relative risk for exacerbation rate 
and hazard ratio for time to first exacerbation from non-significant to significant and 
also has an impact on the effect size of interventions; stressing the urgent need for 
the use of a consistent definition in research studies[63]. 
 
1.16 Epidemiology of exacerbations 
The frequency of exacerbations identified by studies range from 0.99 to 3.83 per 
person/year[64, 65], but the average frequency reported is 2 per person/year.  This 
range reflects the heterogeneity of both the disease phenotype and study 
methodology.  Studies in the East London Cohort have provided valuable insights 
into the epidemiology of exacerbations, and using diary cards have identified the 
highest exacerbation rates -2.92-3.36 per person/year.  These have the advantage of 
capturing milder, self managed and unreported exacerbations[59, 66, 67].  These 
studies have also postulated that there is a sub-group of patients who suffer more 
frequent exacerbations; importantly this group suffered from worse respiratory 
symptoms, lower quality of life scores and more rapid decline in lung function[56] 
suggesting that identification of this group might allow targeting of healthcare 
resources and provide new insights into disease mechanisms. 
 
Estimations of hospitalisation rates and mortality are complicated by many 
confounding factors; including disease severity, comorbidities and socioeconomic 
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conditions.  But the literature suggests that Individuals can expect between 0.15 and 
0.25 hospital admissions per year with an average length of stay 8.7 days[68].  
Mortality rates between 2.5% and 24% have been reported in hospital inpatients[69, 
70], but this increases to 43% in those requiring mechanical ventilation[71]. 
 
1.17 Aetiology of exacerbations 
Respiratory tract infection by both bacteria and viruses are the leading cause of 
exacerbations, identified in up to 70%[72], however a wide range of non-infectious 
aetiologies have been identified including air pollution[73] by ozone and particulate 
matter[74], climatic factors including air temperature[66, 75] and cardiovascular 
events - particularly pulmonary embolism[76, 77].  In approximately 1/3rd of severe 
exacerbations a cause is not identified[78].  The role of infection in acute 
exacerbations is discussed in more detail later in this chapter. 
 
Disease mechanisms in COPD exacerbations 
1.18 Oxidative stress 
Reactive oxygen species (ROS) are unstable pro-oxidant compounds with an 
unpaired electron, which have been implicated in a wide range of tissue injuries and 
inflammation[79].  Common examples include the oxygen metabolites superoxide 
(O2
-), hydroxyl (OH-) and peroxide (O-O2-) where the unpaired valence shell electron 
can lead to extensive cellular damage.  The process of oxidation involves a 
substance losing an electron, whereas compounds gaining an electron have 
undergone reduction.  There is a significant burden of ROS in the lungs, the majority 
released from mitochondria as a by-product of normal metabolism, but also released 
by other cellular processes and immune responses such as phagocytosis.  The 
measurement of oxidative stress in the lungs is problematic, mainly due to the 
instability and short life span of ROS and delays in collecting and processing 
respiratory samples.  Strategies to measure oxidative stress have therefore included 
direct measurement of oxidative burden (e.g. NO or H2O2 in EBC), the physiological 
response to oxidative stress (e.g. antioxidants or enzymes in sputum/blood) and the 
effect of oxidative stress on proteins, lipids and DNA (e.g. lipid peroxidation products 
in EBC)[80-83]. 
 
1.19 Sources of oxidative stress 
Cigarette smoking is a potent source of oxidants and measurements have found that 
a typical puff contains 4x1014 free radicals[84].  There is a complex mixture of 
chemical substances in cigarette smoke, and free radicals have been identified in 
32 
 
both the gas and tar phases.  Within the gas phase highly reactive peroxyl and NO 
have been found at concentrations of 500-1000ppm[85].  Radicals in the tar 
component are more stable, but these subsequently form the epithelial lining fluid 
which produces ROS, particularly H2O2, for a longer period of time[86].  Endogenous 
production of ROS is increased in COPD.  Inflammation leads to increased numbers 
and more active macrophages which produce an excess of O2
- and H2O2[87].  In 
addition the airspaces of smokers contain higher levels of free iron which is able to 
generate OH through the Fenton and Haber-Weiss reaction[88].  Macrophages from 
COPD subjects have higher intracellular iron levels than smokers[89] and release 
more free iron in vitro than those from non-smokers[90].  ROS are also released from 
epithelial cells; type II alveolar cells have been shown to release similar amounts of 
O2
- and H2O2 to macrophages[91] and in vitro were able to inactivate 1-AT[92].  
Neutrophilia is frequently identified in COPD and these cells contribute significantly to 
oxidative stress, particularly during the respiratory burst when endogenously 
produced radicals are released in response to the presence of pathogens[93, 94]. 
 
1.20 Induction of oxidative stress 
It has been proposed that COPD develops in a subset of smokers, in whom 
antioxidant mechanisms are overwhelmed and a high level of oxidative stress 
results[95].  There is considerable indirect evidence to suggest that oxidative stress 
is increased in the lungs in stable COPD and that during exacerbations this is 
increased still further, but the mechanisms behind this are poorly characterised.  As 
described above, inflammatory cells appear to play an important part.  With 
increasing cell number the oxidative burden worsens, mediated particularly through 
the respiratory (oxidative) burst which is produced by activated immune cells.  
Macrophages and neutrophils produce the highly active free radical O2
- from oxygen 
under the influence of NADPH oxidase enzymes.  In health this process benefits the 
immune system by killing pathogens.  Indeed a deficiency of NADPH oxidase 
enzymes leads to chronic granulomatous disease and tissue destruction resulting 
from pathogen persistence.  However in disease this illustrates a potential 
mechanism of increased ROS and particularly during an infective exacerbation of 
COPD when the immune system may be over stimulated.  Neutrophilia is frequently 
found in COPD and in the face of infectious agents, neutrophils produce 
hypochlorous acid (HOCl) under the influence of myeloperoxidase enzymes, which 
also has potent oxidant effects.  Once inflammation is established, oxidative stress 
itself can further propagate the inflammatory milieu by enhancing proinflammatory 
gene expression.  This positive feedback occurs through the activation of oxidant 
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sensing transcription factors such as nuclear factor kappa light chain enhancer of 
activated B cells (NFB) and activator protein-1 (AP-1)[96, 97]. 
 
Hydrogen peroxide (H2O2) is a derivative of free radicals and endogenously produced 
in neutrophil peroxisomes by dismutation (a reaction in which two distinct products 
are formed) of O2
- and glycolate oxidase.  Exogenous sources mainly include 
cigarette smoke and air pollution[98].  Endogenous H2O2 production is upregulated 
when neutrophils are exposed to cigarette smoke; studies in rabbit lung have 
demonstrated neutrophil activation and increased adhesion in the pulmonary 
circulation[99].  In EBC H2O2 is a direct measurement of oxidants and is increased in 
smokers[100] and COPD both when stable and during exacerbations[101].   
 
Adenosine receptors actions are complex and can have both a pro- and anti-
inflammatory effect; however in the lower airway in COPD they appear to have an 
association with airflow obstruction[102, 103].  On alveolar macrophages from COPD 
subjects adenosine receptors are down regulated and this has been shown to be 
mediated by oxidative stress, in a process ameliorated by the addition of the reducing 
agent N-acetyl cysteine (NAC)[104]. 
 
1.21 Nitrosative stress 
Reactive nitrogen species (RNS) are also highly active in the lungs; derivatives of 
nitric oxide (NO) include nitrite (NO2
-) and peroxynitrite (ONOO-).  NO is produced 
from arginine under the influence of nitric oxide synthase (NOS) which is present in 
both a constitutive and inducible form, the latter found in respiratory epithelium and 
macrophages in the lung.  NO is also present in cigarette smoke at high 
concentrations (up to 100mg/L) where it acts as an oxidant[85]. 
 
Elevated levels of exhaled NO have been reported in stable COPD in some 
studies[105, 106], but others have not demonstrated either increased NO or 
iNOS[107].  The reasons for this contradiction are not clear, but may reflect the 
heterogeneity of inflammation in AECOPD or the combination of current and ex-
smokers in the studied groups.  Although Rutgers et al did not find increased NO 
concentration in the COPD subjects, the levels did correlate with sputum 
eosinophilia.  Two studies of exhaled NO in exacerbations have found elevated 
levels at the time of hospital admission, which fell with recovery and correlated with 
improvements in FEV1, demonstrating the potential role of oxidants in the aetiology of 
acute exacerbations[108, 109]. 
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1.22 Tissue consequences of oxidative and nitrosative stress 
Isoprostanes, which are prostaglandin like compounds, are produced by free radical 
catalyzed lipid peroxidation of essential fatty acids (chiefly arachidonic acid).  They 
act indirectly as bronchoconstrictors and pro-inflammatory mediators and are 
produced independently of the cyclooxygenase enzyme.  They can be used as 
markers of oxidative stress and to gauge the degree of damage to target 
proteins[110].  8-isoprostane levels in EBC are increased in stable COPD[111] and 
still further at the time of exacerbation[112].  Plasma lipid peroxidation products are 
also increased[95], at least partly due to activation of NFB.  The levels of which are 
both elevated and associated with increased nuclear localisation in airway epithelial 
cells[113] of smokers and COPD subjects. 
 
H2O2 causes direct protein damage and an important example is the loss of 1-AT 
anti elastase activity.  This occurs through oxidation of methionine residues at 
position 351 and 358 which render the active site of the enzyme ineffective[114]. 
 
1.23 Oxidative stress in COPD 
As discussed above oxidative stress markers are increased in COPD, in addition 
several studies have identified an association between airflow limitation and markers 
of oxidative stress linked to cellular inflammation in COPD[94, 115].  However there 
is a lack of longitudinal data with no studies focusing on this specifically and little 
direct evidence of causation of COPD by ROS.  Several pathogenic mechanisms 
have been proposed however and these include worsening of the 
protease/antiprotease balance, epithelial cell damage, increased neutrophil 
sequestration mucus hypertrophy and increased apoptosis.   
 
1.24 Antioxidant control 
Counterbalancing the reactive oxygen and nitrogen species in the lung is the 
antioxidant system.  This can be considered in terms of the enzymatic (super oxide 
dismutase [SOD], thiorodoxin and glutathione peroxide & S-transferase) or non-
enzymatic (glutathione [GSH], ascorbate, urate, -tocopherol and bilirubin) 
antioxidants.  Oxidative stress occurs when the antioxidant system is unable to 
neutralise the burden of ROS/RNS.   
 
An antioxidant is a substance able to delay the process of oxidation and several are 
released by the airway basal cells, suggesting they have an important role in the 
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neutralisation of ROS.  These include secretion of SOD and expression of a 
transmembrane transporter responsible for the efflux of glutathione[116].  Damage to 
the respiratory epithelium not only induces oxidative stress, but also causes damage 
to the antioxidant defences. 
 
Using antioxidant responses to assess oxidative load in COPD has been an effective 
strategy, particularly by measuring GSH which is an important antioxidant in the 
lungs.  GSH levels are considerably higher in BAL from smokers and those with 
stable COPD when compared to non-smokers; reflecting the physiological response 
to increased oxidative stress.  During acute exacerbations the levels of GSH were 
shown to fall in proportion to the severity of the exacerbation, presumably reflecting 
the increasing oxidative stress and subsequent overwhelming the anti oxidant 
system[96].  GSH in its reduced form is more prevalent in the lungs of chronic 
smokers[117] but ageing adversely affects the GSH response to cigarette smoke 
exposure[118], suggesting an age related decline in oxidant defences. 
 
1.25 Epigenetics 
Defined by Waddington in 1942, the term epigenetics combines the words epigenesis 
and genetics and encompasses the concept of heritable changes in gene expression 
that can occur without a change in DNA sequence.  The field has become an area of 
intense study in recent years with recognition of its importance in both the normal 
and diseased state.  Responses to environment, behaviour and pathology can be 
governed by epigenetic changes[119]. 
 
1.26 Histone activity 
Histones are proteins which form the core of chromatin.  They allow compaction of 
long lengths of DNA and play an important part in gene regulation.  In 1964 the 
association between diffuse-extended DNA and active RNA was made, and 
conversely it was also shown that repressed DNA and condensed chromatin was not 
associated with mRNA activity[120].  Subsequently an association was made 
between an increase in histone acetylation and enhanced RNA polymerase II activity.  
Histones are divided into 6 major classes, and form an octamer around which the 
DNA is wound.  It is now clear that histone modifications, particularly in the histone 
tail, can alter DNA exposure and hence gene transcription.  Common examples of 
histone modifications are phosphorylation of serine residue 10 and acetylation of 
lysine residue 14 on histone H3 – this is regarded as a sign of active transcription.  
Studies in yeast have demonstrated that histones are acetylated in their resting state 
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and small changes in the number acetylated can result in biophysical changes, so 
only a minimal alteration in the number of lysines acetylated can rapidly change a 
gene from the active to inactive state and vice versa[121]. 
 
1.27 Histone acetylation 
Acetylation of histone tails is catalysed by histone acetyltransferase (HAT) and 
conversely histone deacetylase (HDAC) deacetylates.  Four classes of HDAC have 
been described; the majority of isoenzymes fall into class I and II with Silent 
Information Regulators (sirtuins) forming class III[122].  The discovery of HDAC 11 
with unique characteristics necessitated creation of the fourth class[123].  HDACs are 
phosphoproteins and their control and activation is complex, but it appears that the 
activity is modified according to their phosphorylation status[124].  A study using lung 
tissue and alveolar macrophages identified an association between reduced HDAC 
activity and increasing clinical severity of COPD[125].  HDAC plays a pivotal role in 
repressing pro-inflammatory cytokines and reduced HDAC activity was associated 
with worse airway inflammation in severe COPD.  mRNA expression of HDAC 
isoenzymes 2, 5 and 8 and HDAC2 protein levels showed graduated reductions with 
more severe COPD.  Chromatin immuneprecipitation (ChIP) was used to measure 
histone 4 acetylation at the IL-8 promoter region where acetylation was associated 
with increased IL-8 mRNA and COPD severity.  In GOLD stage IV COPD HDAC2 
levels were reduced by 95% compared to normal controls.  The mechanism of HDAC 
reduction is not known, but it is likely that oxidative and nitrative stresses are 
responsible.  The increased oxidative stress in COPD and enhanced activity of 
reactive oxygen species and stress kinases result in HDAC degradation[126-128].   
 
1.28 Modulation of HDAC activity 
It is thought that the limited effectiveness of corticosteroids in COPD may be due to a 
deficiency of HDAC[129].  Steroids act, at least partly, by recruiting HDAC to repress 
inflammatory gene transcription.  These compounds are therefore less effective in 
COPD when compared to disease states with normal or near normal HDAC levels; 
for example steroid responsive asthma. 
 
It has been postulated that low dose theophylline may help to restore HDAC activity 
and act to potentiate the effect of steroids.  In a study of macrophages from stable 
asthmatic subjects HDAC activity was increased following treatment with 4 weeks of 
theophylline[130], although the mechanisms behind this effect are not fully 
understood.  Furthermore in a study of AECOPD using low dose theophylline it 
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appeared to enhance the anti-inflammatory effect of steroids and demonstrated 
improved HDAC2 activity in sputum samples[131].  The study was a single blind 
randomised design, lacked a placebo control and had relatively small subject 
numbers, however the findings appear to support the hypothesis that theophylline 
can restore HDAC2 activity in vivo and that HDAC2 deficiency is a mechanism for 
increased inflammation during exacerbations. 
 
A recent study demonstrated that knockdown of a class III HDAC (sirtuin-SIRT1) 
using either oxidative stress, a sirtuin inhibitor or silencing RNA led to elevated matrix 
metalloproteinase-9 (MMP-9) levels.  The finding that SIRT1 is a negative regulator 
of MMP-9 demonstrates a possible molecular mechanism for increased protease 
activity in COPD[132].   
 
There has been interest in modulating HDAC activity with the use of specific 
inhibitors (HDACi), particularly using trichostatin A (TSA).  The majority of clinical 
research has been in oncology as a potential chemotherapeutic agent, but some 
studies have investigated the role of HDACi in inflammation, and although reduced 
HDAC levels have usually been associated with worsening inflammation, the effects 
on HDAC inhibition in some studies have contradicted this[133].  This demonstrates 
that the links between HDAC activity and inflammation are not fully understood.  
Overall the effect of TSA at the protein level was to reduce IL-6 and TNF- 
concentrations; the anti-inflammatory effect was found to be additive to that of 
dexamethasone[133]. 
 
An ex vivo study of cultured epithelial cells from COPD and control subjects with RV 
(rhinovirus 39) demonstrated an increase in inflammatory cytokines in COPD 
subjects compared to controls (IL-6 & IL-8).  However there was no difference in 
HDAC2 or HDAC4 expression between the two groups, nonetheless there was a 
tendency to reduced expression of the transcription repressor SIRT1 in COPD 
subjects[134]. 
 
1.29 HDAC activity and immune function 
Finally a potential link between HDAC activity and immune function has been 
postulated[135].  Should attenuated host defence responses be associated with 
reduced HDAC activity, this finding would have significant implications for AECOPD.  
In this study Rogers et al demonstrated that HDACi reduced expression of host 
defence genes including pattern recognition receptors, kinases and cytokines; 
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additionally an in vivo model of infection demonstrated that HDAC inhibition impaired 
macrophage function and natural host defence, resulting in increased susceptibility of 
mice to bacterial and fungal infections.   
 
1.30 Inflammatory mediators 
It is beyond the scope of this chapter to provide a full review for the many cytokines 
and chemokines which may be involved in the pathogenesis of COPD.  However the 
following is a brief summary of the proteins that I have measured in the sputum and 
BAL supernatant in this study accompanied by a rationale for their study in the 
context of COPD and AECOPD.  Several of the inflammatory mediators have been 
shown to be increased during AECOPD, but data has been obtained from a wide 
range of studies with different inclusion criteria and at different time points during an 
exacerbation. 
 
1.31 Matrix metalloproteinase-9 (MMP-9) 
Produced by macrophages, the matrix metalloproteinase (MMP) family of enzymes 
have a role in COPD pathogenesis by inducing emphysematous tissue damage.  
MMP-12 was the first of this family to be identified and found to be elastolytic when 
released from mouse macrophages activated by latex beads[136].  Subsequently 
MMP-12 knockout mice were shown to be resistant to emphysema after exposure to 
cigarette smoke[137] providing further evidence for their role in lung tissue 
destruction.  MMP-9 is highly active in elastin degradation and both mRNA and 
protein levels were elevated in studies of BAL from COPD subjects compared to 
controls[138] and furthermore the biological activity of MMP-9 was increased in 
COPD subjects[139].  Counter balancing the effects of MMPs are tissue inhibitors of 
matrix metalloproteinases (TIMP) enzymes.  These are also produced by 
macrophages, and the levels of these protective enzymes were found to be 
increased following in vitro stimulation of BAL macrophages from non smokers when 
compared to both healthy smokers and COPD patients[139].  MMP-9 levels are 
increased in AECOPD[140]. 
 
Mucus hypersecretion is pathognomonic of chronic bronchitis and in rodent models 
propenal – a simple aldehyde found in cigarette smoke - has been shown to induce 
epithelial damage and mucin production through activation of MUC5AC gene.  
Knockout mice experiments have indicated that this occurs through synthesis, 
secretion and activation of MMP-9[141], providing another mechanism for disease 
causation by this enzyme. 
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1.32 Granulocyte macrophage-colony stimulating factor (GM-CSF) 
GM-CSF is a 127 amino acid cytokine with structural similarities to growth factors IL-
2, IL-3 and IL-5.  It acts by binding a heterodimeric receptor formed from an alpha 
and beta chain.  GM-CSF receptor signalling is complex, reflecting the diverse 
actions of GM-CSF which include cell differentiation, activation and promotion of an 
inflammatory response.  Transcription factors NFB and PU.1 have both been shown 
to be activated by GM-CSF and the latter to induce terminal differentiation of alveolar 
macrophages[142].  GM-CSF has a positive feedback role in promoting inflammation 
in the lung, where it is produced by the majority of cell types present; it also acts as a 
chemoattractant for eosinophils. 
 
Studies in COPD have demonstrated conflicting results on GM-CSF concentrations 
in sputum, but this maybe due to the rapid reduction in levels following internalisation 
of the GM-CSF-receptor complex[143].  More recent studies have identified elevated 
levels of GM-CSF in both BAL and sputum of stable COPD patients, which are 
significantly increased at exacerbation[144, 145].  As glucocorticosteroids mediate 
their response through HDAC, it has been postulated that the inability of these drugs 
to suppress GM-CSF in COPD may be due, at least in part, to HDAC2 deficiency. 
 
Macrophages play a central role in COPD where their numbers are increased in both 
airways and parenchyma.  By producing excess GM-CSF in response to cigarette 
smoke and virus or bacterial infection inflammatory cells are increased further and 
positive feedback is reinforced.  This has led to interest in a therapeutic role for GM-
CSF suppression.  While untested in human subjects there are some data to support 
this rationale; particularly using drugs which are effective or show promise in COPD.  
Studies include an in vitro study of cilomilast, a novel phosphodiesterase 4 inhibitor 
(PDI), which reduced GM-CSF secretion in cells from induced sputum[146].   Other in 
vitro studies demonstrated reduced levels of inflammatory cytokines, including GM-
CSF after exposure to formoterol and salmeterol in monocyte derived macrophages 
(MDM) [147] and the sirtuin activator resveratrol[148, 149] in smooth muscle cells 
and alveolar macrophages (AM) from COPD subjects.  Resveratrol, isolated from red 
wine extract, has antioxidant and anti-inflammatory properties which may act through 
an alternative pathway to corticosteroids. 
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1.33 Interferon gamma (IFN-) 
IFN- is a pivotal member of both the innate and adaptive immune systems.  It is the 
only member of the type II interferon family and belongs to a group of proteins known 
as macrophage activating factors.  It is a dimer formed from two interlocking 6 
subunit alpha-helices.  Produced by natural killer (NK) cells (innate) and CD4 and 
CD8 cells (adaptive), it is the archetypal cytokine of Th1 cells.  IFN- has many 
biologically important actions, including the ability to inhibit virus replication, promote 
macrophage activity and activate inducible nitric oxide synthase (iNOS).  There are 
no studies to date that have identified elevated levels of IFN- protein in COPD, but 
IFN- producing Th1 cells have been identified in increased numbers in COPD[150, 
151]. 
 
1.34 Interleukin 10 (IL-10) 
The anti-inflammatory cytokine IL-10 is produced predominately by monocytes and 
acts to down regulate Th1 cytokines, including IFN-, IL-2, TNF- and GM-CSF.  In 
response to virus infections it is released by cytotoxic T cells, suppressing NK cells 
and so damping down the innate immune response.  In disease states associated 
with excess inflammation it has been hypothesised that IL-10 deficiency may play a 
role.  Indeed, levels of IL-10 have been found to be reduced in sputum samples from 
COPD[42] patients compared to healthy non-smoking and smoking controls and 
genetic studies have identified IL-10 polymorphisms in 1-antitrypsin deficient[152] 
and COPD populations[153].  Recombinant human IL-10 has been effective in 
controlling inflammatory bowel disease, supporting a possible role for use in COPD.  
However when IL-10 was over expressed in a rodent model airway inflammation was 
increased[41], suggesting that health may depend on optimum levels of IL-10. 
 
1.35 Interleukin 12 (IL-12) 
The biologically active heterodimer of IL-12 is IL-12p70, formed from p40 and p35 
subunits.  The expression of the p40 subunit is tightly controlled and released from 
activated macrophages and B cells.  The cytokine is involved in regulation and 
differentiation of Th1 cells and therefore the maintenance of a Th1/Th2 balance.  It 
can reduce the response to allergens and enhances production of IFN- and TNF-.  
The role of IL-12 in COPD has not been well characterised but was found to be 
increased in EBC of COPD subjects[154].  However a genetic polymorphism study 
failed to identify differences in the rate of the IL-12 allele between control and COPD 
subjects[155]; furthermore in this study IL-27, which acts synergistically with IL-12 
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and is a closely related member of the IL-12 family appeared to have a protective 
role in COPD.  A study of bacterial colonisation in COPD identified significantly 
higher IL-12 levels in subjects colonised with H. influenza[156] compared to those 
without, but not those with other bacterial species identified in the study, further 
illustrating the uncertainty of IL-12‟s role in COPD. 
 
1.36 Interleukin 1 beta (IL-1) 
This proinflammatory cytokine is released from a variety of cells, particularly 
activated macrophages, as a pro-protein.  It then undergoes caspase 1 dependent 
activation, having several biological effects similar to TNF-.  These include 
leukocytosis through neutrophil release and proliferation and activation of B cells, 
promotion of apoptosis and induction of cytokines including IL-8, IL-6, GM-CSF, TNF-
 and IL-2.  It also induces adhesion molecules, such as intercellular adhesion 
molecule 1 (ICAM-1).  In COPD levels have been found to be elevated in both stable 
and exacerbated COPD in EBC[154] and IL-1 polymorphism studies have found a 
susceptibility association with COPD[157].  In cultured human bronchial epithelial 
cells enhanced IL-1 release and reduced glutathione (GSH) were found, 
demonstrating greater susceptibility to cigarette smoke and oxidative stress in COPD 
subjects[117]. 
 
An in vitro study of C pneumoniae infection of alveolar macrophages (AM) and 
peripheral blood mononuclear cells (PBMC) from COPD subjects demonstrated an 
imbalance of pro- and anti-inflammatory cytokines, with a six and fourfold respective 
increase in IL-1 secretion when compared to healthy controls[158].  This suggests a 
possible role for IL-1 in enhancing the inflammation seen during an infective 
exacerbation.  Interest has focused on nuclear proteins which can act as carrier 
molecules and bind with high affinity to inflammatory cytokines, High-Mobility Group 
Box 1 (HMGB1) protein is an example recently studied in the context of COPD and 
IL-1[159].  Here levels of this protein were found to be elevated in BAL from COPD 
subjects compared to healthy smokers and non-smokers, and IL-1 levels positively 
correlated in all smokers.  Although in small numbers it was also shown that IL-1-
HMGB1 complexes were present in AM from COPD subjects.  It was postulated that 
the presence of these complexes may be responsible for the prolongation of 
inflammation in COPD. 
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1.37 Interleukin 2 (IL-2) 
IL-2 is a cytokine which promotes T cell activation and expansion of naive T cells 
when it is produced by activated T cells.  It may also be able to activate AM and 
fibroblasts through receptors located on these cells; where it is able to enhance 
inflammation and possibly pulmonary fibrosis.  IL-2 plays a central role in initiating 
the adaptive immune response and this is exploited as a target for therapeutic 
immunosuppression with drugs such as cyclosporin and tacrolimus. 
 
There is evidence that T cell activity is abnormal in COPD and a study of peripheral 
blood T cell apoptosis found an increased rate in COPD subjects compared to 
controls and that differences in levels of IL-2 were not responsible for this[160].  Also 
a randomised double blind placebo controlled study of an immunomodulator drug, 
AM3, demonstrated restoration of IFN- levels and normalisation of PBMC 
proliferation in response to PHA which was not identified after addition of IL-2 to the 
culture[161].  Few studies have examined the role of IL-2 in COPD directly, however 
in a retrospective study of emphysema patients it was found that subjects with stable 
COPD had higher levels of IL-2 compared to a group with rapidly declining lung 
function[162]. 
 
1.38 Interleukin 6 (IL-6) 
The pro-inflammatory cytokine IL-6 is produced by a wide range of cells both within 
and outside the immune system.  It is active as an acute phase mediator and 
promotes a range of systemic responses to infection including inducing pyrexia.  The 
production of IL-6 by AM following stimulation by PAMP illustrates the key role IL-6 
plays in pulmonary host defence.   
 
Interest in the role of IL-6 in COPD pathogenesis is considerable, it has been found 
to be elevated in serum and sputum of stable and exacerbated subjects and to be 
associated with reductions and a faster decline in lung function.  Specifically following 
experimental infection with RV in asthmatic and COPD subjects IL-6 levels were 
found to be elevated in BAL and sputum respectively [163, 164].  In a cohort study of 
COPD exacerbations IL-6 levels in serum were elevated leading to an increase in 
plasma fibrinogen and suggesting a possible mechanism for an excess of thrombotic 
events seen following AECOPD[165].  There is evidence that IL-6 can up regulate C 
reactive Protein (CRP) at the transcriptional level and this is supported by a study 
designed to assess the reproducibility of IL-6 measurements in COPD patients over a 
year[166], where it was also shown that IL-6 and CRP levels correlated.  As with 
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other cytokines; genetic polymorphism studies have identified links between 
populations of COPD subjects and specific inflammatory gene promoters; in a study 
by He[167] several IL-6 promoter polymorphisms were found to be associated with a 
greater decline in FEV1 and increased susceptibility to COPD amongst smokers.  
However the precise role of IL-6 in COPD is not well understood, as illustrated by an 
in vitro study on the effect of commonly used drugs, which demonstrated that RV 
induced IL-6 levels were suppressed by pre-treatment with fluticasone but actually 
augmented by salmeterol exposure[168].  Given that 2 agonists have many 
beneficial effects in both asthma and COPD more research is needed to clarify the 
role of IL-6 in this area. 
 
1.39 Interleukin 8 (IL-8) 
IL-8 was the first chemokine to be discovered and belongs to the CXC (-chemokine) 
family.  It is produced by a range of cell types, including macrophages, epithelial and 
endothelial cells and acts as a neutrophil and T cell chemoattractant through a G-
protein coupled receptor.  By activating neutrophils it facilitates release of stored 
enzymes and produces the respiratory burst through oxygen free radical and nitric 
oxide generation.  By this mechanism it leads to host defence and tissue destruction 
which are the hallmarks of neutrophilic inflammation.  IL-8 also promotes the 
formation of leukotriene B4 (LTB4) through activation of 5-lipoxygenase.  LTB4 is itself 
a powerful pro-inflammatory mediator, with chemoattractant properties.  There is 
evidence of a positive feedback loop whereby elastase released from neutrophils 
under the influence of IL-8 stimulates epithelial cells to produce yet more IL-8 and 
LTB4 further propagating the inflammatory response[169, 170].  
 
In the airways IL-8 expression can be induced by a wide range of both immunological 
and non-immunological stimuli including cigarette smoke[171] and indeed higher 
levels of IL-8 are detected in BAL[172] and epithelial cells[173] from healthy smokers 
when compared to non-smokers.  In COPD IL-8 is elevated still further when 
compared to controls and asthmatic subjects[174].  IL-8 levels have been found to 
correlate with the degree of airflow limitation; where levels in sputum show a negative 
correlation with the FEV1/FVC [175] ratio and a positive correlation with the rate of 
decline in FEV1[176].  The interaction of cigarette smoke extract (CSE) and RV 
infection has been studied in vitro using epithelial and BEAS2B cells and 
demonstrated that these two stimuli in combination augmented IL-8 induction by 
more than the additive effect of either alone and they promote IL-8 release through 
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different mechanisms[177].  Studies of IL-8 in EBC during exacerbations have 
produced conflicting results with IL-8 detectable in one but not in another despite 
similar methodology[178, 179].  So although it seems likely that IL-8 plays a central 
role in the development and proliferation of inflammation in COPD, a recent study to 
assess the potential role of sputum neutrophil count as a biomarker found only a 
weak correlation with serum IL-6 and IL-8[180] suggesting that there are many other 
factors which influence the inflammation in COPD.  A blinded study of an IL-8 
monoclonal antibody in COPD failed to demonstrate a benefit in lung function or 
exercise tolerance however[181], although there was a modest improvement in 
breathlessness. 
 
1.40 Tumour necrosis factor alpha (TNF-) 
TNF- is a pro-inflammatory cytokine and a member of the acute phase protein 
family which includes IL-1, IL-6, IL-8 and GM-CSF, many of which augment TNF- 
release.  It is produced predominantly by macrophages but also secreted from many 
other cell types in the respiratory tract including epithelial cells, T cells and mast 
cells.  It plays a complex part in immune regulation with several functions identified; it 
is able to activate epithelial cells, macrophages and antigen-presenting cells (APC), 
induce apoptosis in areas of pulmonary inflammation, stimulate matrix 
metalloproteinases release from macrophages and induce adhesion molecules.  
TNF- also exerts a pro-inflammatory role through IL-8 release, which is 
synergistically increased by the presence of CSE[182]. 
 
TNF- has been shown to increase airway hyperresponsiveness and sputum 
neutrophilia in normal subjects[183] and is elevated in the sputum of smokers[184] 
and still further increased in COPD[174].  Additionally it is associated with systemic 
inflammation, muscle wasting and weight loss seen in COPD[73, 185].  There have 
been contradictory results from genetic studies, but a study in COPD identified those 
with a TNF- polymorphism had a lower BMI and greater annual FEV1 decline when 
compared to those without[186].  Despite hopes that removing excess TNF- might 
provide a therapeutic role, anti TNF- therapy has been disappointing in COPD and 
appears to be largely ineffective[187]. 
 
1.41 Eotaxin 
Originally identified in BAL from allergic guinea pigs, Eotaxin is a member of the CC 
chemokine family and the most potent and selective eosinophil chemoattractant with 
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additional weak T cell chemotaxis properties.  It is a ligand for several chemokine 
receptors, chiefly CC chemokine receptor 3 (CCR3), which is abundant on 
eosinophils.  Interest has focused on asthma and allergic diseases but studies in 
COPD have demonstrated higher levels of eotaxin in BAL from stable COPD 
compared to controls[188] and those with rapid decline in lung function[162]. 
 
1.42 Eotaxin-3 
Eotaxin-3 is closely related to Eotaxin and has similar properties, chiefly as an 
eosinophil chemoattractant.  There is limited data on the role of Eotaxin-3 in both 
stable and exacerbations of COPD.  In asthma increased concentrations have been 
found when compared to normal controls[189] and expression in bronchial biopsies is 
elevated following allergen challenge[190]. 
 
1.43 Interferon gamma-induced protein 10 (IP-10) 
IP-10 is a CXC chemokine released from airway smooth muscle under the influence 
of IFN- and TNF-, acting synergistically at transcription level[191].  It is a 
chemoattractant for immune cells, including macrophages, mast cells and T cells.  
Levels have been found to be elevated in COPD[192], steroid resistant asthma[193] 
and at the time of virus induced exacerbations of asthma[194].  A recent study in the 
East London COPD cohort identified serum IP-10 as a potential biomarker for RV 
induced exacerbations [195].  The study identified higher serum IP-10 levels in 
COPD subjects at baseline and demonstrated a correlation between sputum RV load 
and serum IP-10.  This data suggests that IP-10 activity may be involved in immune 
mediated inflammation in COPD and could play a part in RV induced COPD 
exacerbations.  A study of RV infected epithelial cells cultured ex vivo demonstrated 
increased IP-10 protein levels which were associated with higher vial titre and copy 
number[196].  Together results from these studies strengthen the evidence for IP-10 
being an important mediator in RV induced COPD exacerbations. 
 
1.44 Monocyte chemotactic protein 1 (MCP-1) 
MCP-1 plays a role in the recruitment of monocytes, basophils and T-cells to sites of 
tissue injury and inflammation; it is secreted by both macrophages and monocytes.  
The MCP-1 receptor, CCR2, has been shown to mediate the activation of MAPK 
(Mitogen-activated protein kinase), a key kinase in the regulation of mucin in 
bronchial epithelium[197].  This mechanism may promote goblet hyperplasia and 
hence the pathogenesis of airway disease and interestingly there are elevated levels 
of MCP-1 in EBC, sputum, BAL and bronchial epithelium of smokers and patients 
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with COPD[198-200].  In vitro experiments have demonstrated an increase in MCP-1 
release following RV infection of human monocytes and bronchial epithelial 
cells[201].  In a clinical study designed to identify biomarkers which correlate with 
Body mass index, Airflow obstruction, Dyspnoea, Exercise capacity scores 
(BODE)[202], MCP-1 was found to be elevated in COPD subjects compared to 
healthy smokers and correlated with FEV1 and 6 minute walk test (6MWT)[203]. 
 
1.45 Monocyte chemotactic protein 4 (MCP-4) 
MCP-4 is a member of the CC chemokine family and acts as a chemoattractant for 
monocytes, eosinophils, T-lymphocytes and basophils.  It shares sequence identity 
and receptors with eotaxin[204] where its role in allergic disease has been confirmed 
by the demonstration of increased mRNA and protein levels in asthmatic BAL, sub-
mucosa and epithelium when compared to airways of non-allergic control 
subjects[205, 206].  In vitro expression has been shown to be induced by IL-1 and 
TNF-[205]. 
 
1.46 Macrophage derived chemokine (MDC) 
MDC acts on the CCR4 receptor and is secreted by macrophages and dendritic cells.  
It has chemotactic activity for monocytes, natural killer and dendritic cells[207].  MDC 
expression is augmented by a wide range of mediators, specifically 
lipopolysaccharide, IL-1, TNF-, IL-4 and IL-13; whereas IFN has inhibitory 
effects[208].  MDC has been found to be elevated in models of several lung diseases 
including pulmonary fibrosis, acute asthma and cigarette smoking.  However in the 
smoking model, no increase in Th2 cells was identified, suggesting that MDC may 
act differently in inducing inflammation in the presence of cigarette smoke[209]. 
 
1.47 Macrophage inflammatory proteins alpha and beta (MIP-1) and (MIP-1) 
Macrophage inflammatory proteins are chemokines released by macrophages; two 
major subtypes „alpha‟ and „beta‟ have been identified.  They activate neutrophils and 
eosinophils and can stimulate the release of inflammatory cytokines including IL-1, 
IL-6 and TNF-.  MIP-1 is increased in chronic bronchitis patients [198] and levels 
have been shown to correlate with eosinophils in COPD patients sputum[210].  MIP-
1 was increased in a mouse model of respiratory syncytial virus (RSV) infection and 
airway pollution with carbon black[211] and in a study of bronchial epithelium from 
subjects with mild COPD MIP-1 was also found to be increased[212]. 
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1.48 Thymus and activation regulated chemokine (TARC) 
Thymus and Activation Regulated Chemokine (TARC) belongs to the CC chemokine 
family, it is expressed primarily in the thymus but also in stimulated peripheral blood 
mononuclear cells.  It is a key component in the recruitment of Th2 cells during the 
allergic response[213] and a specific ligand for CC chemokine receptor 4 (CCR4).  In 
COPD, elevated mRNA expression of TARC has been found in the bronchial mucosa 
and bronchoalveolar lavage when compared to non-smoking controls[193].  
Interestingly elevated TARC levels were also identified in non-obstructed smokers 
when compared to non-smoking controls, and this persisted after cessation of 
smoking[193].  In a murine study of RSV infection, TARC was found to be expressed 
and dependent on active virus replication[214].  TARC levels were also shown to be 
increased by Poly(IC) a synthetic analogue of viral dsRNA[215], despite this the role 
of TARC in human RV infection is poorly understood, particularly in COPD. 
 
1.49 Cellular inflammation 
Pathologically the hallmark of COPD exacerbations is an increase in airway 
inflammation above that found in stable disease.  The mechanisms underlying this 
acute-on-chronic inflammation are likely to be central to disease understanding; 
however defining precisely the inflammatory changes occurring at exacerbation has 
proved difficult.  There are conflicting studies in the literature, as discussed below, 
some identifying a predominance of neutrophils, some eosinophils and some 
macrophages.  These inconsistencies highlight the difficulties of performing research 
studies during exacerbations of airway disease and are likely to reflect the range and 
complexities of study designs, for example differences in disease definition, severity 
and aetiology; subject smoking status and prescribed medications (particularly 
corticosteroids) and the time of sampling during the exacerbation.  This is particularly 
important as the nature of inflammation is likely to change from onset of the 
exacerbation to recovery and with different aetiological agents. 
 
1.50 Neutrophils 
Through the release of elastase and the destruction of connective tissue, neutrophils 
have been regarded as a central player in COPD inflammation.  Indeed both the 
number and function of neutrophils are altered in COPD; a study using radiolabeled 
fibronectin demonstrated enhanced chemotaxis and extracellular proteolysis by 
neutrophils from subjects with COPD when compared to smoking controls[216].  
However there have been relatively few studies performed during exacerbations, at 
least partly due to the difficulty of obtaining samples or performing studies during 
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acute exacerbations.  Where studies have been performed, the majority have 
demonstrated neutrophilia in biopsies, BAL[145, 217] and induced sputum[1] 
although some have not demonstrated any change in neutrophil number[218, 219].  
During exacerbations the neutrophil chemoattractants ENA-78 and IL-8 have both 
shown to be increased[217, 220] and this is likely to be at least one mechanism of 
enhanced neutrophil number.  The local tissue consequences of neutrophilic 
inflammation are increased mucus secretion through mucus gland hyperplasia and 
increased airway oedema and airway narrowing from vascular protein leakage.  
These changes have significant clinical sequelae as illustrated by the finding that 
increasing neutrophilic inflammation is associated with worsening airway 
obstruction[221]. 
 
1.51 Macrophages 
The key role of macrophages in the pathogenesis of COPD has become evident in 
recent years.  Numbers of macrophages are increased in active smokers and COPD 
patients[222] although absolute numbers appear unchanged during exacerbations; 
where neutrophils and eosinophils are known to increase[140].  Derived from blood, 
around 15% of circulating monocytes are destined to become either airway, 
interstitial or alveolar macrophages.  Dendritic cells develop from the same 
pluripotent stem cell as macrophages and have features in common, but tend to 
possess enhanced antigen presenting cell activity and reduced phagocytic activity 
when compared to macrophages. 
 
Macrophages have a broad range of functions, but central to this is their activity to kill 
bacteria and remove foreign and damaged tissue by phagocytosis.  They also take 
part in the mucociliary transport system where they play a key part in pathogen 
clearance.  The pathogenic effects of macrophages in COPD are likely to be 
mediated through both a loss of normal physiological function and an excessive 
release of toxic cytokines, resulting in tissue damage.  An example of aberrant 
behaviour by alveolar macrophages in COPD is demonstrated by impaired 
phagocytic activity.  In vitro studies of radio or fluorescently labelled bacteria have 
demonstrated reduced phagocytosis when compared to controls[223].  This finding 
may partly explain the increased incidence of bacterial infections and lower airway 
colonisation (particularly by Haemophilus influenzae) found in COPD.  Of interest a 
further in vitro study demonstrated that treatment with the macrolide antibiotic 
azithromycin improved phagocytosis of apoptotic bronchial epithelial cells and 
neutrophils – suggesting a possible therapeutic role for this class of drug[224, 225]. 
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Excessive elastase production in COPD was historically attributed to the neutrophil.  
But a shift of attention to the role of the macrophage has demonstrated excessive 
enzymatic release that can potentially lead to the development of emphysema[226].  
The mediators which are implicated in this process are the family of MMP enzymes.  
First described by observing the degradation of elastin by mouse macrophages, 
MMPs are now recognised as central to the pathogenicity of COPD and observed to 
increase in exacerbations[136, 140]. 
 
As highly active immune cells, macrophages produce a wide range of inflammatory 
cytokines including IL-6, IL-8, TNF-, IL-1, MCP-1 and growth related oncogene 
alpha (GRO-) all of which are increased in the sputum of COPD patients both in the 
stable and exacerbated state[174, 227].  These in turn enhance neutrophilic 
inflammation but emphasise the importance of macrophages in driving pathogenesis 
in COPD.  Finally macrophages are also a major endogenous source of oxidants 
which are discussed later in detail but represent a mechanism of tissue damage in 
COPD. 
 
1.52 Eosinophils 
Although there is controversy surrounding the presence of eosinophilic inflammation 
in COPD, it has been detected during exacerbations[228] and in the stable 
state[229].  The importance of eosinophils in COPD is starting to be elucidated, with 
reductions of eosinophilic airway inflammation being associated with important 
clinical outcome measures including improvements in lung function, health status and 
exercise capacity[230-232].  In a study using targeted therapy to reduce eosinophil 
numbers, severe exacerbations were also reduced[233].  Interestingly, exacerbations 
where a virus was identified were associated with a sputum eosinophilia and 
independent of bacterial co-infection, this remained the best predictor of aetiology[1].  
In a RV challenge study in healthy volunteers bronchial biopsies demonstrated tissue 
eosinophilia following infection[234], although these results were not statistically 
significant. 
 
Driving eosinophil recruitment, cellular adhesiveness and survival are Th2 helper cell 
cytokines, particularly IL-5 and eotaxin[235].  Eosinophils have been shown to 
release a number of toxic granular products, specifically eosinophilic cationic protein 
(ECP), eosinophil peroxidase (EPO), eosinophil derived neurotoxin (EDN) and major 
basic protein (MBP).  In vitro and in vivo experiments have demonstrated that the 
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activity of these degranulation products is related to tissue injury and although the 
majority of work has been performed in asthma it seems that overlapping pathology 
may be present in COPD[236].  Although a causal link between eosinophils and the 
pathogenesis of COPD has not been established, elevated ECP has been found in 
BAL[237], serum[238] and sputum[239, 240] of COPD subjects during both the stable 
and exacerbated state.  Finally indirect evidence of tissue damage from eosinophilia 
in COPD was demonstrated in a study where ECP levels correlated with CT derived 
emphysema scores and an enhanced response to bronchodilation[241]. 
 
1.53 T lymphocytes  
The role of T cells in exacerbations of COPD is not well understood.  In the stable 
state there are increased numbers of cytotoxic CD8+ cells and a recent study in 
exacerbations found a fall in the CD4+/CD8+ cell ratio compared to the stable 
state[242], suggesting that CD8+ cells increase in number during an exacerbation.  
However another study failed to show an increase in CD4+ or CD8+ cells in bronchial 
biopsies from COPD subjects compared to smokers (although this may reflect the 
low number of subjects in the control group)[243].  It has also been proposed that 
CD8+ T cells and the chemokine „regulated upon activation, normal T cell expressed 
and secreted‟ (RANTES) may interact to promote apoptosis of virus infected 
cells[39]; this acts a possible explanation for the severity of virus induced 
exacerbations and the more rapid decline in lung function in those COPD patients 
who suffer frequent exacerbations[56], as increased apoptosis could lead to more 
tissue destruction and worsening emphysema. 
 
1.54 Infection and AECOPD 
Infection is the most common cause of COPD exacerbations; implicated as the 
aetiological agent in over 80% of acute exacerbations[244].  Bacteria have 
traditionally been regarded as the leading cause, but with new molecular techniques 
enabling improved detection of respiratory viruses, interest in their role has 
flourished.  In a study of hospitalised patients with an acute exacerbation, an infective 
agent identified in 78% of cases; 30% bacterial, 23% virus and 25% co-infection with 
both virus and bacteria[1]. 
 
1.55 Viruses 
It has long been known that infection with a respiratory virus worsens symptoms in 
patients with airway disease; a year-long observational study demonstrated that 
respiratory virus infection resulted in an excess of lower respiratory tract (LRT) 
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symptoms in subjects with chronic bronchitis compared to healthy controls[245].  The 
mechanisms by which virus infection induces an exacerbation remain unclear, 
however in exacerbations associated with the presence of common cold symptoms 
the severity and recovery time of exacerbations was increased[246] and had 
elevated inflammatory markers[218] such as IL-6.  Exacerbations in which viruses 
are detected are more common in the winter months[247] when levels of respiratory 
viruses are greater in the community and temperatures lower[248] and these are 
more likely to result in hospitalisation.  Respiratory viruses which are frequently 
associated with exacerbations include RV, influenza, coronaviruses and RSV. 
 
Investigations into the potential role of respiratory viruses in acute exacerbations 
were originally performed using serology and culture; in these studies virus detection 
rates ranged from 26-39%[249, 250].  However when more sensitive molecular 
techniques have been employed detection rates have increased, particularly for RVs 
which are relatively resistant to culture methods[251].  The first study to employ the 
polymerase chain reaction (PCR) in COPD detected respiratory viruses in 
approximately 40% of exacerbations[252], the majority of which were RVs, the 
finding was repeated when again RVs were associated with the majority of acute 
exacerbations requiring hospital admission[253], where overall in 58% of 
exacerbations a RV was detected. 
 
1.56 Bacteria 
Bacterial infection is frequently implicated in the cause of AECOPD where the most 
commonly detected species are Haemophilus influenzae, Moraxella catarrhalis, 
Streptococcus pneumoniae and Staphylococcus aureus.  However controversy 
surrounding the aetiological role of bacterial infection in acute exacerbations has 
existed for several decades[254, 255].  Although bacteria are detected in sputum 
from over 50% of exacerbations[256] there is a higher than expected rate in the 
stable state, 25-30% in several studies[1, 257].  Treating exacerbations with 
antibiotics is beneficial when compared to placebo, but the effect is less than might 
be expected if acute bacterial infection was causing the majority of exacerbations.  
The balance between host defence and pathogen virulence is central to the process.  
It has been postulated that either an increase in bacteria load or the acquisition of a 
new bacterial strain leads to an exacerbation, and this later hypothesis is supported 
by work from Sethi where acquisition of a new strain of H. influenzae was associated 
with worsening of symptoms[258].  Historical studies using only simple bacterial 
culture would not have detected this change in strain.  Finally patient factors 
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influence species and detection rates, for example disease severity is associated 
with increased bacterial infection rates at exacerbation, particularly when the FEV1 
falls below 50% predicted.  In these patients the bacterial species identified are also 
different with higher levels of H. influenzae and Pseudomonas aeruginosa 
infection[259] particularly in critically ill patients[260]. 
 
1.57 Co-infection 
The concept that bacterial infection can occur secondary to an antecedent virus 
infection has been present for many years[261], however no studies have 
demonstrated a causal relationship.  The lag period between virus and subsequent 
bacterial infection may result in difficulty in virus detection and few studies employ 
longitudinal methodology.  There is evidence of reduced bacterial phagocytosis 
following RV infection[262] and this would provide one mechanism for secondary 
bacterial infection. 
 
Whether bacterial infection occurs as a consequence or coincidence a recent study 
demonstrated that co-infection was a serious event.  In this study of hospitalised 
patients with an exacerbation, 25% were found to be co-infected with both virus and 
bacteria.  This group had more marked lung function impairment and longer 
hospitalisation when compared to those with no infection[1].  This suggests that 
where virus and bacteria are present simultaneously they act synergistically to 
worsen airway inflammation and increase exacerbation severity, this field merits 
urgent further research in view if these interesting findings and the high number of 
patients affected. 
 
1.58 Rhinoviruses 
Rhinovirus is a member of the Picornovirus family and is a positive strand RNA virus 
of which over 100 serotypes exist.  It is the most frequent cause of the common cold, 
responsible for up to 80% in the autumn[263] and despite the seasonal peak from 
September to April it is detected throughout the year[264].  Transmitted through 
aerosols, fomites and hand to hand contact, they are unable to survive in low pH 
environments and have an optimal growth temperature of 33oC. 
 
Historically detection of RV has been problematic due to the high number of 
serotypes and difficulty in performing culture, but PCR technology has allowed more 
rapid and sensitive detection to be possible.  It was thought that replication could only 
take place in the upper airway (rhino: nose, virus: poison) although now replication in 
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the lower airway has been shown to occur[265].  Divided into major and minor 
groups, RV16 is a member of the former whose cellular receptor is ICAM-1.  Infection 
induces cellular apoptosis but they cause less direct cell death and inflammation than 
many other respiratory viruses such as influenza.  To date no vaccine has been 
developed due to the large number of serotypes, but this therapeutic strategy 
remains of research interest.  In addition a group of RV has recently been identified 
based on sequence analysis data[266].  The RV-C group has been identified in up to 
50% of RV infections in young children and maybe associated with a more severe 
clinical illness. 
 
1.59 Common cold 
In normal healthy subjects a common cold induces mild upper respiratory tract 
symptoms and an increase in airway responsiveness[267].  However in the elderly 
and young children infection can induce more severe lower respiratory tract 
symptoms[268, 269], although this is rare.  The major harm from RV infection occurs 
in the setting of airways disease and was originally demonstrated in asthma, both in 
adults[270] and children[271].  The evidence for COPD has been discussed 
elsewhere.  In smoking subjects there is evidence of increased severity and 
frequency of respiratory infection in smokers(Kark and Lebiush 1981; Cohen, Tyrrell 
et al. 1993; Arcavi and Benowitz 2004).  The mechanisms for this are not clear, but a 
study in mice identified impairments in innate immunity following cigarette smoke 
exposure.  At least partly explained by suppression of apoptosis following exposure 
to virus pathogen associated molecular patterns (PAMP)[272]. 
 
1.60 Mechanism of RV induced inflammation 
The precise mechanisms of RV induced inflammation are not known.  Replication of 
RV in epithelial cells has been identified in both in vitro and in vivo studies[273, 274] 
and then subsequently in macrophages[275].  Many mediators have been shown to 
be increased in RV infection, including IL-1, IL-6, IL-8, IL-10, IL-11, TNF-, 
RANTES, MPO and ECP[276-278].  RV infection has less cytopathic effects than 
many other viruses and so it seems likely that much of the inflammatory response 
occurs as a result of the innate inflammatory response, mediated by increases in the 
mediators described above.  It is possible that in the face of increased inflammation 
present in COPD this leads to an additional influx of cells and excess symptoms.  
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1.61 RV induced oxidative stress 
In vitro experiments have demonstrated induction of intracellular oxidant production 
within 20 minutes of RV infection; this rapid production of O2
- release mirrors the time 
course of NFB activation[279].  It was also shown that reduced glutathione inhibits 
RV induction of ICAM-1 and TNF- in a dose dependent manor.  Glutathione was 
only found to exert this effect in its reduced state but not in its oxidised state, 
suggesting that redox mechanisms are central to the effect. 
 
The severity of RV infection and levels of IL-8 in nasal lavage have been found to 
correlate.  In an attempt to investigate the mechanisms for this, the BEAS2B 
respiratory epithelial cell line was infected with RV[280].  The study demonstrated 
elevated levels of H2O2 suggesting a role of oxidative stress in the pathogenesis of 
RV infection.  Addition of the anti-oxidant NAC inhibited RV induced NFB activation 
and IL-8 release, demonstrating that reduction of oxidative mediators may reduce the 
immune mediated effects of RV infection[280]. 
 
A study of primary epithelial cells from COPD patients cultured ex vivo showed an 
increase in oxidative stress genes following RV infection[134].  In addition mRNA for 
DUOX 1 & 2, which are H2O2 generating enzymes, was found to be increased.  This 
suggests a possible mechanism for increased oxidative stress in COPD.  However in 
another study, levels of DUOX 1 & 2 from bronchial brushings were reduced in 
COPD patients[281].  The reason for this contradiction is not clear but may relate to 
differences in severity of disease or smoking status between the study subjects. 
 
Although oxidative stress may occur as the result of RV infection and be responsible 
for an excess inflammatory response, there is also evidence that nitrosative stress 
plays a part in the normal host defence response.  NO has antiviral properties and is 
induced in vitro and in vivo by RV infection[282], suggesting a pivotal role in health as 
part of the normal innate immune response.  Supporting this an experimental RV 
infection of healthy volunteers the expression of iNOS was increased and this 
correlated with exhaled NO, virus clearance and reduced symptom scores[283].  The 
mechanism of this effect is not fully known, but NO is known to inhibit RV induced 
production of IP-10.  This action has been found to be through blocking virus 
activation of NFB and interferon regulatory factors (IRF).  It has been suggested 
that NO donors may provide a therapeutic approach to virus induced exacerbations 
in COPD[284]. 
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1.62 Experimental RV infection 
There is a long history of human experimental rhinovirus infection.  It has been 
performed in healthy volunteers to study transmission, infectivity, serological 
responses and immune mechanisms[285, 286].  Additionally human challenge has 
been used to evaluate potential antiviral therapies[287, 288].  Numerous studies 
have also been performed in asthmatic patients to gain insights into mechanisms of 
exacerbation.  These have demonstrated correlation between airway inflammation 
and virus load, NO induction and Th2 cytokine excess[289, 290].  However there has 
only been one published study of experimental RV infection in COPD[164], and the 
insights gained from this study and the absence of adverse events suggest it seems 
likely that this methodology will prove useful in the future.   
 
The introduction to this thesis has illustrated the significant magnitude of disease 
burden from COPD across the globe, with particular emphasis on the central role of 
acute exacerbations in the morbidity and mortality associated with the disease.  An 
enormous amount of human suffering occurs as a result, especially from infection 
with RVs, which have been shown to be a major aetiological factor in exacerbations 
of airways disease.  In this study the unique experimental RV induced COPD 
exacerbation model will be used to increase knowledge and understanding of the 
mechanisms involved in virus induced exacerbations of COPD.  By focusing on the 
relationship between oxidative and nitrative stress and epigenetic factors this body of 
work investigates an area which has not been studied previously.  These studies and 
the use of this model in the future may provide inroads towards developing 
treatments that could improve outcomes in this burdensome disease. 
 
1.63 Hypotheses 
The central hypotheses to be tested are that RV infection leads to (i) increases in 
markers of oxidative and nitrative stress in induced sputum supernatant, (ii) reduced 
activity of HDAC2 isoenzymes in macrophages isolated from sputum and BAL and 
(iii) increases in pro inflammatory cytokines in sputum and BAL supernatant and that 
these effects are exaggerated in COPD subjects when compared to both non-
smoking and smoking non-obstructed controls.  In addition it is hypothesised that 
non-smoking controls experience reduced lower respiratory tract symptoms and 
lower total virus load compared to COPD subjects and smokers when experimentally 
infected with RV.  The proposed mechanism is that RV induced oxidative stress 
leads to ubiquitination and subsequent proteasomal degradation of HDAC2. 
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Therefore to investigate this hypothesis, groups of COPD and smoking and non-
smoking control subjects were recruited and experimentally infected with RV16.  
Samples were collected to enable confirmation of virus infection and spirometry and 
symptom scores were recorded to enable identification of features representative of 
an exacerbation in COPD subjects.  
 
Subsequently pro-inflammatory cytokines and chemokines were measured to both 
confirm and explore the degree of excess inflammation in COPD subjects compared 
to controls.  Finally the HDAC2 activity was measured in sputum and BAL 
macrophages and oxidative and nitrative stress measured in samples collected from 
study subjects. 
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Chapter 2: Materials and methods 
 
2.1 Outline of clinical experimental design and procedures 
Experimental challenge of subjects with RV16 was performed in a similar manner to 
the pilot and validation study of COPD exacerbations performed at Imperial College, 
London[164, 291].  Briefly baseline samples of exhaled breath condensate (EBC), 
nasal lavage (NL), induced sputum (IS), blood and fibre optic bronchoscopy (FOB) 
were obtained prior to infection and repeated on subsequent visits.  Subjects 
attended for 8 visits 3, 5, 7, 9, 12, 15, 21 and 42 days post infection.  Sampling and 
the study timetable are illustrated in Figure 2.1.  Lung function and symptom data 
were also recorded throughout the study.  In addition to COPD subjects, two non-
obstructed control groups of smoking and non-smoking subjects were recruited.  The 
aim was to recruit 12 subjects per group (36 in total). 
 
2.2 Inclusion and exclusion criteria for study subjects 
During the study the safety and well being of all volunteers was the main priority, the 
criteria for participating have been maintained from an initial pilot study performed at 
St Mary‟s hospital[291].  In this study it was first shown that experimental RV 
infection of COPD subjects was safe and induced features of an acute exacerbation.  
The study presented here was the first to include a non-smoking control group, and 
the inclusion criteria for participating was identical to smoking controls except for the 
smoking pack year history which was changed to 0. 
 
Inclusion criteria 
2.3 COPD 
Subjects in the COPD group were recruited according to the following criteria: 
 Age 40-75 years 
 Medical history or clinical diagnosis of COPD (GOLD stage II) 
 No history of asthma or allergic rhinitis 
 No atopy on skin testing 
 Cumulative smoking history of over 20 pack years 
 Post-bronchodilator FEV1 80% and 50% predicted for age and height 
 Post-bronchodilator FEV1/FVC ratio less than 70% 
 -agonist reversibility of less than 12% predicted FEV1 and 200ml 
 Absence of current or previous history of significant respiratory disease (except 
COPD) 
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 Absence of significant systemic disease 
 
2.4 Non-smoking controls 
 Age 40-75 years 
 No history or clinical diagnosis of COPD  
 No history of asthma or allergic rhinitis 
 Not atopy on skin testing 
 No smoking history 
 Post-bronchodilator FEV1 >80% predicted for age and height 
 Post-bronchodilator FEV1/FVC ratio >70%  
 Absence of current or previous history of significant respiratory disease 
 Absence of significant systemic disease 
 
2.5 Smoking controls 
 As non-smoking controls, with the exception of smoking history: 
 Cumulative smoking history of over 20 pack years 
 
Exclusion criteria 
 
2.6 COPD 
 Any clinically relevant or significant systemic disease 
 Pregnant or nursing women 
 COPD exacerbation within the previous 8 weeks 
 Treatment with oral or inhaled steroids now or in the previous 3 months, current 
use of  long-acting β-agonists, nasal spray, anti-histamine, leukotrienes or tiotropium 
 Shortness of breath score at screening over 1 or total lower respiratory tract 
score over 7 
 Antibodies to rhinovirus 16 in a titre >1:2 
 
Although not specifically included as inclusion or exclusion criteria, practical 
considerations were considered prior to subject‟s enrolment in the study; for example 
distance of travel availability between work hours.  Additionally administration of the 
seasonal influenza vaccine in the previous year was recorded for all subjects.   
 
The inclusion and exclusion criteria for study subjects are included below and 
summarised in table 2.1.   
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Inclusion () & exclusion (X) criteria COPD Controls 
 Smoking Non-
Smoking 
Age 40-75 years    
Clinical diagnosis of COPD, GOLD stage II   X X 
History of asthma or allergic rhinitis X X X 
Atopic on skin testing X X X 
Cumulative smoking history (pack years) >20 >20 0 
Post-bronchodilator FEV1 (% predicted) 80 & 50 >80 >80 
Post-bronchodilator FEV1/FVC ratio (%) <70 >70 >70 
-agonist reversibility (% predicted FEV1 & 
ml)  
<12% & 200   
Absence of history of significant respiratory 
disease  
(excluding 
COPD) 
(including 
COPD) 
(including 
COPD) 
Significant systemic disease X X X 
Any clinically relevant abnormality on 
screening medical 
X X X 
Pregnant or nursing women X X X 
AECOPD or common cold in last 8 weeks X X X 
Treatment with oral/inhaled steroids in last 
3month, current use of LABA, nasal spray, 
anti-histamine/-leukotrienes, tiotropium 
X X X 
SOB score at screening >1 or total LRT 
score >7 
X X X 
Serum antibodies to rhinovirus 16 in a titre 
>1:2 
X X X 
 
Table 2.1 Inclusion and exclusion criteria for subjects recruited into the study, (Long acting 
beta agonist (LABA), Shortness of breath (SOB) and Lower respiratory tract (LRT) 
 
Individual subjects were required to attend for 12 visits over the duration of the study.  
Bronchoscopy could only be performed on Monday, Wednesday or Friday in 
conjunction with established NHS sessions at St Mary‟s Hospital.  Figure 2.1 outlines 
the overall study protocol, with individual study visits shown in boxes across the time 
line of the project.  Ethical approval for the study was obtained from St Mary‟s Local 
Research Ethics Committee; Patient information sheet and REC letter in appendix, 
(study number 07/H0712/138). 
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Summary of study visits and procedures performed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FOB: Fibre Optic Bronchoscopy 
EBC: Exhaled Breath Condensate 
NL: Nasal Lavage 
PFT: Full Pulmonary Function Tests 
CXR: Chest X-ray 
ECG: Electrocardiogram 
Daily spirometry and symptom diary card throughout the study period 
Sputum 
EBC 
NL 
Spirometry 
 
Day 5 
 
Sputum 
EBC 
NL 
Spirometry 
 
Day 3 
Acute  
 
Sputum 
EBC 
NL 
Spirometry 
 
Day 9 
 
FOB 
NL 
Blood 
Day 7 
 
Sputum 
EBC 
NL 
Spirometry 
Day 15 
 
Sputum 
EBC 
Spirometry 
PFT, NL 
 
Day 12 
 
Inoculation 
(RV16) 
NL 
Blood 
 
Day 0 
 
 FOB 
 Day -14 
   Baseline 
 
Sputum 
EBC + NL 
Spirometry 
Blood 
 
 
Day 42 
Sputum 
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NL 
Spirometry 
 
Day 21 
    Recovery 
Spirometry 
Skin prick 
Blood
  Screening   
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Figure 2.1 Outline of study visits and timetable.  Screening (blue), baseline (green), 
acute (red) and recovery (orange) phases shown 
 
2
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 Visit 
CXR & 
ECG EBC, 
NL, Sputum 
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2.7 Subject screening 
Subjects were recruited through advertisements in local newspapers and on the 
internet.  Attempts to recruit through hospital outpatient clinics, general practitioners 
surgeries or support groups were largely unsuccessful, mainly due to the disease 
severity of COPD patients in these settings.  Initial contact with volunteers was made 
by telephone and a pro forma screening questionnaire (see example in appendix) 
completed, this enabled exclusion of unsuitable subjects and the formation a 
database for volunteers interested in future research projects.  In total approximately 
1550 subjects were screened by telephone.  Of those 176 attended hospital clinic in 
person for full screening.  Approximately 45% of subjects were subsequently 
excluded after being found to be RV16 seropositive. 
 
2.8 Clinic screening visit 
Individuals attended St Mary‟s Hospital, London for a standardised clinic screening 
visit.  A Patient Information Sheet was provided and informed consent obtained from 
all subjects prior to enrolment in the study.  A full medical history and examination 
were performed followed sequentially by clinic spirometry, skin prick tests and 
venepuncture.  Results obtained that were not compatible with the 
inclusion/exclusion criteria ended the consultation. 
 
2.9 Pulmonary function testing 
Spirometry was performed on each clinic visit and during screening in accordance 
with the BTS/ARTP guidelines[292].  Measured using a Micro Medical MicroLab 
spirometer (Micro Medical, Kent, UK), subjects inhaled maximally then performed a 
forced exhalation to forced residual capacity (FRC), the best of 3 manoeuvres was 
recorded.  In addition full pulmonary function testing in St Mary‟s Hospital lung 
function laboratory was performed at baseline and on day 12 or 15 post-inoculation 
by Association for Respiratory Technology and Physiology (ARTP) accredited NHS 
staff according to established protocols.  At the baseline test FEV1 reversibility was 
assessed by administration of 200g of salbutamol using a metered dose inhaler 
(MDI) and large volume spacer with spirometry repeated after 15 minutes.  Subjects 
also recorded spirometry values daily at home using a portable Micro DL spirometer 
(Micro Medical, Kent, UK).   
 
2.10 Skin prick testing 
Skin prick testing was used to define the atopic status of volunteers.  Those with one 
or more positive reactions were excluded from the study.  A drop of aeroallergen 
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(specifically grass pollen, house dust mites, cat hair, dog hair, Aspergillus fumigatus, 
Alternaria alternate, Cladosporium herbarum, mugwort, silver birch and 3 trees) was 
placed on the labelled inner forearm and lancets used to make a small scratch.  
Histamine and 0.9% saline were included as positive and negative controls 
respectively.  Positive reactions were defined as a weal 3mm greater than the 
negative control.  No subjects were taking antihistamine medications or had used 
topical medication on the arm. 
 
2.11 Venepuncture 
Screening and baseline blood samples were collected and then on days 7 and 42 
post infection.  On day 7 full blood count (FBC) and C-reactive protein (CRP) 
analysis was performed in accredited NHS laboratories.  On day 42 serum was 
obtained to assess status of RV16 serology.  The protocol was subsequently 
amended in the final stages so that blood was collected additionally on days 9, 12, 15 
to enable investigation of serum markers following RV infection.  Peripheral blood 
mononuclear cells (PBMC) were collected and processed as described below on 
days 0, 7 and 42.  Serum separation was performed by centrifuging a 10ml plain 
Vacutainer® tube of blood at 3500g (4500rpm) for 10 minutes and aliquoted in 6 x 
200μL aliquots for storage at –80oC. 
 
2.12 RV16 serology testing 
RV16 serology testing was performed on heat inactivated (56oC in water bath for 
30minutes) serum from the screening and day 42 visit.  RV16 neutralising antibody 
levels were assessed using a HeLa cell monolayer in a 96 well plate.  50L of serum 
was serially diluted from 1:2 to 1:64 followed by the addition of 50L of RV16 stock 
virus containing 100 tissue infective dose 50% (TCID50) to each well.  The plate was 
shaken for 1 hour at room temperature.  Finally 100L of freshly stripped HeLa cells 
at a concentration of 2 x 105ml-1 were added, before incubating the plate at 37oC for 
three days.  Virus positive (RV16 and cells, no serum) and negative (media and cells, 
no serum) controls were included in each plate and neat serum (no RV16) was also 
included.  A typical plate layout and picture of completed assay is shown in figure 
2.2.  Antibody titre was defined by the greatest serum dilution where cytopathic effect 
(CPE) was identified.  Seroconversion occurred when antibodies were present with at 
least a 4-fold increase in titre from baseline.  During screening, subjects were 
excluded from the study if an antibody titre ≤1:2 was found. 
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Figure 2.2a Illustration of typical serology plate after completed assay, showing red wells from 
cytopathic effect (CPE) of virus and yellow wells from cellular monolayer 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
M M M M M M RV RV RV RV RV RV 
B 
1:64  1:64  1:64  1:64  1:64  1:64  
C 
1:32  1:32  1:32  1:32  1:32  1:32  
D 
1:16  1:16  1:16  1:16  1:16  1:16  
E 
1:8  1:8  1:8  1:8  1:8  1:8  
F 
1:4  1:4  1:4  1:4  1:4  1:4  
G 
1:2  1:2  1:2  1:2  1:2  1:2  
H 
S S S S S S S S S S S S 
 
 
Figure 2.2b Illustration of typical serology plate layout as shown in figure 2.2a, Columns 1-2, 
3-4, 5-6, 7-8, 9-10, 11-12 represent individual subjects (S - neat serum, M - media alone, RV - 
virus alone, 1:2 to 1: 64 serial serum dilution)  
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2.13 Experimental infection with RV16 
The RV16 inoculum has been used previously and details of safety testing and 
isolation from volunteers are published[267].  It is considered a representative strain 
of major group rhinoviruses, responsible for inducing common colds in the 
community.  A 2L volume of virus inoculum, approximately equivalent to 10 TCID50, 
was thawed and diluted with 1.98ml of normal (0.9%) saline.  Inoculation was 
performed in a specified clinical room by nasal inhalation using a DeVillbiss 286 
atomizer.  Subjects were administered the dose using two puffs per nostril.  As an 
amendment to the protocol, in the last 16 subjects 250L of 0.9% saline was used to 
irrigate the atomizer after RV administration in attempt to increase successful 
infection rates and wash residual RV from the atomizer.   
 
2.14 Symptom scores 
Subjects were asked to complete an upper and lower respiratory tract symptom 
score chart every day.  These were commenced approximately 2 weeks prior to the 
baseline bronchoscopy through until study completion on day 42. 
 
2.15 Upper respiratory tract symptoms 
The scoring system for upper respiratory tract (URT) symptoms was based on the 
Jackson criteria, which has been validated in an experimental infection study and 
used in many subsequent experimental RV infection studies[293-295]. An example of 
the diary card used is shown in figure 2.3.  Symptoms (sneezing, headache, malaise, 
chills, nasal discharge, nasal obstruction, sore throat, cough and fever) were graded 
daily on a scale of 0 to 3, (where the criteria ranged from: 0 = no symptoms to 3= 
severe symptoms).  A clinical cold was considered to be present if 2 of the following 
3 criteria were present: 
 
 A cumulative symptom score of at least 14 over a 6-day period 
 The subjective impression of a cold 
 Rhinorrhoea present on at least 3 days 
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Please score symptoms in the boxes as shown.    
0 = no symptoms    1 = mild      2 = moderate     3 = severe  
 
Figure 2.3 Example of URT diary card used for daily symptom recording 
 
2.16 Lower respiratory tract symptom scores 
Most definitions of an AECOPD used in the literature[59, 296, 297], including the 
GOLD guidelines[12], focus on a change in patients baseline symptoms beyond the 
normal day-to-day variation to make a diagnosis of an exacerbation.  Study subjects 
were asked to complete a daily LRT symptom score card which was based on 5 
typical symptoms of an AECOPD (breathlessness, wheeze, cough, sputum 
production and sputum quality).  Each variable was evaluated on a rating-scale with 
higher scores indicating more severe symptoms, breathlessness and wheeze scored 
0 to 4 and the other parameters scored 0 to 3.  The possible individual total daily 
score ranged from 0 to 17.  An example of the LRT card and scoring scheme is 
shown in figure 2.4.  An exacerbation was defined by an increase in total LRT score 
Date       
Day number            
Sneezing       
Runny nose       
Blocked or stuffy nose       
Sore throat or hoarse voice       
Headache or face pain       
Generally unwell       
Chill, fever or shivery       
Cough       
Total score       
Medications (name and dose)       
1.       
2.       
3.       
4.       
Spirometry       
Peak flow (PEFR)           
FEV1                   
FVC                     
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over baseline level of at least 2 points on 2 consecutive days.  At the time the original 
RV16 COPD exacerbation model was established there was no validated measures 
of day-to-day variation in symptoms in the literature, but these have now been 
published[298, 299] and are broadly similar to the one used in this study. 
 
 
  
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
BREATHLESSNESS 
 
Not 
breathless 
at rest or 
on exertion 
Breathless 
on 
moderate 
exertion (eg 
Walking 
quickly) 
Breathless on 
mild exertion 
(eg Walking on 
level ground) 
Breathless 
on minimal 
exertion (eg 
Getting 
washed) 
 
Breathless 
at rest 
 
WHEEZE 
 
None 
 
Present on 
moderate 
exertion 
 
 
Present on 
mild exertion 
 
Present on 
minimal 
exertion 
 
Present at 
rest 
 
COUGH 
 
None 
Mild (eg 
morning 
only) 
 
Moderate 
 
Severe 
 
 
SPUTUM 
PRODUCTION 
 
None 
 
Small 
amount of 
sputum 
(<30ml) 
 
Moderate 
amount of 
sputum (30 – 
100ml) 
 
Large 
amount of 
sputum 
(>100ml) 
 
 
SPUTUM QUALITY 
 
None 
 
Mucoid 
(clear) 
 
Mucopurulent 
(yellow) 
 
Purulent 
(green) 
 
 
 
 
 
Date      
Day number          
BREATHLESSNESS      
WHEEZE      
COUGH      
SPUTUM PRODUCTION      
SPUTUM QUALITY      
Total score      
 
Figure 2.4 Example of LRT diary card used for daily symptom recording 
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2.17 Correcting for baseline symptom scores 
There are variations in the way that individual subjects score and perceive their 
symptoms despite the use of a standard rank scoring system for symptoms.  In 
addition some subjects, particularly those with COPD, experienced increased 
symptoms prior to infection when compared to the control group subjects.  Finally we 
predicted that the baseline or acute bronchoscopy may induce additional symptoms 
in subjects. Therefore baseline symptoms were corrected for in the following ways: 
 
 The total daily score for both upper and lower respiratory tract symptoms from 
day 1 to 42 were corrected for individual baseline symptoms, achieved by 
subtracting the mean score of day -3 to 0 from post-infection results. 
 
 The total URT score between days 7 to 12 was corrected for the effects of the 
acute bronchoscopy (on day 7) by subtracting the mean score from days -14 
to -9. 
 
 In addition the daily symptom scores were calculated in two week blocks as 
shown in figure 2.5.  The pre-baseline and baseline phase were defined as 
the points 14 days prior, and then post, baseline bronchoscopy (on day -14).  
The two week phase from day 0 to day 14 was termed the acute phase, with 
the subsequent 14 day period the recovery phase.  The final two week period 
of the study was defined the convalescent phase. 
 
 
 
 
Figure 2.5 Division of study time course into two week blocks to examine upper and lower 
respiratory tract scores 
 
2.18 Safety criteria 
In order to identify any subjects in the study who were becoming excessively unwell 
the following safety criteria were established for defining a severe exacerbation[164]: 
 An increase in shortness of breath score by 2 points or more on 2 
consecutive days. 
 An increase in wheeze score by 3 points or more on 2 consecutive days. 
Pre-baseline Baseline Acute Recovery Convalescence 
Days -28 to -14 Days -14 to 0 Days 0 to 14 Days 15 to 28 Days 28 to 42 
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 A fall in FEV1 or PEF of 40% or more from baseline. 
 The subject developed a subjective feeling of severe exacerbation and 
wished to have treatment. 
 The study doctor decided that the subject had a severe exacerbation and 
required treatment.  
If a subject fulfilled any 2 of the first 3 criteria or either of the last 2 they would be 
defined as having a severe exacerbation, withdrawn from the study and medical 
treatment initiated on the clinical judgement of the investigators. 
 
2.19 Nasal lavage 
A nasal lavage specimen was collected on all study visits, primarily for virus 
detection.  With the subjects head extended and soft palette closed, up to 10ml of 
sterile normal saline was instilled into each nostril using a Pasteur pipette.  Subjects 
then gently blew their nose into a sterile universal container.  Lavage fluid was stored 
on ice and then vortexed and aliquoted into 500L volumes and stored at –80oC. 
 
2.20 Induced sputum 
Induced sputum was collected by inhalation of hypertonic saline using an ultrasonic 
nebuliser (DeVilbiss U3000 Ultraneb) in line with European Respiratory Society 
(ERS) guidelines[300].  The majority of subjects tolerated 5% saline, but occasionally 
it was necessary to use 3% or 4% saline in intolerant subjects.  The FEV1 was 
recorded and subjects rinsed their mouth prior to commencing induction.  After 10 
minutes subjects ceased inhalation and were asked to report any adverse symptoms 
(for example chest tightness or breathlessness) and if either these or a fall in FEV1 of 
>20% was recorded then the procedure was stopped.  Where no adverse events 
occurred the procedure was continued until an adequate sputum sample was 
collected or the subject felt unable to continue. 
 
Sputum samples were placed on ice and processed in the laboratory directly after 
collection, broadly using established protocols.  Briefly the total sample was poured 
onto a Petri dish and weighed, sputum plugs were selected from saliva by 
macroscopic inspection using a Pasteur pipette and forceps.  Two plugs were 
removed and stored unprocessed at –80oC for subsequent virus and bacterial 
studies.  A further aliquot was selected for microbiological analysis, weighted and 
diluted 1:1 by weight with 0.1% dithiothreitol (DTT, Sigma, UK) (1% stock in distilled 
water diluted to 0.1% in phosphate buffered saline [PBS]) to facilitate 
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homogenisation.  This sample was mixed well and transferred to St Mary‟s Hospital 
Microbiology Laboratory for semi-quantitative bacteriology assessment. 
 
The remaining sample was diluted with a volume of 4 times 0.1% DTT by weight, 
before mixing thoroughly and filtering via a 70µm cell strainer to remove mucus and 
debris.  The same volume of PBS was added before centrifuging at 453g (1500rpm) 
for 10 minutes at 4oC.  The sputum supernatant was then aliquoted and stored at –
80oC.  The cell pellet was washed and resuspended in PBS before centrifuging again 
(conditions as before).  Finally the cells were resuspended in 1ml of simple 
macrophage media (Gibco, Invitrogen) and counted by haemocytometer with trypan 
blue staining to obtain total cell count.  Sufficient cells were removed to make up to 6 
cytospin slides, at a concentration of 20 000 cells per slide, using the Shandon 
cytospin at 400rpm for 5 minutes.  Slides were air dried and 2 stained using the 
Shandon Diffquick kit.  4 slides were stored unstained at –20oC. The remaining 
sputum cells were diluted with 3ml of macrophage media, distributed across wells of 
a modified polystyrene flat bottom adhesive culture plate (Falcon, Becton Dickinson, 
USA) and incubated for 2 hours at 37oC and 5% CO2 to facilitate macrophage 
separation by adhesion to the well base.  After 2 hours adherent cells were washed 
from the well base using a cell scraper and centrifuged (18.8g for 7 minutes) to 
obtain a cell pellet which was stored immediately at –80oC.   
 
2.21 Bacteriology 
Bacteriological analysis was performed according to the following protocol by NHS 
staff in an accredited microbiological laboratory.  10l of the homogenate was 
inoculated onto a plate of chocolate agar, blood agar + optochin disc, CLED agar and 
Sabouraud agar and spread with a loop for discrete colony detection.  100l of the 
homogenate was added to 5ml sterile saline and mixed for a 1:100 dilution.  50l of 
the 1:100 dilution was added to 5ml sterile saline, the final dilution being 10-4.  20l of 
the 10-4 dilution was inoculated onto a blood and chocolate agar and spread over the 
entire surface with a loop.  The blood and chocolate agars were incubated at 37oC in 
CO2, the CLED and Sabouraud agars at 37
oC without CO2.  Interpretation of the 10
-4 
dilution cultures was as follows (cfu – colony forming units): 
0-2 colonies  106 cfu/ml 
2-20 colonies  107 cfu/ml 
20-200 colonies 108 cfu/ml 
>200 colonies  109 cfu/ml 
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Only potentially pathogenic bacteria were counted and identification with subsequent 
sensitivity testing performed.  Normal flora was reported as such. 
 
2.22 Bronchoscopy 
Bronchoscopy was performed in the endoscopy unit at St Mary‟s Hospital according 
to BTS guidelines[301].  Informed consent was obtained from fasted subjects who all 
received 2.5mg of nebulised salbutamol and 0.5mg of ipratropium bromide prior to 
commencing the procedure.  Subjects were offered sedation with intravenous 
midazolam, titrated to a maximum dose of 10mg.  Topical lignocaine was applied to 
the nasopharynx, vocal cords (2ml of 4%) and large airways (12ml of 2%).  Blood 
pressure, heart rate and oxygen saturations were monitored throughout the 
procedure by a dedicated independent observer.  Oxygen was administered via 
nasal cannula according to pulse oximeter readings.  Samples were collected in the 
following order: (i) bronchial brushings, (ii) bronchoalveolar lavage (BAL) & (iii) 
bronchial biopsies.  After the procedure subjects remained nil by mouth and were 
observed for two hours, then provided with transportation home and contact 
telephone number with 24 hour availability. 
 
Bronchoscopy sample collection 
 
2.23 Bronchial brushings 
Six 10mm (BC-202D-5010 Olympus, Japan) disposable cytology brushes were used 
to collect epithelial cells from the left lower lobe sub-segmental bronchi.  Five 
brushes were immediately washed and transferred in warmed media for further 
processing in the laboratory, the sixth brush was snap frozen whole unprocessed on 
dry ice before transferring to liquid nitrogen storage. 
 
2.24 Bronchoalveolar lavage  
BAL was performed by irrigation of the left upper lobe bronchus using up to 240ml of 
sterile 0.9% saline.  Aspirated BAL fluid was collected into a plastic trap before 
transferring to polypropylene tubes for transport to the laboratory on ice. 
 
2.25 Bronchial biopsies 
Six bronchial biopsies were taken from the segmental and sub-segmental bronchi of 
the right middle and lower lobe using 1.8mm Radial Jaw (1523, Boston Scientific, 
USA) serrated needle free biopsy forceps.  Four biopsies were placed immediately in 
4% paraformaldehyde and two were snap frozen on dry ice. 
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2.26 Cell sample processing 
BAL and PBMC cells were processed and subsequently stimulated in the laboratory 
immediately after collection. 
 
2.27 BAL 
The sample was vortexed briefly and the total volume collected recorded.  6ml was 
aliquoted (unprocessed & unfiltered) and frozen at –80oC for subsequent virus 
studies.  The remaining sample was filtered through a 100µm cell strainer and then 
centrifuged at 453g (1500rpm) for 10 minutes at 4oC.  The supernatant was stored in 
1ml aliquots at –80oC and after washing; the cells resuspended in 1ml of simple 
macrophage media (Invitrogen, UK), prior to counting total cell number using trypan 
blue and a haemocytometer.  Cells for cytospin slides and macrophage separation 
(minimum 4 x 106 cells) were removed using the same method for sputum described 
above.  Any remaining BAL cells were used for ex vivo stimulation.  These were 
diluted to a concentration of 2 x 106 per ml and 1ml added to a 50ml Falcon tube for 
stimulation in the following conditions in this priority order (LPS: lipopolysaccharide, 
PHA: phytohaemagglutinin): 
 Media 
 RV16 
 Filtered RV16 
 LPS 10g/ml 
 PHA 10g/ml 
 LPS 0.1g/ml 
 PHA 1g/ml 
1ml of RV, filtered RV (FRV) or media was added to cells and incubated for 1 hour 
(virus infection time) followed by centrifuging and resuspending the cells in their final 
conditions; media, LPS or PHA (RPMI media with 10% FCS, 3% HEPES and 1% 
Penicillin/Streptomycin).  After incubating for 48 hours supernatant was stored at –
80oC and cells frozen in 350L RLT lysis buffer; where sufficient cells were obtained, 
an additional time point at 24 hours was added. 
 
2.28 Peripheral blood mononuclear cells (PBMC) 
Freshly collected blood in lithium heparin Vacutainer® tubes was diluted 1:1 with 
sterile PBS.  This mixture was added carefully drop wise to 3.5ml of histopaque in 
15ml Falcon tubes which were centrifuged at 1320g (2500rpm) for 30 minutes at 
room temperature with accelerator and brake switched off.  The PBMC layer was 
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removed with a Pasteur pipette before washing cells in basic media.  Cells were then 
counted, stimulated and harvested in the same was as BAL cells described above. 
 
2.29 Cryopreservation of cells 
Excess PBMC were stored in fetal calf serum (FCS) and 20% dimethyl sulfoxide 
(DMSO) added drop wise at a concentration of 5 x 106 per ml before freezing at –
80oC for 24hours before transfer to liquid nitrogen. 
 
2.30 PCR 
A freshly frozen (-80 oC) unprocessed sputum plug was diluted prior to PCR analysis.  
The plug was thawed and sample volume made up to 1ml using nuclease free water 
followed by vigorous pipetting and vortexing to break up sample.  This was then 
made up to 5ml of nuclease free water and re-frozen at (-80 oC). 
 
2.31 PCR for other respiratory viruses 
To exclude incidental co-infection with respiratory pathogens other than RV, the 
presence of adenoviruses, coronaviruses, human metapneumovirus, influenza, 
parainfluenza, RSV, Mycoplasma pneumoniae and Chlamydia pneumoniae was 
excluded using PCR with the random hexamer methods as previously published[252, 
302]. 
 
2.32 Quantitative PCR for picornavirus 
Quantitative PCR (qPCR) was performed to detect the amount of picornavirus in NL, 
sputum and unfiltered BAL stored as described at -80oC.  RNA was extracted from 
samples using the QIAamp virus RNA mini kit (Qiagen) with reverse transcription 
performed using the omniscript RT kit (Qiagen) and addition of random hexamer 
primers as per manufacturer‟s instructions.  Biosystems ABI Prism 7700 sequence 
detection system was used with AmplitaqGold DNA polymerase, a picornavirus 
specific primer pair (forward oligo 5‟- GTG AAG AGC CSC RTG TGC T-3‟, reverse 
oligo 5‟-GCT SCA GGG TTA AGG TTA GCC-3‟) and a FAM/TAMRA labelled 
picornavirus probe (FAM-TGA GTC CTC CGG CCC CTG AAT G-TAMRA).  A master 
mix was made up consisting of Qiagen quantitect probe mix, forward primer (50nM), 
reverse primer (300nM), probe (100nM) and RNase inhibitor.  23µL of PCR 
mastermix was added to 2µL cDNA in each well of a 96 well Taqman plate. 
 
The thermal cycle conditions used were: 50oC 2 minutes, 95oC 10 minutes then 45 
cycles x 95oC 15s / 55oC 20s / 72oC 40s.  Fluorescence data was collected for each 
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cycle and the cycle number (Ct) at which fluorescence rose above threshold was 
determined (threshold used for RV in data analysis was 0.09).  Negative extraction 
(water), negative PCR (template only) and positive extraction (RV16 stock) was 
included.  A standard curve was produced on each qPCR plate processed by 
including 2µL of RV plasmid serially diluted 10 fold from 107 to 100 copies.  Results 
were expressed for each sample in terms of copies/ml for nasal lavage and BAL and 
copies/ml for sputum by reference to the standard curve and taking into account both 
dilution factors inherent in processing to RNA. 
 
2.33 Sputum and BAL cell counts 
Cytospin slides from induced sputum and BAL were prepared and stained as 
described above.  These were blinded and the first hundred cells per microscope 
field view counted. 
 
2.34 Meso scale discovery platform 
The Meso Scale Discovery (MSD) platform (Maryland, USA) was used to measure 
chemokines and cytokines in sputum and BAL supernatant; performed following 
manufactures guidelines.  The technique enables quantitative detection of between 1 
and 9 mediators per well in a 96 well plate format using a Multi-spot® technique.  
This technology utilises a capture antibody attached to each spot within the well 
which enables measurement of multiple mediators simultaneously.  
Electrochemiluminescence of detection antibody is then recorded with an internal 
high sensitivity camera (Sector imager). 
 
Briefly, the protocol requires addition of 25µL of blocking solution to each plate well 
before incubation (RT at ~600rpm) for 30 minutes.  Following plate washing either 
25µL of unknown sample or standard was added to the plate, which was then 
incubation for period of 2 hours.  Repeat washing is followed by addition of 25µL of 
detection antibody and incubation for 1 hour.  Finally 150µL of read buffer is added 
and the plate passed through the Sector imager for reading.  The MSD assay has 
been used in sputum supernatant from COPD subjects and a range of mediators 
shown to be detectable[303]. 
 
2.35 ELISA 
ELISA was performed in ex vivo BAL samples for interferon alpha and beta 
according to manufactures guidelines (Invitrogen, UK). 
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2.36 Potential of antioxidant assay (PAO) 
The Potential of Antioxidant (PAO) assay (Japan Institute for the Control of Aging, 
Japan) was used to assess the total antioxidant capacity in EBC, sputum and BAL 
supernatant.  In this process the cupric ion (Cu++) is reduced by any types of 
antioxidant present in the substrate to the copper (1) ion (Cu+).  This in turn reacts 
with bathocuprine to induce a chromatic change, detectable on a plate reader at a 
wavelength of 480nm.  The assay is used as an indirect measure of oxidative stress; 
as oxidative stress increases the detectable antioxidant is reduced. 
 
2.37 Griess assay 
The Griess assay was performed to measure nitrative stress in sputum, BAL 
supernatant and EBC.  The assay is a modification of that first described by Peter 
Griess in 1879 and relies on a diazotization reaction.  Griess reagents were made in-
house by adding 10g of sulphanilamide (S9251, Sigma, UK) to 950ml distilled water 
with 50ml phosphoric acid (H3PO4) (Griess 1) and 5g of napthylethyl-endiamide 
dihydrochloride (N9125, Sigma, UK) added to 1L distilled water (Griess 2).  All 
analysis was performed with the same batch of reagents stored at 4oC in light 
protective containers.  A nitrate standard curve was prepared using sodium nitrite 
(S2252, Sigma, UK) at concentrations from 1mM, 500µM, 250µM, 125µM, 62.5µM, 
31.25µM, 15.63µM 7.82µM 3.91µM 1.96µM, 1µM to 0µM (PBS alone).   
 
Briefly an equal volume of Griess reagents 1 & 2 were mixed and allowed to 
equilibrate, 100µL of standard or sample was added to duplicate wells of a 96 well 
plate before addition of 100µL complete (combined) Griess reagent.  Top standard 
changes to a dark purple instantly, then shake plate for 5 minutes before recording 
colourimetric values at 550nm on a standard plate reader.  Data was analysed by 
linear regression to the standard curve.   
 
2.38 HDAC2 immunoprecipitation and activity 
The HDAC2 isoenzyme was isolated from macrophage pellets obtained from sputum 
and BAL samples.  Immunoprecipitation (IP) using the HDAC2 antibody (Insight 
Biotect, UK) and PureProteome® Protein A magnetic beads (Millipore, USA) was 
performed.  HDAC activity was measured using an HDAC activity assay (Cayman 
Chemicals, USA).  Briefly the protocol involved addition of radioimmunoprecipitation 
assay (RIPA) buffer to the macrophage pellet obtained from cellular adhesion 
described above.  This was incubated for 30 minutes before combination with the 
HDAC2 antibody and overnight mixing on a sample roller.  Magnetic beads were then 
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added for 2 hours of incubation prior to bead removal.  Finally analysis of HDAC2 
activity was performed in the protein sample and the supernatant used to calculate 
total protein concentration using the bicinchoninic acid assay (BCA).  The BCA was 
performed according to published methods[304].  Results of HDAC2 activity were 
corrected for sample protein levels. 
 
2.39 My role in the project 
I undertook all of the clinical work involved in the study, including obtaining ethical 
approval, recruiting and screening subjects and collecting the samples.  Later in the 
study I had the assistance of a research nurse which enabled more rapid recruitment.  
I performed the laboratory analysis for RV16 serology, to improve sensitivity all 
serology assays were performed in duplicate with a research technician, Dr A 
Telcian.  I inoculated all the subjects and attended all the study visits.  I performed all 
bronchoscopies myself with the assistance of nursing and medical staff.  The formal 
lung function testing was carried out by respiratory technicians in the pulmonary 
function laboratory at St Mary‟s Hospital.  I performed all the cell culture work 
including growing the virus used for in vitro studies; specifically this involved ex vivo 
stimulation and storage of BAL and PBMC samples.  I performed all the processing 
of the BAL, PBMCs and sputum samples, the latter with some assistance of a 
research technician.  The microbiological analysis of sputum for bacteria was carried 
out in the accredited microbiology laboratory at St Mary‟s Hospital.  The qPCR and 
PCR for other respiratory viruses was performed by technicians in our laboratory.  I 
performed all the MSD, PAO and Griess analysis in the study.  HDAC2 IP and 
activity assays were performed by researchers collaborating on the project at the 
Royal Brompton Campus.  I performed statistical analysis with assistance of Dr M 
Bafadhel, PhD student 
 
2.40 Statistical analysis and software used 
Statistical analysis was performed using SPSS version 18 (Chicago, IL) and PRISM 
version 5 (San Diego, CA).  All parametric and non-parametric data is presented as 
mean (standard error of the mean) and median (interquartile range), log transformed 
data is presented as the geometric mean (95% confidence interval).  One way 
analysis of variance (one way ANOVA) was used to compare parametric means 
across groups.  Chi squared analysis was used to compare proportions.  For 
comparison of clinical and mediator changes between baseline and study visits the 
paired T-test was used and the Mann Whitney U test for non-parametric 
comparisons.  Correlations of clinical characteristics, mediator analysis and 
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experimental assays were assessed by Pearson‟s correlation (r) coefficient for 
parametric data and Spearman‟s coefficient (rs) for non-parametric data.  A p value 
of < 0.05 was taken as the threshold of statistical significance.   
 
Study visits were assumed to be independent of each other.  This enabled analysis 
of clinical characteristics, inflammatory mediators and experimental assay results 
using linear regression.  Validation of study visit independence was performed by 
demonstrating that: (i) virus load in the sputum and nasal lavage was significantly 
different on study visits for all subjects and for subject groups; (ii) the intra-class 
coefficient between visits was not significant indicative of no repeatability of virus 
load on study visits; and (iii) multiple regression analysis modelling that demonstrates 
that study visit was not a significantly independent predictor of virus load measured in 
the sputum or lavage of subjects.  
 
Microsoft Office Excel spreadsheet and Access database were used to record all 
study results and to investigate related parameters.  EndNote X2 (Thomson Reuters) 
was used for bibliographic database management. 
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Chapter 3: Clinical characteristics of study population  
 
3.1 Introduction 
In this chapter the demographic data and clinical characteristics of subjects recruited 
into the study are presented.  The upper and lower respiratory tract symptom scores 
and lung function results are shown at baseline and following RV16 infection; with 
relationships between them described.  The hypothesis studied in this chapter is that 
(i) Upper respiratory tract (URT) and lower respiratory tract (LRT) symptom scores 
and airway obstruction are increased in COPD subjects compared to controls 
following RV16 infection, (ii) Smoking subjects experience an excess of URT & LRT 
symptom scores and falls in lung function compared to non-smoking subjects 
following RV16 infection and (iii) Non-infected subjects do not experience changes in 
URT & LRT symptom scores or lung function following unsuccessful RV16 
inoculation. 
 
Results 
3.2 Recruitment of subjects 
Subjects were recruited through respiratory clinics and advertising in local 
newspapers between January 2008 and December 2010.  Subject recruitment is 
illustrated in the consort diagram, figure 3.1. 
 
3.3 Withdrawal of study subjects 
The majority of subjects that were not eligible to participate in the study were 
screened out by telephone interview.  The most common reason for this was disease 
severity in the COPD group, particularly as many subjects were using medications 
listed in the exclusion criteria (frequently inhaled corticosteroids).  Amongst control 
subjects the majority withdrew from the study because of the duration of the project 
and the time commitment required or because they did not wish to have a flexible 
bronchoscopy.  A substantial proportion of subjects (42%) who were otherwise 
suitable were excluded as they had detectable RV16 antibodies.  There were 50 
subjects who were serology negative and suitable for the study who withdrew.  The 
main reason that subjects withdrew is that they were unable to commit the time 
required to participate or they rescinded consent after screening. 
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Figure 3.1 Consort diagram of experimental RV infection in COPD study, number shown = 
total subjects included in each group (NS non-smoking control, Smk smoking control) 
  
Excluded 
following 
telephone 
screening  
(1355) 
Assessed 
for 
eligibility 
 
(1553) 
Attended 
clinic for 
screening  
 
(198) 
 
Excluded 
following 
clinic 
screening 
(22) 
 
RV16 
serology 
tested 
 
(176) 
 
Inoculated 
with RV16 
 
(52) 
 
Withdrew 
from 
study  
 
(50) 
 
RV16 Ab 
positive 
(excluded) 
 
(74) 
 
RV16 Ab 
negative 
(included)  
 
(102) 
 
Not 
infected 
 
(22) 
 
Successful 
RV 
infection 
 
(30) 
 
9 COPD 
10 Smk 
11 NS 
9 COPD 
5 Smk 
8 NS 
79 
 
3.4 Demographics of all study subjects 
There were 52 subjects (19 non-smoking controls, 15 smoking controls and 18 
COPD subjects) recruited for experimental RV16 inoculation.  The clinical 
characteristics of this study group are shown in table 3.1. 
 
 
 
 
Table 3.1 Clinical baseline characteristics for all subjects entering the study.  Data presented 
as mean (standard error of the mean) unless stated. * mean (range), † median (interquartile 
range), (p: one way ANOVA or Chi squared test) 
 
 
 
 
 
 
 
 
 
 
 
 Non smokers 
N=19 
Smokers 
N=15 
COPD 
N=18 
p value 
Male, n (%) 9 (47) 8 (53) 13 (72) 0.286 
Age* 59 (46 to 71) 54 (41 to 66) 59 (44 to 72) 0.076 
Current smokers, n (%) 0 (0) 13 (87) 14 (78) <0.001 
Ex-smokers, n (%) 0 (0) 2 (13) 4 (22) <0.001 
Pack year history* 0 (0 to 0) 32 (21 to 51) 39 (25 to 57) <0.001 
Body mass index, kg/m
2 
25.1 (1.0) 26.9 (1.0) 25.8 (1.1) 0.475 
FEV1 (L) 3.06 (0.22) 3.14 (0.17) 2.01 (0.10) <0.001 
FEV1 % predicted 106 (4) 99 (3) 65 (2) <0.001 
FVC (L) 3.86 (0.26) 4.08 (0.23) 3.55 (0.21) 0.331 
FVC % predicted 110 (4) 105 (4) 91 (2) <0.001 
FEV1/FVC, % 79 (1) 77 (2) 58 (2) <0.001 
Peak expiratory flow (L/min) 464 (25) 455 (24) 372 (21) 0.048 
SpO2 at rest, %† 97 (3) 98 (2) 96 (3) 0.280 
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3.5 Defining successful RV infection 
Successful experimental infection of subjects was deemed to have occurred if any 
one of the following criteria was met: 
 
 Detection of ≥ 150 RV RNA copies by real time PCR (RT-PCR) in either: (i) 
nasal lavage, (ii) sputum or (iii) BAL samples. 
 An RV16 neutralising antibody titre of at least 1:4 from serum collected 6 
weeks after inoculation. 
The level of 150 copies was established based on the sensitivity and lower limit of 
detection in the qPCR assay.  This was similar to the lower limit used in previous RV 
challenge studies in our department. 
 
3.6 Successfully RV infected subjects 
Of the 52 subjects challenged with RV16, 30 (11 non-smoking controls, 10 smoking 
controls and 9 COPD subjects) were judged to have been successfully infected.  The 
clinical characteristics of these subjects are shown in table 3.2.  There were no 
differences in the proportions of subjects in each study group who were challenged 
with RV16 and then found to have been successfully infected; 11 of 19 (58%) non-
smokers, 10 of 15 (66%) smokers and 9 of 18 (50%) of COPD subjects, (chi square 
p=0.356).  On the criteria of frequency of infection no study group demonstrated an 
increased susceptibility to experimental RV infection. 
 
3.7 Demographics of successfully RV infected subjects  
Successfully RV infected subjects were age and sex matched between the COPD 
and both control groups but post hoc analysis showed that non-smokers were older 
than non-smoking controls.  Cigarette smoke exposure between non-obstructed 
smoking controls and COPD subjects was also matched for pack year history (mean 
pack year difference 7, p=0.155).  In accordance with the screening criteria the FEV1 
% predicted and FEV1/FVC ratio were significantly different between the groups 
(p<0.001).  Non-smoking and smoking control subjects were matched for lung 
function, with no statistical difference in FEV1 or % predicted FEV1 (FEV1 mean 
difference -0.212, 95% CI -0.800 to 0.376, p=0.648; % predicted FEV1 mean 
difference 5.9, 95% CI -4.7 to 16.5, p=0.364). 
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 Non Smokers 
N=11 
Smokers 
N=10 
COPD 
N=9 
p value 
Male, n (%) 4 (37) 4 (40) 6 (67) 0.351 
Age* 62 (53 to 71) 53 (41 to 66) 60 (44 to 72) 0.014° 
Current smokers, n (%) 0 (0) 10 (100) 8 (89) <0.001 
Ex-smokers, n (%) 0 (0) 0 (0) 1 (11) <0.001 
Pack year history* 0 (0 to 0) 32 (21 to 51) 39 (25 to 50) <0.001• 
Body mass index, kg/m
2
 24.2 (1.2) 26.0 (1.3) 26.6 (1.8) 0.449 
FEV1 (L) 2.70 (0.17) 3.01 (0.20) 2.08 (0.15) 0.005° 
FEV1 % predicted 103 (4) 98 (4) 69 (2) <0.001° 
FVC (L) 3.48 (0.20) 3.88 (0.30) 3.41 (0.27) 0.405 
FVC % predicted 109 (4) 103 (5) 91 (3) 0.031° 
FEV1 /FVC, % 78 (1) 78 (2) 61 (2) <0.001° 
Peak expiratory flow (L/min) 410 (27) 435 (38) 368 (25) 0.295 
SpO2 at rest, %
†
 97 (4) 98 (4) 96 (3) 0.579 
 
 
 
 
Table 3.2 Clinical baseline characteristics for all subjects successfully infected with RV16.  
Data presented as mean (+/- SEM) unless stated, *mean (range), †median (interquartile 
range) (p shown in table - one way ANOVA) (°p<0.05 controls vs COPD, •p=0.16 Smk vs 
COPD, Tukey analysis) 
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3.8 Symptom scores uncorrected for baseline and effects of bronchoscopy  
As described in chapter 2, Material and Methods, subjects recorded daily upper and 
lower respiratory tract symptom scores from two weeks prior to the baseline 
bronchoscopy until study completion on day 42.  The raw uncorrected total symptom 
scores in two week blocks are displayed in the following section.  The data has been 
presented in two week blocks to allow investigation of the effect on symptoms scores 
of study procedures and to minimise the effect of day to day variations.  Each of the 
two week phases contain separate interventions as described in the Materials and 
Methods chapter.  Uncorrected scores are presented here to enable direct 
comparison of each phase of the study, which has been divided into pre-baseline, 
baseline, acute, recovery and convalescence phases. 
 
3.9 Upper respiratory tract symptom scores in infected and non-infected 
subjects 
To assess the effect of successful RV16 infection on symptom scores, the URT score 
in two week blocks for all subjects who were judged to either have been successfully 
infected or not infected are shown in figure 3.2.  In a two way ANOVA comparison 
when the two groups were compared, there was a significant increase in the scores 
between infected subjects versus non-infected only during the acute fortnight (mean 
difference -26, 95% CI -48 to -4, p<0.05).  There was no difference between the 
groups when any other two week time block was compared (p>0.05). 
 
In infected subjects only, the mean score during the acute phase was significantly 
higher than in any other two week interval, (p<0.0001, one way ANOVA, with Tukey‟s 
multiple comparison analysis).  In non-infected subjects Tukey‟s analysis determined 
that the pre-baseline and acute phase score were significantly different using a one 
way ANOVA analysis, p<0.05. 
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Figure 3.2 Total mean two week phase URT score in all infected and non-infected subjects.  
Higher scores were recorded in infected subjects compared to non-infected only during the 
acute phase.  In infected subjects acute phase scores were higher than any other phase 
assessed.  Data presented mean +/- SEM, (*p<0.05, two way ANOVA, †††p<0.0001, †p<0.05 
one way ANOVA) 
 
3.10 Upper respiratory tract symptom phase scores in infected and non-
infected study groups 
To investigate whether there are differences between individual study groups in URT 
symptom severity either at baseline, or at any of the four other two week phases of 
the study, the results of URT scores in two week blocks have been presented for 
non-smokers, smokers and COPD subjects and comparison between groups at each 
phase performed by one way ANOVA.  In the non-infected subjects there was no 
significant difference between any of the study groups at any time point, figure 3.3.   
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Figure 3.3 Total mean two week phase URT score in non-infected subjects.  No significant 
difference between groups at any time period.  Data presented mean +/- SEM, (one way 
ANOVA, p>0.05) 
 
When the URT score from infected subjects was examined by individual study group, 
there was no difference between the scores at any time period, figure 3.4 (one way 
ANOVA, p>0.05). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Total mean two week URT phase score in infected subjects.  No significant 
difference between groups at any time period.  Data presented mean +/- SEM, (one way 
ANOVA, p>0.05) 
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3.11 Lower respiratory tract symptom phase scores in infected and non-
infected subjects 
The two week block LRT scores for all infected and non-infected subjects are shown 
in figure 3.5.  This demonstrated that only during the acute phase was there a 
difference between infected and non-infected subjects.  There was a higher mean 
acute phase score in infected subjects compared to non-infected subjects, (unpaired 
t test, total score 44 vs 38 p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Total mean two week LRT phase score in all combined infected and non-infected 
subjects.  Higher score recorded in infected subjects during the acute phase only.  Data 
presented mean +/- SEM, (unpaired t test, ***p<0.001) 
 
3.12 Lower respiratory tract symptom phase scores in infected and non-
infected study groups 
When the two week phase LRT scores in non-infected subjects was considered, no 
difference between groups during the pre-baseline and baseline time periods was 
recorded.  However during the acute, recovery and convalescent period the COPD 
subjects had higher scores than non-smoking controls in a two way ANOVA analysis 
and Bonferroni‟s post test, figure 3.6. 
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Figure 3.6 Total mean two week phase LRT score in non-infected subjects.  Significant 
difference between non-smoking and COPD subjects at acute, recovery and convalescence 
phase, no significant difference between smoking and COPD subjects at any time point, (two 
way ANOVA, *p<0.05, **p<0.01) 
 
 
In infected subjects there was no difference in LRT phase scores between the three 
study groups during the pre-baseline and baseline period.  During the acute phase 
COPD subjects had significantly greater scores than both control groups; with no 
difference between smoking and non-smoking controls during this time period.  In the 
recovery and convalescence period LRT scores in COPD subjects remained higher 
than in non-smoking controls, figure 3.7. 
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Figure 3.7 Total mean two week phase LRT score in infected subjects.  No difference 
between control groups at any time point, greater scores in COPD subjects as shown.  
(**p<0.01, ***p<0.001, two way ANOVA)  Increase in COPD subjects score between baseline 
and acute periods, (paired t test, †p<0.05) 
 
A significant increase in LRT scores from baseline following RV infection only 
occurred in the acute phase in COPD subjects, when baseline was compared to the 
acute period the mean scores increased from 65 to 85, p=0.015, (paired t test).  In 
control subjects there was no difference in mean score between baseline and acute 
time periods, figure 3.7. 
 
3.13 Daily symptom scores corrected for baseline and effects of bronchoscopy 
Daily upper and lower respiratory tract total symptom scores were corrected for pre-
infection levels, by subtracting the mean of symptom scores from days -3 to 0.  This 
was performed to eliminate baseline symptoms and enable between group analyses.  
Additionally URT scores were corrected for the effects of the post infection 
bronchoscopy between days 7 and 12 by subtracting mean day -14 to -9 score.  Only 
URT symptoms were corrected for the effects of bronchoscopy, as there was no 
evidence of an effect on LRT scores and correction resulted in a dip below preceding 
day‟s values.  A similar pattern was identified in previous RV exacerbation studies in 
COPD.  Henceforth only corrected total URT and LRT scores are discussed.  The 
results of these are summarised below.   
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3.14 Daily corrected upper respiratory tract symptom scores in infected and 
non-infected subjects 
URT scores in both RV infected and non-infected subjects are illustrated in figure 3.8 
and demonstrate that successfully infected subjects had significantly greater URT 
scores than those who were not infected.  This was evident on days 2 to 7 using an 
unpaired t test between infected and non-infected subjects.  Despite no evidence of 
RV infection there was a significant rise in symptom scores following experimental 
inoculation in non-infected subjects, the paired t test analysis confirmed this on all 
visits after inoculation until day 11.  The pattern of this increase was similar in both 
infected and non-infected subjects.  In those subjects with confirmed infection there 
was significantly increased URT symptoms scores from inoculation until day 20, 
analysed using a paired t test from baseline.  The peak increase in URT symptom 
scores occurred on day 5 (mean difference (95%CI) URT score on day 5 from 
baseline 4.52 (2.31 to 6.72), p<0.001). 
 
3.15 Daily corrected upper respiratory tract symptom scores in infected 
subjects between groups 
To assess the effect of RV infection on URT symptom scores in individual groups, 
figure 3.9 illustrates the time course in non-smokers, smokers and COPD subjects.  
The peak URT score (mean difference URT score, 95%CI) occurred on day 4 in non-
smoking controls 4.70 (1.44 to 7.97), p=0.01; on day 5 in smoking controls 6.61 (0.29 
to 12.92), p=0.04 and on day 3 in COPD subjects 3.94 (-0.21 to 8.08), p=0.060. 
 
There was a statistically significant difference in mean URT scores between the three 
study groups on day 15 (p=0.030, one way ANOVA); determined with post hoc 
Tukey‟s analysis to be between non-smokers and smokers (mean difference -2.6, 
95% CI -5.1 to -0.1, p=0.035). 
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Figure 3.8 Corrected total daily URT symptom scores for all infected and non-infected subjects following RV challenge.  Data presented as mean +/- SEM, 
(unpaired t test between infected and non-infected subjects, *p<0.05, **p<0.01) 
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Figure 3.9 Corrected total daily URT symptom scores for infected subjects by group following RV challenge, significant difference between groups on day 15 
in smoking subjects.  Data presented as mean +/- SEM, (one way ANOVA, *p<0.05) 
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To investigate the duration of increased URT symptoms following RV infection the 
time taken for scores to return to baseline has been calculated.  This was performed 
using Kaplan-Meier analysis for the time in days of URT symptom scores to return to 
baseline.  This was not different between the three study groups, p=0.64, log rank 
test, figure 3.10.  It took until day 17, 18 and 21 for half of the subjects in the non-
smoking, COPD and smoking groups respectively to return to baseline scores. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Time to taken to return to baseline for URT symptom scores in all infected 
subjects classified according to study group. Dashed line indicates time at which 50% of the 
subjects returned to baseline symptom scores, (log rank test, p=0.64) 
 
3.16 Daily corrected lower respiratory tract symptom scores in infected and 
non-infected subjects 
The time course of total LRT scores in both infected and non-infected subjects is 
shown in figure 3.11.  There was a trend to a higher mean LRT score in subjects who 
were successfully infected compared to non-infected subjects, but this difference was 
not significant at any time point when analysed with an unpaired t test. 
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3.17 Daily corrected lower respiratory tract symptom scores in infected 
subjects by group 
In infected subjects a one way ANOVA analysis showed a significant difference 
between the mean scores of the three groups on days 2, 3, 14, 15, 18, 19, 34, 35 
and 36, figure 3.12.  Only on day 3 was this associated with a significantly higher 
LRT scores between COPD subjects and non-smoking (mean difference 1.99, 95% 
CI 0.58 to 3.40; p=0.004) and smoking controls (mean difference 1.80, 95% CI 0.22 
to 3.38; p=0.022), when analysed using Tukey‟s test. 
 
The area under the curve (AUC) for the cumulative LRT scores between days 0 and 
7 was significantly higher in the COPD group compared to non-smoking and smoking 
controls, AUC mean (SEM) 15.3 (3.4), 4.8 (1.5), and 6.6 (6.6) respectively, p=0.017, 
assessed using one way ANOVA.  This data demonstrates that acute RV infection 
induces symptoms of an exacerbation in COPD subjects during the first week of 
infection.  Additionally this rise is independent of the possible effects of bronchoscopy 
and pre-morbid symptoms as the scores have been corrected for baseline values.  
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Figure 3.11 Corrected total daily LRT symptom scores for all infected and non-infected subjects following RV challenge, no significant difference between 
infected and non-infected subjects at any time point.  Data presented as mean +/- SEM, (unpaired t test, p>0.05)  
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Figure 3.12 Corrected total daily LRT symptom scores for infected subjects by group following RV challenge, significant between group differences indicated 
on days 2, 3, 14, 15, 18, 19, 34, 35 & 36.  Data presented as mean +/- SEM, (one way ANOVA, *p<0.05, ** P<0.01) 
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In order to evaluate any between group differences in the time taken for symptoms to 
return to baseline levels, a Kaplan Meier plot is shown in figure 3.13.  This illustrates 
the prolongation of LRT symptoms in COPD subjects compared to both smoking and 
non-smoking controls, p=0.05 log rank test.  The time taken for 50% of subjects to 
return to their baseline LRT score was 15, 22 and 35 days in non-smoking controls, 
smoking controls and COPD subjects respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Time taken for return to baseline LRT symptom scores for infected subjects in 
individual study groups.  Dashed line indicates time at which 50% of the subjects returned to 
baseline symptom score, (Log rank test, p=0.05 COPD vs controls) 
 
 
 
3.18 Daily lower respiratory tract score domains in all infected subjects 
When the individual domains of the LRT score were analysed the mean scores in 
individual domains were small and correcting these for baseline levels resulted in 
fractional numbers.  The scoring system is formed from integers and so the reliability 
and clinical utility of this data was uncertain.  Therefore individual domains of the LRT 
score have been presented uncorrected for baseline values. 
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The composite LRT score comprises scores from five individual domains, namely 
breathlessness, wheeze, cough, sputum production and sputum quality as described 
in Material and Methods, chapter 2.  The score of all individual domains in 
successfully infected subjects over the time course of the study is shown, figure 3.14.  
This illustrates a trend to greater burden of symptoms arising from cough in the first 
two weeks following RV infection and from the sputum quality domain after day 24.  
Further conclusions cannot be drawn about individual domains from this data as 
there is considerable overlap in scores; however it is possible to observe that the rise 
in total LRT score following RV infection is driven by increases in all five domains. 
 
3.19 Daily lower respiratory tract score domains in study groups 
The scores for the three study groups in the breathlessness, wheeze, cough, sputum 
production and sputum quality domains are shown in figures 3.15 to 3.19.  The AUC 
for scores between day 0 and 7 was calculated for each study group in the five LRT 
domains.  These were significantly higher in the COPD group compared to the 
control subjects for 4 of the 5 domains.  Specifically AUC for breathlessness (7.1, 0.2 
and 2.8; p=0.003), cough (9.4, 3.3 and 5.2; p=0.031), wheeze (7.1, 0.05 and 1.4; 
p=0.0003) and sputum production (8.2, 1.9 and 4.2; p=0.006) was higher in the 
COPD group that the non-smoking and smoking controls respectively.  Whilst only in 
sputum quality scores was there no significant difference between the AUC of the 
study groups. 
  
97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Individual domains of LRT score in all infected subjects.  Data presented as mean +/- SEM, (one way ANOVA, p>0.05) 
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Figure 3.15 Daily breathlessness scores in infected study groups.  Data presented as mean +/- SEM, (one way ANOVA, p>0.05) 
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Figure 3.16 Daily wheeze scores in infected study groups.  Data presented as mean +/- SEM, (one way ANOVA, p>0.05) 
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Figure 3.17 Daily cough scores in infected study groups.  Data presented as mean +/- SEM, (one way ANOVA, p>0.05) 
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Figure 3.18 Daily sputum production scores in infected study groups.  Data presented as mean +/- SEM, (one way ANOVA, p>0.05) 
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Figure 3.19 Daily sputum quality scores in infected study groups.  Data presented as mean +/- SEM, (one way ANOVA, p>0.05) 
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3.20 Lung function results in infected and non-infected subjects 
Full lung function testing using the helium dilution technique was performed on all 
subjects at baseline and day 12 (+/- 3 days) following RV16 infection at St Mary‟s 
Hospital pulmonary function laboratory.  Testing was performed according to 
BTS/ERS criteria by ARTP accredited technicians.  Subjects also performed 
spirometry on all scheduled clinic visits prior to sputum induction and completed daily 
peak flow and spirometry measurements at home. 
 
The results of formal lung function testing from all subjects enrolled in the study are 
shown in table 3.3.  Data obtained on day 12 has been presented in both infected 
and non-infected subjects, when these results were compared only the TLC was 
found to differ between the groups; being lower in infected compared to non-infected 
subjects (mean difference TLC 0.99L, 95% CI 0.17 to 1.82; p=0.039).  There was no 
significant difference in any of the other parameters (p>0.05). 
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Table 3.3 Full lung function parameters in all subjects at baseline and those successfully and 
not successfully infected with RV at day 12.  Data presented as mean (SEM).  MEF50 Maximal 
expiratory flow at 50%; TLC Total lung capacity; ResV Residual volume; FRC Functional 
residual capacity; DLCO Carbon monoxide diffusion capacity; KCO Carbon monoxide 
diffusion capacity corrected for alveolar volume (*p<0.05) 
 
 
 
 Day 0 Day 12 
 Study entry Non-infected 
subjects 
Infected subjects 
FEV1 (L) 2.69 (0.13) 2.82 (0.26) 2.55 (0.13) 
FEV1 % predicted 93 (4) 92 (7) 92 (4) 
FEV1/FVC ratio, %  67 (2) 65 (3) 67 (2) 
MEF50 % predicted 65 (6) 68 (11) 66 (6) 
TLC, L 6.3 (0.2) 6.9 (0.4) 5.9 (0.2)* 
TLC, % predicted 105 (5) 107 (5) 103 (2) 
ResV, L 2.3 (0.1) 2.3 (0.2) 2.1 (0.1) 
ResV, % predicted 105 (5) 106 (11) 101 (6) 
FRC, L 3.5 (0.2) 3.7 (0.3) 3.3 (0.2) 
FRC, % predicted 110 (6) 114 (10) 108 (5) 
DLCO, ml 
CO/min/mmHg 
6.7 (0.3) 7.0 (0.6) 6.4 (0.3) 
DLCO, % predicted 78 (3) 77 (6) 75 (3) 
KCO, ml 
CO/min/mmHg/L 
1.18 (0.04) 1.13 (0.10) 1.14 (0.04) 
KCO, % predicted 81 (3) 80 (8) 76 (3) 
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3.21 Formal lung function in infected subjects  
The parameters recorded during formal lung function testing pre- and post infection 
are shown in the three study groups in table 3.4.  In the non-smoking control group 
there was no significant change in any measurement between baseline and the day 
12 visit.  Following RV16 infection airway obstruction increased in smokers; with a 
significant fall in FEV1/FVC ratio (mean difference change from baseline 3.4%, CI 
95% 0.3 to 6.4, p=0.034).  In COPD subjects there was a significant decrease in the 
absolute and percent predicted FRC (0.3%, 95% CI 0.6 to 3.3, p=0.031) and (10%, 
95%CI 1 to 20, p=0.042) on day 12 compared to baseline.  Neither of these groups 
had changes in other lung function measurements.   
 
Table 3.4 Full lung function data in successfully RV infected subjects by study group.  Data 
presented as mean (SEM), (paired t test analysis; *p<0.05) 
 Non smokers Smokers COPD 
 Day 0 Day 12 Day 0 Day 12 Day 0 Day 12 
FEV1 (L) 2.80 (0.20) 2.83 
(0.20) 
2.90 (0.19) 2.79 (0.22) 1.97 (0.18) 1.97 
(0.15) 
FEV1 % predicted 111 (4) 112 (4) 100 (3) 97 (4) 65 (5) 66 (3) 
FEV1/FVC ratio, 
%  
72.6 (1.6) 73.5 (2.0) 72.7 (1.0) 69.3 (1.6) * 58.5 (2.6) 57.8 (2.7) 
TLC, L 5.7 (0.3) 5.7 (0.3) 5.8 (0.4) 5.9 (0.5) 6.2 (0.4) 6.1 (0.3) 
TLC, % predicted 103.7 (5.0) 105.4 
(4.7) 
102.9 (3.8) 104.7 (3.2) 97.3 (5.7) 98.4 (4.1) 
RV, L 1.76 (0.14) 1.85 
(0.10) 
1.90 (0.21) 2.06 (0.29) 2.72 (0.24) 2.59 
(0.25) 
RV, % predicted 84.0 (6.2) 89.6 (5.6) 97.7 (9.1) 105.3 
(12.5) 
119.6 
(11.0) 
114.7 
(9.8) 
FRC, L 3.4 (0.4) 3.3 (0.3) 2.6 (0.2) 2.8 (0.3) 4.0 (0.4) 3.7 (0.4) * 
FRC, % predicted 119 (15) 116 (7) 90 (7) 98 (9) 122 (11) 112 (11) * 
DLCO, ml 
CO/min/mmHg 
7.0 (0.5) 7.2 (0.5) 5.8 (0.5) 5.7 (0.4) 6.2 (0.4) 6.0 (0.4) 
DLCO, % 
predicted 
87.8 (3.9) 90.8 (3.5) 65.8 (4.6) 65.6 (3.2) 69.1 (3.7) 67.1 (3.6) 
KCO, ml 
CO/min/mmHg/L 
1.31 (0.07)  1.26 
(0.06) 
1.02 (0.06) 1.04 (0.05) 1.12 (0.06) 1.09 
(0.05) 
KCO, % 
predicted 
88.1 (4.4) 85.1 (5.2) 65.7 (3.2) 66.6 (2.4) 79.8 (4.8) 77.6 (3.9) 
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3.22 Clinic spirometry: FEV1 
Spirometry was performed by trained staff according to BTS criteria on each 
scheduled clinic visit.  Absolute and percent predicted values were analysed for all 
subjects who were judged to have been successfully infected with RV.  Changes in 
spirometry readings between baseline and subsequent clinic visits have also been 
calculated. 
Figures 3.20 and 3.21 demonstrate the absolute and % predicted FEV1 for each 
study group over the study time course.  This illustrates clearly the between group 
difference at baseline and reflects graphically the screening criteria.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Time course of FEV1 values recorded during clinic spirometry in study groups.  
Data presented as mean +/- SEM, (one way ANOVA, p<0.001 between controls and COPD, 
p>0.05 NS and Smk) 
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Figure 3.21 Time course of % predicted FEV1 recorded during clinic spirometry in study 
groups.  Data presented as mean +/- SEM, (one way ANOVA, p<0.001 between controls and 
COPD, p>0.05 NS and Smk) 
3.23 FEV1 change from baseline 
The change in percent predicted FEV1 from baseline in each study group is shown in 
figure 3.22. There was an equal fall of almost 5% in all study groups on day 3.  This 
was a significant drop in non-smoking controls (mean % FEV1 change from baseline -
3.9%, 95% CI -7.4 to -0.3, p=0.035, paired t test).  In COPD subjects the peak 
significant fall occurred on day 15 (mean % FEV1 change from baseline -8.8%, 95% 
CI -16.7 to -0.9, p=0.034, paired t test) and although not statistically significant 
occurred on day 9 in smoking controls (mean % FEV1 change from baseline -10.9%, 
95% CI -22.1 to 0.2, p=0.054, paired t test). 
 
The % FEV1 change from baseline was analysed between groups using one way 
ANOVA.  This did not demonstrate any significant differences between the % 
predicated FEV1 change in study groups at any time point. 
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Figures 3.22 Percent predicted FEV1 change from baseline in study groups over time course 
of study.  Data presented as mean +/- SEM, (one way ANOVA, p>0.05) 
 
To evaluate the effect of RV infection on lung function in the three study groups the 
change in absolute FEV1 from baseline has been plotted in figure 3.23.  In control 
groups (smokers and non-smokers) there was no significant change at any time 
point.  However in COPD subjects there was a significant fall on day 5 (mean 
difference -146mL, 95% CI -276 to -15, p=0.033), day 9 (mean difference -194mL, 
95% CI -327 to -61, p=0.010) and day 15 (mean difference -184mL, 95% CI -337 to -
31, p=0.025), (paired t test). 
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Figures 3.23a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
Figures 3.23b Smoking controls 
 
 
 
 
 
 
 
 
 
 
Figures 3.23c COPD subjects 
Figures 3.23 Change from baseline in FEV1 values over time course of study in (a) non-
smoking controls (b) smoking controls and (c) COPD subjects.  Data presented as mean +/- 
SEM, (paired t test change from baseline, *p<0.05, **p<0.01) 
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3.24 Clinic spirometry – FVC 
The absolute and % predicted FVC over the time course of the study are shown in 
figures 3.24 and 3.25 respectively.  There was no significant difference in absolute 
FVC between study groups across the time points.  The % predicted FVC was lower 
in COPD subjects reflecting the study entry criteria.  These illustrate the fall in FVC in 
cigarette smoke exposed subjects compared to constant levels in non-smokers 
following RV infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24 Change in absolute FVC values over time course of study in study groups.  Data 
presented as mean +/- SEM, (one way ANOVA, p>0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 Change in percent predicted FVC over time course of study in study groups.  
Data presented as mean +/- SEM, (one way ANOVA, p<0.001 between controls and COPD, 
p>0.05 NS and Smk) 
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The change from baseline in FVC is shown in figure 3.26.  The overall trend following 
RV infection in non-smokers showed no change in FVC.  In smoking and COPD 
subjects FVC fell from day 5 to day 21 with a similar magnitude in each group.  There 
was a statistical difference between the mean change from baseline in FVC in the 
study groups on day 12 (p=0.034) and day 15 (p=0.025) using one way ANOVA.  
This did not reach statistical significance on day 9 (p=0.06). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 3.26 Change from baseline in absolute FVC over time course of study in study 
groups.  Data presented as mean +/- SEM, (one way ANOVA, *p<0.05) 
 
3.25 Clinic spirometry – PEF 
Peak expiratory flow (PEF) was performed in addition to spirometry on clinic visits.  
The results of absolute values in each group over the study time course is shown in 
figure 3.27.  This demonstrates a considerable overlap in results between all three 
groups, but a trend to lower mean levels in the COPD subjects and highest levels in 
smoking controls.  When all study subjects were considered there was found to be a 
significant fall from baseline at all time points except day 42.  This illustrates a 
significant increase in airway resistance for 21 days following RV infection in this 
study population, figure 3.28.   
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Figures 3.27 Time course of PEF in study groups.  Data presented as mean +/- SEM, (one 
way ANOVA, p>0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 3.28 Change from baseline in PEF in all RV infected study subjects.  Data presented 
as mean +/- SEM, (paired t test change from baseline, *p<0.05, **p<0.01, ***p<0.001) 
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When the change from baseline was analysed in individual study groups the fall was 
significant in non-smokers on day 9 (p=0.017), 12 (p=0.003) and 15 (p=0.037); in 
smoking controls on day 9 (p=0.04) and in COPD subjects on days 3 (p=0.043), 5 
(p=0.024) and 9 (p=0.007) (paired t test).  The overall trend demonstrates greatest 
fall from baseline in COPD subjects and least in non-smoking controls, figure 3.29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 3.29 Change from baseline in absolute PEF over time course of study in study 
groups.  Data presented as mean +/- SEM, (paired t test change from baseline, NS °p<0.05, 
°°p<0.01, Smk *p<0.05, COPD •p<0.05, ••p<0.01)  
 
3.26 Home spirometry 
Subjects were asked to perform spirometry daily from recruitment to day 42 of the 
study using a hand held spirometer.  The FEV1 values recorded from this data are 
displayed in figure 3.30.  The lower FEV1 in COPD subjects is evident with a decline 
from mean baseline levels occurring at day 6.  It took until approximately day 19 for 
the mean FEV1 to return to baseline values in COPD subjects compared to day 8 in 
control subjects.  The baseline levels have been indicated on the figure for control 
and COPD subjects with a dotted line.  The values in control subjects appear to rise 
in the first week after RV infection.  From approximately day 20 they are higher than 
baseline levels in all subject groups.  This data represents interesting trends but was 
subject to considerable intra subject variation. 
0 3 5 9 12 15 21 42
-100
-75
-50
-25
0
25
NS
Smk
COPD


*



Days post infection
C
h
a
n
g
e
 P
E
F
 f
ro
m
 b
a
s
e
li
n
e
 (
L
m
in
-1
)
114 
 
 
 
 
 
 
 
 
 
 
Figures 3.30 Time course of FEV1 values in study subjects recorded from home spirometry.  
Dashed line represents mean FEV1 at baseline.  Data presented as mean +/- SEM, (one way 
ANOVA, p<0.001 between controls and COPD, p>0.05 NS and Smk) 
 
3.27 Sputum total cell counts 
Results of all non-epithelial cells counted in sputum samples are displayed in this 
section.  These were counted blind to the infection status of the subjects.  The total 
cell count in all infected subjects combined was significantly higher when analysed 
using an unpaired t test on days 9 and 12 than in non-infected subjects.  There was 
no difference between the two groups at other time points, figure 3.31.   
 
When individual subject groups were analysed using a one way ANOVA it was found 
that the mean total sputum cell count was significantly different on days 9, 12 and 15.  
It was greatest in COPD subjects on days 12 and 15, but there was a trend to higher 
levels in COPD subjects throughout the study, and lowest in non-smokers.  In 
smoking controls the count was greater than non-smokers only on day 9, figure 3.32. 
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Figure 3.31 Total non-epithelial sputum cell count in RV infected and non-infected subjects.  
Higher cell counts recorded on days 9 and 12 in infected subjects.  Data presented as mean 
+/- SEM, (unpaired t test, *p<0.05, **p<0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32 Total non-epithelial sputum cell counts in RV infected subjects by study group.  
Significant mean group difference in counts on days 9, 12 and 15.  Data presented as mean 
+/- SEM, (one way ANOVA, *p<0.05, **p<0.01)  
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3.28 BAL volume and total cell counts 
The volume of BAL fluid recovered during bronchoscopy was analysed to evaluate 
between or within group differences.  Excessive variations in recovery of BAL could 
lead to confounders in recovery of cells or mediators measured in these samples.  
The same volume of saline was instilled during each bronchoscopy performed, 
240ml.  Despite a small trend to lower BAL recovery in the COPD group, there was 
no significant difference either between groups or within groups at different time 
points, figure 3.33.  Analysis of mediators measured in BAL will be presented later in 
this work, chapter 5.  Methods of correcting for dilution or variation in cell count vary 
and are not standardised; here they have not been corrected for either the cell count 
or the BAL volume. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33 Volume of BAL recovered during baseline or acute bronchoscopy in infected 
subject groups.  Data presented as mean +/- SEM.  No difference between groups at either 
time point (one way ANOVA) and no difference at time points in individual groups (paired t 
test) 
 
BAL cell counts from infected and non-infected subjects were then examined, figure 
3.34.  No significant difference was found between the infected and non-infected 
groups at baseline.  However on day 7 only the cell count in infected subjects had 
increased significantly from baseline, (p=0.012, paired t test). 
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Figure 3.34 Total BAL cell count at baseline and day 7 in all infected and non-infected 
subjects combined.  Cell count increased significantly only in infected subjects.  Data 
presented as mean +/- SEM, (paired t test, *p<0.05) 
 
3.29 BAL cell count by infected study group 
BAL cell counts from infected subjects in the three study groups were then analysed 
to identify between group differences pre- and post infection.  There was a difference 
between the mean cell counts of all three groups at baseline, p=0.034, (one way 
ANOVA) but not at day 7.  Tukey analysis identified that smoking controls had a 
significantly higher average cell count than non-smoking controls, p=0.019 at 
baseline, figure 3.35.  On day 7 there was a trend to lower counts in the non-smoking 
controls with similar mean cell count in COPD and smoking subjects. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35 Total BAL cell count at baseline and day 7 in infected groups, difference between 
groups at baseline only.  Data presented as mean +/- SEM, (one way ANOVA, *p<0.05) 
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The change in BAL total cell count between baseline and day 7 in individual study 
groups was then analysed, figure 3.36.  There was a significant increase in the mean 
cell count in non-smoking controls between baseline and day 7, p=0.006.  In COPD 
and smoking subjects there was a small increase in the total cell count at day 7 
compared to baseline but this was not significant, (paired t test).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 3.36a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 3.36b Smoking controls 
 
 
0 7
1.5
2.0
2.5
3.0
3.5
Days post infection
L
o
g
1
0
 B
A
L
 c
e
ll
 c
o
u
n
t 
(1
0
6
/L
)
0 7
1.0
1.5
2.0
2.5
3.0
††
Days post infection
L
o
g
1
0
 B
A
L
 c
e
ll
 c
o
u
n
t 
(1
0
6
/L
)
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 3.36c COPD subjects 
Figure 3.36 Total BAL cell count at baseline and day 7 in infected (a) non-smoking subjects, 
(b) smoking subjects and (c) COPD subjects, significant increase from baseline only in non-
smokers.  Data presented as mean +/- SEM, (††p<0.01, paired t test) 
 
3.30 Effect of season on infection rates 
To investigate if the time of year that subjects were experimentally inoculated with 
RV16 had an influence on the rates of successful infection, the total number of 
infected and non-infected subjects were calculated per month, figure 3.37.  This data 
represents the culmination of the period between July 2008 and August 2010.  The 
highest rate of successful infection was achieved during January (3/3 subjects) 
followed by August (8/11 subjects). 
 
However because there was an uneven distribution of inoculation episodes over the 
year and to related infection rates to respiratory virus seasons the infection rates 
were calculated by quarter, figure 3.38.  There was no significant difference between 
quarter 4 & 1 (October to March) and quarter 2 & 3 (April to September) in a chi 
squared analysis, p=0.29.  There was a trend to differences between the groups, with 
the number of successful infections being greater during the spring and summer, and 
a small excess of unsuccessful infections occurring during autumn and winter. 
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Figure 3.37 Number of successfully infected and non-infected subjects by month of 
experimental RV16 inoculation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38 Total number of infected and non-infected subjects inoculated with RV16 by 
season, October to March (quarter 4 & 1) and April to September (quarter 2 & 3), (p=0.29, Chi 
square) 
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3.31 Chapter discussion 
 
In this chapter results for a considerable amount of demographic, symptomatic and 
lung function data has been presented.  The overall screening and recruitment 
statistics for the study are also shown.  This illustrates the large number of subjects 
who were screened to take part in the study but were subsequently not eligible.  
Although there was a large dropout rate between screening and inoculation, the 
study population met the inclusion criteria and are representative of the study groups 
defined.  The demographic data presented for successfully infected subjects shows 
that the COPD and control groups were age and sex matched although between 
control groups the non-smoking subjects were older than smoking controls.  There 
was no difference in baseline spirometry between the two control groups.  The mean 
FEV1 at baseline in the COPD group was 2.08L (69% predicted), demonstrating the 
relatively mild disease severity of this group.  The criteria for defining successful RV 
infection has been maintained from previous studies[164, 291], although due to 
variations in qPCR technique the lower limit of RV detection was greater in this study.  
It is not possible to define infection in an experimental study with complete certainty, 
but there are several reasons to be confident that the definition used in this study 
was accurate.  Those subjects judged to have been infected all met more than one of 
the parameter for defining infection and the majority met them all.  When 
independent makers such as total sputum cell count were analysed, they were found 
to be significantly greater in the infected subjects compared to non-infected subjects.  
This provided further evidence of the accurate definition of RV infection in the study. 
 
Although not intended to form a sham infection group, the non-infected subjects can 
provide evidence of potentially confounding factors involved in the study; such as the 
placebo effect of experimental infection, nasal inoculation and the sample collection 
procedures involved in the project.  The factors which may have predisposed 
subjects not to become infected with RV have not been specifically examined in this 
study; however there are no demographic, symptomatic or spirometric differences 
between these groups to suggest a mechanism for resistance to infection. 
 
3.32 RV infection leads to increased upper and lower respiratory tract 
symptoms 
Initially symptom scores were analysed in five two week blocks over the entire time 
course of the study.  This was done to minimise „noise‟ due to day to day variation in 
scores and to enable comparison of the effect of key study events between time 
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periods.  Specifically the pre-baseline scores represent a period of stable symptoms 
with no study interventions.  The baseline period included the first bronchoscopy and 
the acute period incorporated RV challenge, bronchoscopy and sampling in clinic.  
Recovery and convalescent periods included only occasional clinic sampling.  As 
both the successfully and unsuccessfully infected subjects underwent the same 
procedures the effect of RV infection on upper and lower respiratory tract symptoms 
can be compared.  Additionally comparison between time periods within groups 
makes assessment of the potential impact of a study procedure possible.  Finally this 
provides justification for only correcting URT scores for the impact of bronchoscopy 
on day 7, because when non-infected subjects were considered there is an increase 
between pre-baseline and baseline URT scores not seen in LRT scores. 
 
Only during the acute period was a difference seen in symptom scores between 
infected and non-infected subjects, with statistically greater upper and lower 
respiratory tract scores in infected subjects compared to non-infected.  This provides 
additional evidence that the infected and non-infected groups have been correctly 
defined, as LRT scores did not form part of the criteria for defining infection and no 
subject was defined as being successfully infected or not only on the basis of URT 
scores alone.  The validity of the scoring systems used is also supported by this 
finding as subjects in which RV was not detected had significantly lower scores than 
in those who it was. 
 
3.33 Upper and lower respiratory tract symptoms in non-smoking controls 
This is the first RV challenge study of COPD subjects to include a non-smoking 
control group.  Analysis of the differences in symptom scores between these two 
groups has not been possible previously.  When the two week block data for URT 
scores was analysed there was no statistical difference between these two groups at 
any time point.  However there was a trend to higher scores in COPD subjects in 
every two week block.  URT symptoms have been reported in COPD although are 
not a well recognised feature of the disease.  A study in Sweden randomly screened 
approximately 8500 subjects in the population with a postal questionnaire and 
reported nasal symptoms in 33% of those who replied, amongst self reported 
asthmatics and COPD patients this rose to 45% and 40% respectively[305].  Two 
later studies in the East London COPD cohort reported nasal symptoms of 75% and 
88% in COPD subjects, although these studies lacked a control group, the authors 
were able to conclude that nasal symptoms are common in COPD patients and have 
an adverse impact on quality of life[306, 307].  Interestingly it has been reported that 
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the incidence of nasal symptoms increase with age[308], and these symptoms 
typically occur as a result of degenerative changes, comorbidities or medication side 
effects.  The background rate of URT symptoms reported by non-smokers in the 
study presented here may reflect the increased age in this group and the findings by 
Montnemery et al of nasal symptoms in up to a third of the population.  When non-
infected non-smoking controls are reviewed it is again evident that bronchoscopy has 
a higher than expected impact on URT symptoms, indicated by the increase from 
pre-baseline to baseline scores.  The effect of alternate day nasal lavage and 
induced sputum is noted by comparing baseline to acute time periods, and this had 
little impact on total scores.  If this is extrapolated to the infected subjects it offers 
support to the hypothesis that the increase between baseline and acute periods is 
due to RV infection to the greatest extent and not the sampling procedures per se.  
The main limitation of these conclusions is that the potential placebo effect on 
subjects of RV infection cannot be measured, and may have contributed to an 
excess of symptom reporting.  Post RV infection scores over the full time course of 
the study show no statistical difference in URT symptoms between non-smoking 
controls and COPD subjects.  Between days 4 to 7 the trend is for mean score in 
non-smokers to be greater than COPD subjects but at all other time points in the 
study this pattern is reversed. 
 
LRT scores in non-smokers were less in all two week blocks compared to both other 
groups, and statistically less that COPD subjects during the acute, recovery and 
convalescent time periods.  When the daily LRT scores were studied there was a 
lower mean score in non-smoking controls throughout the full time course of the 
study and this was significantly reduced on days 2, 3, 15, 18 and 19 compared to 
smoking controls and COPD subjects.  The data presented in this chapter therefore 
confirms previous findings in RV challenge studies in COPD of exaggerated 
symptoms consistent with an exacerbation compared to smoking controls[164].  
However the inclusion of a non-smoking control group provides additional 
information, including evidence that LRT symptoms are exaggerated and prolonged 
in non-obstructed cigarette exposed subjects compared to non-smokers. 
 
3.34 RV infection increased lower respiratory tract symptoms only in COPD 
subjects 
When symptom scores in two week blocks was analysed, the total LRT scores had a 
trend to be greater in the COPD subjects at all time points in infected and non-
infected subjects.  The scores were significantly higher in COPD subjects compared 
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to non-smoking controls in the acute, recovery and convalescent periods for both 
infected and non-infected subjects.  The difference between these two groups in non-
infected subjects would not be predicted, but may be explained by several factors.  
There is a modest increase in LRT scores in the COPD group between baseline and 
the acute period which is likely to reflect the influence of frequent sampling and the 
scores then remain unchanged until the end of the study.  However in non-smoking 
controls the trend is for scores to fall from baseline to convalescence, reflecting 
minimal effect of frequent lower airway sampling in non-smokers compared to 
controls.  In addition subject numbers are even smaller in the non-infected group, 
making interpretation of the findings less reliable.   
 
In those subjects who were infected successfully, only during the acute period was 
the LRT scores significantly higher in the COPD subjects compared to both control 
groups.  Additionally only COPD subjects had a significant increase in symptoms 
between the baseline and acute time periods.  In combination this data supports the 
hypothesis that RV infection leads to increased LRT symptom scores in COPD 
subjects and not controls, and that during a two week period after infection features 
of an exacerbation are present.  These two findings were not present in the non-
infected subjects. 
 
There are potential limitations to self reported symptom score data.  Subjects may 
not report symptoms consistently over the duration of the study.  Initial enthusiasm or 
close attention to symptoms in the early part of the study may lead to over reporting, 
but at later time points fatigue or familiarity with symptoms may lead to under 
reporting.  Individual subjects perception of symptoms is likely to vary considerably 
and despite attempts to standardise the scoring system with written definitions there 
was evidence from individuals diary cards of wide variations in symptom scoring.  
The total number of successfully infected subjects was lower than anticipated and the 
small numbers are likely to have an impact on the reliability and reproducibility of 
symptom scores, also reducing the opportunity to identify statistically significance 
differences.  Given these limitations it is possible to conclude that LRT symptom 
scores increase only between the baseline and acute period in COPD subjects and 
that this provides symptomatic evidence of an exacerbation similar in nature to those 
reported in naturally occurring exacerbations. 
 
In addition data presented in chapter 4, Virology and Bacteriology, demonstrated that 
both upper and lower respiratory tract symptom scores correlate strongly with virus 
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load in nasal lavage and sputum respectively.  Although discussed in detail later, this 
adds considerable biological credibility to the symptom scores described in this 
chapter. 
 
3.35 RV infection resulted in impaired spirometry 
Formal lung function testing was performed on one occasion after RV infection and 
did not demonstrate differences compared to baseline in COPD subjects.  The 
absolute falls in lung function tended to be greater in smoking subjects; both in 
airway obstruction (FEV1/FVC ratio) and FEV1.  However when clinic spirometry was 
considered, only the COPD group demonstrated a significant fall in FEV1 compared 
to baseline levels, with absolute falls of 146ml, 194ml and 183ml on days 5, 9 and 15 
respectively.  This was identified on days 5, 9 and 15 and demonstrates the benefit of 
repeated longitudinal measurements in this study.  Interestingly the FEV1 in COPD 
subjects fell significantly from baseline prior to the bronchoscopy on day 7, offering 
supporting evidence that any subsequent changes were not the result of sample 
collection procedures – specifically repeated nasal lavage, induced sputum and a 
bronchoscopy.   
 
Peak flow fell significantly compared to baseline in all RV infected groups on day 9.  
In COPD subjects the PEF was reduced at earlier time points (days 3 & 5) by 44 and 
50 Lmin-1 respectively and the maximum fall compared to baseline occurred on day 
9, with a mean decline of 67Lmin-1.  Only non-smokers had falls in PEF at later time 
points.  The relationship between changes in PEF and FEV1 in the COPD subjects 
raises further questions.  It is possible that earlier falls in PEF may represent 
changes in larger airways followed by small airway abnormalities and reduced FEV1 
later in the time course.  There was a trend to falls in FVC from baseline in smoking 
and COPD subjects and an increase in non-smokers.  The peak fall in COPD was 
210ml on days 9 and 15 and 190ml in smoking subjects on day 9.   
 
Data collected from home spirometry contained considerable daily intra subject 
variation, and therefore its validity could be questioned.  However it is seen that the 
trend is for greater and more prolonged fall in FEV1 only in COPD subjects in data 
collected this way.  In control subjects the values either remained similar or increased 
compared to baseline.  It is not clear why spirometry results recorded in a domiciliary 
and clinic setting should vary so much, other than due to the supervision and 
encouragement of clinical staff, but this has limited further analysis of this data. 
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Overall the spirometric data from this study supports the concept that experimental 
RV infection results in a fall in peak flow in all subjects and markers of obstruction in 
smoke exposed subjects.  Additionally as only the COPD group had a significant fall 
in FEV1 from baseline levels these subjects have spirometric features consistent with 
an exacerbation after RV infection. 
 
3.36 Total sputum and BAL cell counts - Confirmation of successful infection 
Comparing the total non-epithelial sputum cell counts in infected and non-infected 
subjects demonstrated significantly higher counts on days 9 and 12 in infected 
subjects.  In BAL there was a significant increase in cell count between baseline and 
day 7 samples only in RV infected subjects.  Total cell counts in these samples did 
not form part of the criteria for defining successful RV infection and therefore the 
finding of increased cell counts only in infected subjects adds independent support to 
the definition used for successful RV infection.  This conclusion is based on the 
assumption that higher cell counts would be found in RV infected subjects reflecting 
increased inflammation in these subjects compared to the non-infected.   
 
3.37 Sham RV infection 
Although not initially intended to form a control group – the non-infected subjects can 
be considered as a sham infection group as they underwent identical sampling and 
study procedures to those later found to have been infected.  Identification of 
successful infection was performed after subjects had completed the study and so 
subjects and investigators were effectively blinded to infection status during study 
execution.  A weakness of previous virus challenge studies has been the lack of a 
sham infection control group; studies have typically disregard non-infected subjects 
from analysis of the primary outcome[164], although others have included a saline 
control arm[309].  However the increase of approximately 1 point in URT and LRT 
symptom scores between days 0 and 7 in non-infected subjects demonstrates the 
considerable perception of symptoms by study participants.  Enrolled subjects were 
highly motivated and their awareness of symptoms is likely to have been heightened 
during this period, which may have contributed to over reporting or perception of 
symptoms. 
 
The study protocol did not include a sham infection group from the outset and non-
infected subjects were not randomised to receive active RV16 inoculum or not.  
Important limitations should be considered before regarding these subjects as a 
reliable control group.  There may be unmeasured environmental or genetic factors 
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which have induced resistance to infection, and therefore made comparison of 
biological markers with infected subjects unreliable.  Previous studies have reported 
differences in susceptibility to respiratory virus infection measured by many factors 
including psychological stress[309], sleep efficiency[310] and alcohol consumption[3], 
illustrating the range of potential confounding factors. 
 
Despite the potential limitations discussed of using non-infected subjects as a control 
group future work to investigate potential mechanisms of resistance to RV infection 
might be justified.  The inclusion of a double blinded sham control group in the 
protocol of future studies would enable comparisons with successfully infected 
subjects.  This would be particularly useful to investigate biological responses to RV 
infection while eliminating potential confounding factors from sample collection, 
perception of illness and bias from study investigators, but necessitates the use of 
considerable extra time, finances and personnel. 
 
3.38 Sputum total cell counts 
When the sputum cell count between groups was examined in the infected subjects it 
was found that the COPD group had a trend to higher levels throughout the entire 
time course.  There was a significant difference between means of the three groups 
on days 9, 12 and 15; these were significantly greater in COPD subjects on days 12 
and 15.  This reflects a greater burden of lower airway inflammation in these 
subjects, and offers further evidence of features of an exacerbation in COPD 
subjects following RV infection.  Only in non-smoking subjects did the BAL cell count 
increase significantly between baseline and post infection sampling.  This group had 
the lowest counts at baseline, and the increase is likely to reflect the normal immune 
response to infection.   
 
Comparison with published data 
3.39 Lower RV infection rate than anticipated 
A greater than expected number of subjects who entered the study were not 
subsequently defined as being successfully infected with RV16.  In the previous RV 
challenge study of COPD subjects the successful infection rate was 88%[164], 
compared to a rate of 58% in this study.  The reason for this difference is not known, 
and may be multifactorial.  These could include differences in inoculum titre or 
effectiveness of delivery, or may reflect variations in host immunity in a separate 
group of subjects. 
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The method of experimental inoculation was the same in both studies; an identical 
atomizer (DeVillbiss 286, UK) was used and the technique of experimental infection 
was the same, although performed by different individuals.  The successful infection 
of subjects was evenly distributed throughout the whole recruitment period, 
suggesting that there was not a delay in learning or becoming proficient in the 
technique of inoculation.  The RV16 inoculum used in both studies was prepared 
from the same stock.  However this has undergone a series of dilutional steps in 
order to define the lowest infective dose[291].  These aliquots were stored in normal 
saline at –80oC for a period of years and although original RV16 stock had been 
stored for decades at –80oC this had been in a glycerol based vehicle.  The 
differences in storage methods may have led to degradation of the inoculum over 
time, thus contributing to reduced infection rates in this study. 
 
The definition of successful infection and the qPCR technique was maintained 
between both studies; however there are other possibilities for the discrepancy 
between infection rates.  Although RV16 serology was tested in all subjects prior to 
inoculation, a different batch of in vitro RV16 was used to test serology between 
studies and this may have resulted in incomparable titres being recorded.  
Additionally a degree of immune cross reactivity may exist between RV serotypes, it 
is therefore possible that seasonal RV immunity derived from naturally occurring 
colds conferred increased immunity on the subjects recruited in the more recent 
study.  Finally it is not known if the season in which experimental RV inoculation is 
performed has an impact on the rates of successful infection.  Data presented in this 
chapter did not identify a statistically significant difference between infection rates 
and the seasons, but there was a trend to higher infection rates during spring and 
summer suggesting that successful infection maybe more difficult during the time of 
year when community respiratory virus infections are more common.  This indicates 
that an effect similar to herd immunity may be contributing during periods of high 
respiratory tract infections in the community. 
 
3.40 Inclusion of non-smoking control subjects 
This is the first RV challenge study performed in COPD subjects which has included 
a non-smoking non-obstructed control group.  Healthy non-smoking subjects have 
participated in RV challenge studies of asthma[290, 293] and to investigate the 
mechanisms[3, 309] and treatments[311, 312] of the common cold.  However few 
studies have enrolled subjects over the age of 50 years or included a population of 
the age range recruited to this study (40 to 75 years).  The mean age of non-smoking 
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controls was 62 years and therefore older than those in most previous RV challenge 
studies.  It is known from community based studies of respiratory virus infections that 
the elderly experience an increased burden of symptoms and mortality compared to 
younger subjects[313, 314].  The data in this chapter reporting increased LRT 
symptom scores and falls in spirometry following RV infection is supported by 
published studies.  However this data is the first to enable an accurate description of 
the time taken for symptoms to return to baseline levels and a comparison with 
otherwise healthy smoking subjects.   
 
The inclusion of a non-smoking control group in this study adds power and enables 
the investigation of the confounding effects of cigarette smoke exposure.  It is 
recognised that individuals who smoke experience increased symptoms following 
respiratory virus infection compared to non-smokers[2-4].  Comparisons between the 
non-smoking and smoking control group in an otherwise well matched population 
enables evaluation of the effect of cigarette exposure follow RV infection.  
Surprisingly LRT symptoms reached a similar peak in the early time points following 
inoculation, but tended to return to baseline more quickly in non-smoking controls.   
 
Additionally comparison between the non-smoking control group and COPD subjects 
enables investigation of the effect of RV infection in older subjects with no respiratory 
illness and those with a serious respiratory disease, effectively allowing direct 
comparison between the symptoms of a common cold and an exacerbation.  
Because smokers experience an excess burden of symptoms, non-smoking subjects 
are arguably a more appropriate control group for comparison with COPD subjects, 
particularly those who are ex-smokers.  In this study 8 of 9 COPD subjects and all 
smoking controls were active smokers.  Due to the time taken to recruit subjects, no 
attempt was made to manipulate this fraction.  However if greater time and financial 
resources were available, the inclusion of matched ex-smoking COPD and non-
obstructed ex-smokers with active smoking COPD and non-obstructed subjects 
would be preferable.  Comparison between the groups would enable analysis of the 
effects of smoking and remove a potential confounding factor from the present study 
protocol.    
 
3.41 Lower respiratory tract symptom scores 
There is only one published study with similar longitudinal symptom data to that 
presented in this chapter[164].  LRT scores were significantly greater in COPD 
subjects than smoking controls in both studies following RV infection.  However the 
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work presented is chapter has the additional benefit of an age matched non-smoking 
control group.  Comparison with this group has identified an increased LRT symptom 
burden in non-obstructed smokers, demonstrating the adverse effect of cigarette 
smoking on health status following RV infection.  Particularly as in this study non-
smoking controls were older than smoking controls.  Observational studies have 
identified similar findings[2, 4], as has a respiratory virus challenge study[3].   
 
It is of note that LRT symptoms were reported in control subjects following RV 
infection, albeit at a lower rate than in COPD subjects.  Age is likely to contribute to 
this finding; community studies of RV infection in subjects over 40 years have 
reported LRT symptoms at a rate of approximately 65% compared to 34% in subjects 
under 40[264, 314].  In the data presented in this chapter the COPD and individual 
control groups were age matched, but in the study by Mallia et al COPD were older 
than smoking controls.  This may represent another reason for more modest between 
group differences identified in the present study compared to Mallia[164].   
 
The similarity between published data and that described here provides evidence 
that this group of experimentally infected COPD subjects experienced an 
exacerbation.  The LRT scores in these subjects increased following RV infection 
beyond normal day to day variation, which forms an integral part of commonly 
accepted exacerbation definitions[12].  Specifically most published COPD 
exacerbation studied use symptomatic definitions modified from Anthonisen 
criteria[296], namely an increase in two major criteria (dyspnoea, sputum purulence 
or sputum volume) or one major and one minor criteria (nasal discharge, wheeze, 
sore throat, cough or fever) for at least two consecutive days[56, 66, 246, 252, 315, 
316] and in patients admitted to hospital[317-319].  The subjects in this group 
experienced significant increases in breathlessness, cough, wheeze and sputum 
production following RV infection and it can therefore be concluded that they 
experienced LRT symptoms similar in effect to those occurring in naturally occurring 
exacerbations. 
 
3.42 Spirometry 
There are few published studies which present prospective spirometry data from an 
exacerbation and many use a time point following the exacerbation as a surrogate for 
baseline.  Additionally variations in spirometric methodology exist, with both 
domiciliary and clinic data or pre- and post bronchodilator results published.  These 
factors make accurate comparison with the results presented in this chapter difficult.  
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The range of fall in FEV1 in published studies is from approximately 25 to 275ml 
depending on the severity of the exacerbation[246, 318, 320-322]. 
 
Interestingly two studies of hospitalised patients identified similar changes to those 
presented here, with an FEV1 fall of 170ml and peak drop on day 14[320, 322].  So it 
can be concluded that the changes in FEV1 identified in this study are broadly similar 
to those found in published studies.   
 
In this experimental RV challenge study PEF fell by a maximum of 67Lmin-1 on day 9 
in the COPD group, this is larger than in most published studies, where PEF falls of 
up to 9-36Lmin-1 during exacerbations have been reported[218, 246, 323].  In the 
only previous RV challenge study in COPD the PEF fell by 121Lmin-1 on day 9 in 
COPD subjects[164].  However the baseline peak flow was greater in this study 
population.  The effect of bronchodilators and the time point of sampling during the 
course of the exacerbation again makes peak flow data difficult to compare; but the 
falls in this study population are greater or similar to those in the published literature.   
 
FVC fell by a similar amount in smoking controls and COPD subjects in this study; 
this is similar to changes reported in a RV challenge study with identical 
methodology.  Mean falls reported in other studies are around 350ml to 530ml[322, 
323], but these probably reflect more severe exacerbations than those induced in this 
study. 
 
Overall the changes described in spirometry in this study are similar to those in 
published studies; this supports the conclusion that the COPD subjects in this study 
experienced an exacerbation following RV challenge. 
 
3.43 Sputum and BAL counts 
Sampling of the lower airway during naturally occurring COPD exacerbations is 
problematic, particularly because mild episodes can be difficult to identify in the 
community and those with more severe disease are often too unwell to undergo 
sputum induction and particularly bronchoscopy for research purposes alone.  Where 
sputum sampling has been performed in the research setting, results are 
contradictory.  In some studies no increase in cell numbers from baseline to 
exacerbation have been identified[218, 219] while in others an increase at the time of 
exacerbation has been found[140, 324]. 
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No consensus on the nature of cellular inflammation in exacerbations has emerged, 
although the majority have reported neutrophilia[1, 217, 220], others have identified 
eosinophilia[1, 228].  This is perhaps surprising given the burden of disease from 
COPD and the number of studies in the literature.  The finding reflects the intrinsic 
heterogeneity of COPD and the broad spectrum of current COPD definitions.  Two 
other factors which are likely to have a particularly potent effect on the nature of 
cellular inflammation identified during an exacerbation are the broad ranges of 
aetiologies and exposure to treatments, particularly inhaled steroid therapy, both pre- 
and peri- exacerbation.  However the finding of significant increases in sputum cell 
count in this work reflects increased inflammation in the lower airway and is broadly 
supported by findings of increased inflammation in the airway reported in the 
literature.  In BAL this study identified an increase in cell numbers in all infected 
subjects after RV exposure, but only in non-smoking controls was there a significant 
increase with a trend to increasing numbers in smoking and COPD groups.  
Published studies have reported an increase in BAL cell numbers during 
exacerbation compared to stable state[96, 145].  The lack of statistically significant 
increase in BAL total cell count from baseline to exacerbation in this study is likely to 
reflect the small sample size, and the trend to increased numbers is supported by 
those findings in published literature.   
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3.44 Conclusion 
 
In this chapter it has been shown that a group of study subjects were successfully 
infected with RV after experimental challenge.  Within this group 9 COPD subjects 
developed symptomatic, spirometric and inflammatory changes consistent with those 
of a naturally occurring exacerbation.   
 
The work supports previous studies that have identified RV as a potential aetiological 
factor in AECOPD.  There was an increase in severity and duration of LRT scores in 
COPD subjects compared to controls, with greater falls from baseline in spirometry in 
these subjects.  The magnitude of these was similar to that in published studies.  The 
results presented here also demonstrate increased lower airway inflammation in 
COPD subjects compared to controls. 
When compared to published data, the features of an exacerbation presented in the 
chapter are broadly similar and support the conclusion that data obtained from 
subjects in this model can be considered comparable to that which would be found in 
naturally occurring RV induced exacerbations. 
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Chapter 4: Virology and bacteriology 
 
4.1 Introduction 
 
In this chapter I present results of RV detection by quantitative PCR (qPCR) in NL, 
sputum and BAL and detection of bacteria in sputum samples.  The association 
between these will be examined and correlations between RV load and symptoms, 
lung function and sputum cell count illustrated.  The hypothesis examined is that RV 
load is greater in COPD subjects compared to controls and that this leads to an 
increased incidence of secondary bacterial infection with exaggerated respiratory 
symptoms and inflammation in COPD subjects. 
 
Results 
 
4.2 Virus load in all infected subjects 
When all successfully infected subjects were examined; the virus load was found to 
peak on day 3 in nasal lavage and fall at each time point until returning to baseline 
levels by day 21.  In sputum, the peak virus load occurred on day 9, with levels also 
returning to baseline by day 21.  Figure 4.1 illustrates the relationship between 
sputum, nasal lavage and BAL virus load, with peak levels of 7.40, 5.88 and 3.80 
log10 copies/ml respectively.  There was a delay of 6 days between sampling time 
points for peak levels in the upper and lower airway.  This may reflect the time taken 
for RV to infect the lower airway after nasal replication.  The magnitude of virus load 
overall was greatest in sputum.  The lower limit of virus detection (log10 copies/mL) 
was 4.7 in sputum, 2.9 in nasal lavage and 1.1 in BAL; this reflects the dilution of 
samples during processing and analysis. 
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Figure 4.1 Time course of virus load in sputum, nasal lavage and BAL of all successfully 
infected subjects.  Data presented as mean +/- SEM 
 
Figure 4.2 and 4.3 show nasal lavage and sputum virus load over the time course of 
the study in all infected subjects.  They demonstrate a significant increase from 
baseline levels on every time point sampled until day 15.  By days 21 and 42 the 
virus load is unchanged from baseline levels in both nasal lavage and sputum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Time course of virus load in nasal lavage of all successfully infected subjects.  
Significant increase when compared to baseline at time points shown.  Data presented as 
mean +/- SEM, (paired t test, ***p<0.001) 
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Figure 4.3 Time course of virus load in sputum of all successfully infected subjects.  
Significant increase compared to baseline at time points shown.  Data presented as mean +/- 
SEM, (paired t test, *p<0.05, ***p<0.001) 
 
Two time points are available for bronchoscopy shown in figure 4.4.  The virus load 
was found to increase significantly following RV infection, from mean (SEM) of 1.16 
(0.23) to 3.89 (0.34) Log10 copies/mL, (p<0.001). 
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Figure 4.4 Pre and post inoculation virus load in BAL of all successfully infected subjects, 
significant increase compared to baseline on day 7.  Data presented as mean +/- SEM, 
(paired t test, ***p<0.001) 
 
4.3 Nasal lavage virus load in study groups 
When the individual study groups were examined the pattern of virus load in nasal 
lavage was found to be similar between COPD subjects and controls, figure 4.5, and 
showed no statistical difference between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Time course of virus load in nasal lavage of all successfully infected subjects by 
study group.  Data presented as mean +/- SEM, (one way ANOVA, p>0.05) 
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Figure 4.6 presents the change from baseline in nasal lavage for virus load in the 
individual study groups.  There was a significant increase in nasal lavage virus load 
in the non-smokers from days 3 to 12 inclusive, with peak virus load detected on day 
5.  In both smoking controls and COPD subjects the virus load was increased from 
days 3 to 15 inclusive; representing a delay of a three day interval for virus clearance 
compared to non-smoking controls.  The peak level occurred on day 3 in the smoking 
group and day 5 in COPD subjects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6b Smoking controls 
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Figure 4.6c COPD subjects 
Figure 4.6 Time course of change from baseline in virus load from nasal lavage in (a) non-
smoking controls, (b) smoking controls and (c) COPD subjects.  Data presented as mean +/- 
SEM, (paired t test analysis from baseline to study time points, *p<0.05, **p<0.01, ***p<0.001) 
 
4.4 Sputum virus load in study groups 
The virus load in sputum from individual groups is shown in figure 4.7.  This 
illustrates an increase after infection with a peak on day 9.  The magnitude was 
greater in the COPD group throughout the study with a trend to higher levels at most 
time points, and significantly higher levels on day 12 compared to both control groups 
(one way ANOVA, p=0.034).  On day 15 the sputum virus load was greater in COPD 
subjects compared to non-smokers (Post hoc Tukey‟s analysis, p=0.046). 
 
 
 
 
 
0 3 5 7 9 12 15 21 42
0
2
4
6
*
***
*** *** ***
*
Days post infection
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
n
a
s
a
l 
la
v
a
g
e
 v
ir
u
s
 l
o
a
d
(L
o
g
1
0
 c
o
p
ie
s
/m
L
)
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Time course of virus load in sputum of all successfully infected subjects by study 
group.  Data presented as mean +/- SEM, (one way ANOVA between groups at study time 
points, *p<0.05, *Day 12 COPD vs NS and COPD vs Smk, *Day 15 COPD vs NS) 
 
The change from baseline in sputum virus load is displayed in figure 4.8.  This was 
increased significantly in non-smokers from days 5 to 9.  In the smoking control and 
COPD group the levels were significantly higher from days 3 to 12 inclusive. 
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Figure 4.8a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
Figure 4.8b Smoking controls 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8c COPD subjects 
Figure 4.8 Time course of change from baseline in virus load from sputum samples in (a) non-
smoking controls, (b) smoking controls and (c) COPD subjects.  Data presented as mean +/- 
SEM. (paired t test, *p<0.05, **p<0.01, ***p<0.001) 
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There was no difference in the virus load in BAL between the three study groups on 
either day 0 or 7 when analysed using a one way ANOVA, figure 4.9.  There was a 
significant increase for all study groups from baseline to day 7 using a paired t test 
analysis, the fold increase was 3.4 in non-smoking controls (p=0.001), 2.5 in smoking 
controls (p<0.001) and 2.3 in COPD subjects (p=0.020). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Pre and post-inoculation virus load in BAL from successfully infected subjects by 
study group.  Data presented as mean +/- SEM, (paired t test increase from baseline, 
**p<0.01 non-smoking controls, ■■■p<0.001 smoking controls and 
•
p<0.05 COPD subjects) 
 
4.5 Sputum bacterial detection in all study subjects 
Semi-quantitative detection of bacteria in sputum was performed as described in the 
Material and Methods chapter.  No bacteria were detected in baseline sputum 
samples for any successfully RV infected subjects.  Following inoculation 11 of the 
30 RV infected subjects had bacteria detected in any sputum sample over the time 
course of the study.  Of the three study groups there were 6 COPD, 2 smoking 
controls and 3 non-smoking controls with a bacterial isolate, of these, pathogenic 
bacteria were detected in 100%, 0% and 33% of study groups respectively, (as 
described in table 4.1). 
 
To investigate the association between RV and bacterial detection, the time course of 
virus and bacterial loads in all subjects have been plotted in figure 4.10.  This 
demonstrates a peak in virus load at day 9 followed by a peak in bacterial CFU load 
at day 15.  Although the absolute numbers are low, the pattern illustrated is of 
increasing bacterial load in parallel to falling virus load. 
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Figure 4.10 Time course of virus load and bacterial load in sputum of all study subjects 
 
4.6 Relationship between virus load and clinical parameters of disease severity 
As demonstrated in figure 4.10 the peak virus load occurred on day 9.  How this 
relates to bacterial culture in subject groups was investigated by analysing the 
bacterial status (both pathogenic and non-pathogenic) of all sputum samples from 
the study groups from day 9 onwards.  Any subject that had bacteria detected on or 
after day 9 was defined as “bacteria positive” and those with none detected were 
defined “bacteria negative”.  There were significantly more bacteria positive subjects 
in the COPD group compared to the controls, (chi square p=0.04).  Figure 4.11 
illustrates this data. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Number of subjects in each study group with bacteria negative or bacteria 
positive sputum samples at any study time point after day 9 inclusive, (chi square, p=0.04) 
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4.7 Detection of pathogenic bacteria in study groups 
Bacteria positive samples were then classified as either “pathogenic” or “non-
pathogenic” according to species frequently associated with respiratory illness and 
shown in table 4.1.  This shows the number of sputum samples in which any bacteria 
were detected in each of the three study groups.  COPD subjects had significantly 
more pathogenic bacteria in sputum samples when compared to controls, p=0.001 
using chi squared analysis, table 4.1. 
 
 
 
 
 
Table 4.1 Definition of “pathogenic” or “non-pathogenic” bacteria and number of positive 
sputum samples by study group (chi square analysis, p=0.001) 
 
 
 
 
4.8 Virus and bacterial load in COPD subjects  
The virus and bacterial load in COPD subjects over the time course of the study has 
been shown to examine the temporal relationship that exists in figure 4.12.  The peak 
virus and bacterial load occurred on day 9 and day 15 respectively.  There was a 
temporal delay between the two measurements, with increasing bacterial counts 
occurring at a time of falling virus load.  There was no correlation between sputum 
virus and bacteria load in all subjects (r=0.16, p=0.551) or in COPD subjects (r=-0.08, 
p=0.855) in corresponding sputum samples collected at the same time. 
 
 
 Non smokers 
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Figure 4.12 Time course of virus load and bacterial load in sputum of COPD subjects only 
 
 
 
4.9 Correlation of nasal lavage virus load and URT symptom scores in all 
subjects 
To explore the relationship between RV infection and reported subjective symptoms, 
total URT symptom score was correlated with virus load in nasal lavage at each time 
point that the two parameters were recorded simultaneously.  In all infected subjects, 
URT and nasal lavage virus load had a highly significant positive correlation, (r=0.42, 
p<0.001), figure 4.13.  This data suggests that the severity of cold symptoms is 
related to the burden of virus load and supports the validity of symptom scores 
displayed in chapter 3. 
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Figure 4.13 Correlation of nasal lavage virus load and corrected URT scores in all infected 
subjects combined, (r=0.42, p<0.001) 
 
4.10 Correlation of nasal lavage virus load and URT symptom scores in study 
groups 
When individual study groups were examined it was found that the correlation 
between these parameters was maintained in all groups, figure 4.14.  It was highly 
significant (p<0.001) in non-smoking and COPD subjects, with the strongest 
correlation identified in COPD subjects (r=0.52) and weakest in smoking subjects 
(r=0.31). 
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Figure 4.14a Non-smoking subjects, (r=0.50, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14b Smoking subjects, (r=0.31, p=0.022) 
 
 
 
 
 
 
 
 
 
Figure 4.14c COPD subjects, (r=0.52, p<0.001) 
Figure 4.14 Correlation of nasal lavage virus load and corrected URT scores in (a) non-
smoking, (b) smoking and (c) COPD subjects 
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4.11 Correlation of sputum virus load and LRT symptom scores 
Next we analysed the relationship between virus load in sputum and LRT symptom 
scores.  There was a significant correlation between total LRT symptom score and 
virus load in sputum, (r=0.50, p<0.001), at each time point that the two parameters 
were recorded simultaneously.  This was similar to the pattern observed in the upper 
airway, figure 4.15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Correlation of sputum virus load and corrected LRT scores in all subjects (r=0.50, 
p<0.001) 
 
Individual subject groups were analysed for the relationship between LRT scores and 
sputum virus load.  There remained a positive correlation between the two 
parameters in each of the groups.  This was weakest in the smoking control group 
(r=0.35) and strongest and most significant in COPD subjects (r=0.63, p<0.001).  
This matches the findings identified in URT scores; and demonstrates that only the 
COPD group had a strong positive correlation between virus load and symptom 
scores in both the upper and lower airway. 
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Figure 4.16a Non-smoking controls (r=0.38, p=0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16b Smoking controls (r=0.35, p=0.012) 
 
 
 
 
 
 
 
 
 
 
Figure 4.16c COPD subjects (r=0.63, p<0.001) 
Figure 4.16 Correlation of sputum virus load and corrected LRT scores in (a) non-smoking 
subjects, (b) smoking subjects and (c) COPD subjects 
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4.12 Correlation between virus load and pro-inflammatory cytokines 
The full results and discussion of mediators measured using the MSD assay in BAL 
and sputum are presented in the following chapter; however the results of 
correlations between inflammatory cytokines and chemokines with virus load in 
sputum have been included here.  This allows investigation of the association 
between RV infection and airway inflammation.  When the virus load and cytokine 
concentrations in sputum samples were correlated a consistent pattern was 
identified, with positive correlations between virus load and increased cytokine levels.  
For all pro-inflammatory cytokines this was strongest in COPD subjects compared to 
controls, where the relationship was frequently not significant. 
 
4.13 Sputum virus load and TNF- 
The correlation between TNF- and virus load is shown in figure 4.17 for all subjects 
combined and in figure 4.18 for individual groups; the relationship was highly 
significant with a Pearson coefficient of 0.52 in COPD subjects.  However in non-
smoking and smoking controls the association was not statistically significant, r=-
0.01, p=0.90 and r =0.05, p=0.68 respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Correlation of sputum virus load and sputum TNF- concentration in all study 
subjects combined (r=0.27, p<0.001) 
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Figure 4.18a Non-smoking controls (r=-0.01, p=0.904) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18b Smoking controls (r=0.05, p=0.681) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18c COPD subjects (r=0.52, p<0.001) 
Figure 4.18 Correlation of sputum virus load and sputum TNF- concentration in (a) non-
smoking controls, (b) smoking controls and (c) COPD subjects 
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4.14 Sputum virus load and IL1- 
When the relationship between virus load and IL1- was examined a similar pattern 
was found, with a strong association only in COPD subjects and not in controls.  The 
correlation coefficients for COPD subjects and non-smoking and smoking controls 
was (r=0.47, p<0.001), (r=0.23, p=0.054) and (r=0.19, p=0.126) respectively.  Figure 
4.19 shows this for all subjects combined and COPD subjects alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19a All subjects combined (r=0.36, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19b COPD subjects (r=0.47, p<0.001) 
Figure 4.19 Correlation of sputum virus load and sputum IL-1 concentration in (a) all 
subjects combined and (b) COPD subjects 
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The results of all correlations between pro-inflammatory cytokines measured using 
the MSD assay and sputum virus load are shown in table 4.2.  These have been 
ranked by Pearson coefficient in COPD subjects, and illustrates that this group 
demonstrates the strongest association between virus load and inflammatory 
mediators.   
 
 
 
Table 4.2 Pearson‟s correlation coefficient for sputum virus load and inflammatory cytokines 
in the three study groups 
 
4.15 Correlation between virus load and chemokines 
Virus load in sputum was correlated with chemokine mediators measured using the 
MSD assay.  A strong positive correlation was found for IP-10 in all subjects, 
however for all mediators there was consistently a stronger correlation in the COPD 
group compared to controls, table 4.3.  Sputum virus load and IP-10 is shown in 
figure 4.20 for all subjects combined and COPD subjects alone, r=0.49, p<0.001 and 
r=0.54, p<0.001 respectively.  In the individual control groups the results were r=0.48, 
p<0.001 and r=0.44, p<0.001 for non-smoking and smoking controls. 
 
 
 
 
 Non-smoking controls Smoking  controls COPD 
 Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value 
TNF- -0.02 0.904 0.05 0.681 0.52 <0.001 
IL-1 0.23 0.051 0.19 0.126 0.47 <0.001 
IL-10 0.04 0.722 -0.04 0.751 0.38 0.001 
IL-8 0.20 0.099 0.07 0.558 0.38 0.002 
IL-6 0.23 0.060 0.05 0.695 0.36 0.002 
IL-2 0.17 0.158 0.04 0.776 0.35 0.003 
IL-12 0.02 0.873 -0.04 0.749 0.25 0.039 
IFN- -0.15 0.226 -0.02 0.891 0.23 0.056 
GM-CSF 0.04 0.727 -0.08 0.526 0.21 0.080 
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Figure 4.20a All subjects combined (r=0.49, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20b COPD subjects (r=0.54, p<0.001) 
Figure 4.20 Correlation of sputum virus load and sputum IP-10 concentration in (a) all 
subjects combined and (b) COPD subjects 
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A significant positive correlation between MCP-1 and virus load was found in COPD 
subjects, this was stronger than in control subjects, figure 4.21. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21a All subjects combined (r=0.36, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21b COPD subjects (r=0.47, p<0.001) 
Figure 4.21 Correlation of sputum virus load and sputum MCP-1 concentration in (a) all 
subjects combined and (b) COPD subjects 
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The correlations between chemokines measured using the MSD assay and virus 
load are shown in the table.  COPD subjects have a stronger correlation than control 
subjects for all parameters measured, the coefficient being greater than 0.3 for IP-10, 
MCP-1, Eotaxin and MIP-1 and less than 0.3 for MDC, MCP-4, TARC and Eotaxin-
3. 
 
 
 
Table 4.3 Pearson‟s correlation coefficient for sputum virus load and chemokines in the three 
study groups 
 
Chapter discussion 
 
4.16 Virus load in nasal lavage and sputum 
Following experimental inoculation the virus load detected in nasal lavage rose in all 
groups, with values significantly greater than baseline from days 3 to 15.  The peak 
virus load occurred on day 3.  There was no significant difference in nasal lavage 
virus load between the study groups at any time point.  In sputum the virus load was 
significantly higher than baseline levels in all three subject groups on days 5 and 9.  
In smoking controls and COPD subjects the levels were also significantly increased 
on days 3 and 12 compared to baseline.  There was a trend to higher virus load in 
sputum in COPD subjects throughout the study, with a significantly greater mean 
virus load on day 12 compared to both control groups.  There was a delay of 6 days 
between peak virus load in nasal lavage and sputum, occurring on days 3 and 9 
 Non-smoking controls Smoking  controls COPD 
 Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value 
IP-10 0.48 <0.001 0.44 <0.001 0.54 <0.001 
MCP-1 0.27 0.027 0.20 0.118 0.47 <0.001 
Eotaxin 0.20 0.103 0.32 0.011 0.39 <0.001 
MIP-1β 0.21 0.081 0.19 0.130 0.33 0.005 
MDC 0.25 0.039 0.23 0.074 0.28 0.020 
MCP-4 0.09 0.470 0.08 0.542 0.28 0.021 
TARC 0.24 0.053 0.20 0.120 0.28 0.022 
Eotaxin-3 -0.00 0.987 -0.01 0.956 0.12 0.312 
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respectively.  There are several reasons why this may have occurred.  Virus was 
introduced via the nose on day 0; with the peak virus load detected in nasal lavage 
on the first subsequent occasion this was performed.  The falling virus load identified 
after this time point is likely to represent immune clearance and virus shedding from 
the nose.  The highest rate of virus replication may occur in the period immediately 
after inoculation, but this depends on the dose of inoculum delivered.  However as 
sampling was not performed on days 1 and 2 it is not possible to comment exactly on 
the time period of this.  In sputum there is a gradual increase in virus load.  The delay 
between the peak virus loads is likely to occur because of the time taken for virus to 
be transferred from the upper to lower airway.  Given the natural site of RV infection 
is the upper airway; an alternative hypothesis is that the host immunological 
response to RV infection is heightened in the upper airway compared to the lower, 
resulting in more rapid and effective clearance of virus from nasal lavage than 
sputum.  Finally, despite attempts to minimise upper airway contamination by asking 
subjects to rinse their mouth with water following sputum induction prior to sputum 
induction and carefully selecting sputum plugs there remains likely to be virus from 
the upper airway detected in sputum samples and may reflect the relatively rapid rise 
in sputum virus load during the early time course of the study. 
 
When the three study groups were analysed individually, COPD subjects had a trend 
to higher mean virus load in sputum throughout the study, which was significantly 
greater on days 12 and 15.  Additionally COPD and smoking controls had 
significantly higher sputum virus load compared to baseline on more time points than 
non-smoking controls.  The reasons for this are not known, but likely to reflect either 
impaired virus clearance or enhanced virus replication in these subjects.  This could 
occur as the result of deficient immunological responses in subjects exposed to 
cigarette smoke leading to prolongation and excessive virus detection, the greater 
levels in COPD subjects suggest that this mechanism is exaggerated in these 
subjects compared to smokers.  Cigarette exposure induces airway inflammation and 
it is possible this interferes with mechanism of innate immunity.  In a study by Mallia 
et al deficient interferon beta levels in COPD subjects compared to smoking controls 
were identified, representing a possible mechanism for increased virus load in COPD 
subjects.  However no similar data exists comparing smoking and non-smoking 
subjects[164]. 
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4.17 Bacterial infection 
Increased bacterial detection in sputum samples collected at time points after peak 
virus load, suggests a possible causative effect of RV on secondary bacterial 
infection.  The peak bacterial load detected with semi-quantitative analysis was found 
on day 15, a time point 6 days later than the peak virus load in sputum and 12 days 
after the peak in nasal lavage.  The rates of sputum samples with bacteria detected 
are higher than expected, because at baseline none of the subjects had bacteria 
identified sputum samples.  By defining subjects as bacteria positive or negative after 
the peak of RV infection, an investigation of the effect of RV infection on bacterial 
rates was possible.  It was found that significantly more sputum samples from COPD 
subjects had bacteria detected than samples from controls.  In addition, the species 
of bacteria identified in the COPD subjects were exclusively those recognised as 
respiratory pathogens.  In subjects from the control groups where bacteria were 
identified these were most likely to be commensal bacteria or those with uncertain 
respiratory pathogenicity.  None of the subjects required treatment after detection of 
bacteria in their sputum samples.  This suggests that although bacteria were 
detected, the impact on health status in the COPD subjects was unclear. 
 
The role of bacterial infection in exacerbation of COPD is also not fully understood.  
Traditionally thought to be a leading cause of exacerbations, bacteria have been 
detected in the stable state of up to 30% of COPD subjects[325] with higher rates in 
studies of increased disease severity[1].  The high rates of bacterial detection in 
sputum of COPD subjects in this experimental RV infection study illustrates that they 
may indeed play a part in exacerbations.  However the detection of bacteria at time 
points after the peak of upper airway symptoms may have detracted focus from the 
investigation of the role of viruses in the pathogenesis of AECOPD.  This could 
explain why virus infection has been under reported as an aetiological agent in 
exacerbations and why secondary bacterial infection has not been studied in COPD.  
Indeed detected bacteria may represent innocent bystanders in the course of the 
exacerbation. 
 
There was no correlation between virus and bacterial load when this was performed.  
However this is not unexpected as the time course between the two parameters is 
not concordant and at times of high virus load there was minimum bacteria detected.  
Further investigation of the association between virus and bacteria is again limited by 
the number of subjects with bacteria detected, but in future studies, with greater 
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numbers identification of an association between peak virus load and the likelihood of 
developing bacteria positive sputum samples could be performed.   
 
4.18 Correlation between virus load and symptom scores 
Strong correlations between both upper and lower respiratory tract symptoms and 
corresponding virus loads were demonstrated in this chapter.  These were found to 
be most significant and strongest in COPD subjects, with Pearson‟s correlation 
coefficients of r=0.52 and r=0.63 for URT and LRT symptom scores respectively.  
These findings are both biologically plausible and add weight to the hypothesis that 
RV infection has a causative role in driving the symptoms of exacerbation.  The 
symptom score results have been corrected for baseline levels and therefore 
accurately reflect the disease burden during the period of RV infection.  A potential 
confounding factor in the strong correlation only in the COPD might have been a 
higher total score as a consequence of background symptoms.  However this has 
been eliminated by baseline correction of scores prior to data analysis. 
 
The positive correlation identified between virus load in nasal lavage and URT 
symptom scores in all infected subjects provides useful evidence to also support the 
validity of the questionnaire used in the study, furthermore this supports the 
hypothesis that greater URT symptoms are experienced at times of greater virus 
load. 
 
4.19 Correlation between virus load and cytokines and chemokines 
The measurement of inflammatory cytokines and chemokines was performed in 
sputum by the MSD platform as described in the Material and Methods chapter.  The 
results of these assays and the concentrations of the mediators over the time course 
of the study are presented and discussed in detail in chapter 5.  However the 
correlation between the concentration of these mediators in sputum and virus load 
have been included in this section.  These results are included here to illustrate the 
possible consequences of changes in virus load on the mediators studied and to 
enable further discussion of the role of virus infection in study subjects, particularly 
those with COPD in whom higher sputum virus loads and stronger correlations 
between virus load and pro-inflammatory cytokines were seen. 
 
The results are consistent across several mediators and show a stronger positive 
correlation in COPD subjects compared to a weaker or absent correlation in controls.  
These results are intriguing; they suggest that RV infection is driving inflammation in 
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the airways of COPD subjects and that this relationship is not present in controls.  
The data supports the hypothesis that increased inflammation is induced in the 
airways of COPD subjects compared to controls by RV infection and that this leads to 
the excess of symptoms observed in this group.  This suggests direct induction of 
host defence mechanisms in COPD subjects in excess of a normal response to RV 
infection, whilst airway inflammation in healthy controls may not necessarily be driven 
directly by virus load. 
 
Although the strong correlations between pro-inflammatory cytokines and virus load 
in COPD subjects do not prove causality it does offer significant support to the 
concept that exacerbations result from RV infection.  The control subjects did not 
demonstrate significant correlations for any of the inflammatory mediators frequently 
associated with exacerbations.  Concentrations of the inflammatory cytokines IL-1, 
TNF-, IL-6 and IL-8 in sputum were found to peak on day 9 (data presented in 
following MSD results chapter) which coincides with the peak of virus load in sputum 
presented in this chapter and this is borne out by the significant linear correlations 
identified.  Additionally this powerful temporal relationship further suggests that virus 
infection may be responsible for increased levels of IL-1, TNF-, IL-6 and IL-8.  The 
mechanism of action leading to a significant correlation between pro-inflammatory 
cytokines and virus load exclusively in the sputum of COPD subjects has been 
investigated in this chapter.  The data in this chapter has also shown increased virus 
loads in the sputum of COPD subjects, having demonstrated increased LRT 
symptoms consistent with an exacerbation in the previous chapter. 
 
The three cytokines most strongly correlated with virus load in COPD subjects were 
TNF-, IL-1 and IL-8.  These are recognised mediators of inflammation and 
elevated levels have been measured during exacerbations of COPD.  However the 
anti-inflammatory cytokine IL-10 was also found to correlate with virus load.  The 
association with virus load and IL-10 identified in COPD subjects suggests that in 
response to an increase in airway inflammation an appropriate IL-10 driven anti-
inflammatory response can be produced. 
 
In all subjects a positive correlation between IP-10 and virus load existed and this 
was the only mediator examined in which healthy controls have a relationship nearly 
as strong as COPD subjects.  IP-10 has been shown to be a strong marker for virus 
associated exacerbations in asthma and COPD[194, 195, 326].  These findings 
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support the concept that IP-10 has a normal role in host immunity to RV infection.  
For the mediators MDC, MCP-4, TARC and Eotaxin-3, there was a significant but 
weak correlation with virus load in COPD subjects, suggesting that they do not play a 
central role in virus induced inflammation during exacerbations. 
 
4.20 Comparison with published data 
An experimental RV challenge of COPD subjects has been performed 
previously[164].  However this is the first study to include a non-obstructed non-
smoking control group.  This enables the analysis of the confounding effect of 
cigarette smoke following RV infection.  Healthy smoking subjects are known to have 
an increased symptom burden following respiratory virus infection[2-4] and this has 
been borne out by the symptom data shown in this study.  A possible mechanism is 
illustrated in this chapter; high virus loads were found in smoking subjects compared 
to non-smoking controls.  In contrast to the previous study[164], virus load in nasal 
lavage from COPD subjects did not demonstrate significantly higher values 
compared to controls.  However, unlike the previously published work, sampling was 
not performed on day 6 which was the only day on which a significant difference was 
found.  In contrast to other RV challenge studies, the data presented in this chapter is 
the first to demonstrate significantly greater virus load in the sputum of COPD 
subjects compared to non-smoking controls. 
 
The relationship between upper and lower airway virus load has been poorly reported 
in the literature, due to difficulties in obtaining samples over a prolonged time period, 
and delays between upper airway infection and development of LRT symptoms.  In a 
study of naturally occurring exacerbations there was higher viral recovery from 
sputum than nasal lavage samples[218, 253].  This is supported by the data shown in 
this chapter with increasing sputum virus load at a time of greater LRT symptoms.  
However in previously published work by Rohde et al, it is likely that the peak virus 
load in nasal samples was missed in their study of hospitalised patients, whereas the 
frequent sampling of the upper airway in this experimental challenge model 
demonstrates an earlier peak in nasal virus load.  The duration of RV detection in my 
study is comparable with a longitudinal study in children, where virus was detected 
up to 21 days after infection[327].  Finally in a study of asthmatics designed to 
examine the relationship between virus load in the upper airway and lower airway 
symptoms, no association was identified[328].  This suggests that exaggerated LRT 
symptoms in COPD subjects can still occur despite no differences between virus load 
in the upper airway between COPD subjects and controls. 
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The role of RV infection in exacerbations of COPD has become increasingly evident 
in recent years.  The availability of PCR has resulted in respiratory viruses being 
identified in approximately 40% of exacerbations and around 2/3rd are due to RVs[1, 
252].  Detection or viruses at the time of exacerbations has provided evidence that 
these have an aetiological role in exacerbations.  The establishment of an 
experimental RV induced exacerbation model in COPD, however also provides 
causative evidence for this hypothesis.  The finding in this study that COPD subjects 
challenged with RV develop features of an exacerbation further supports this 
hypothesis.  In addition data presented in this chapter is the first to demonstrate an 
association between several inflammatory mediators and virus load.  This strong 
correlation only in COPD subjects will add further evidence to the published literature 
that RV infection results in exacerbation.   
 
4.21 Relationship between RV and bacterial infection 
Many studies have identified respiratory infections as the most common cause of 
exacerbations in COPD[1, 329], however recently the differential roles of bacteria 
and viruses in the aetiology of exacerbations has been debated.  The traditional 
belief that bacterial infection led to exacerbations has been questioned after the 
discovery of high levels of bacteria in stable COPD[325].  Additionally new molecular 
techniques have allowed detection of viruses during exacerbations of airways 
disease and in COPD RV are the virus type most commonly identified[315].  
Interestingly there are no in vivo reports in the literature of bacterial infection 
occurring after RV infection, despite reports of RV infection increasing susceptibility 
to bacterial infection in vitro[262, 330, 331]. 
 
Studies of naturally occurring exacerbations have identified the presence of both RVs 
and bacteria[1, 332], however these studies only sampled at a single time point and 
therefore the temporal relationship between the agents cannot be investigated.  
Although when the identification of co-infection with bacteria and viruses occurred 
this was associated with an increased severity of exacerbations[1].  The temporal 
relationship between peak virus and bacterial load on days 9 and 15 respectively in 
my study supports the concept that RV infection results in secondary bacterial 
infection in COPD subjects at a higher rate than in controls subjects.  
 
An important question the data in this chapter poses is whether bacteria are present 
at baseline and not detected by microbiological culture, or whether they are acquired 
during the time course of the study.  The former would suggest that bacteria are in 
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stable state in the respiratory tract of COPD subjects and RV infection disrupts the 
host defence balance leading to bacterial overgrowth.  While the second concept 
suggests that RV infection creates an environment in which acquisition and growth of 
pathogenic bacteria is favoured.  There is published evidence that bacteria present in 
the airways are not detected by standard microbiological culture techniques[333].  
Thus it is likely that pathogenic bacteria were present in the airways of COPD 
subjects in this study and subsequent RV infection led to alteration in the host 
immune response leading to further growth of bacteria to detectable levels. 
 
Work by Sethi et al report that the acquisition of a new bacterial strain led to an 
exacerbation in a longitudinal study of COPD patients[258].  Higher than expected 
levels of bacterial detection in the stable state can be explained by the data 
presented in this study, as exacerbations were characterised by a change in strain 
type between the stable and exacerbated state.  This however does not provide an 
explanation for the relationship between RV infection and bacterial detection, but 
does indicate that a stable balance may exist between host and bacteria which is 
disrupted by RV infection, leading to subsequent bacterial overgrowth. 
 
In my study there was a second peak in symptoms in COPD subject which although 
small may be attributed to secondary bacterial infection.  A prospective study of 
AECOPD identified RV in 20% of exacerbations and bacteria in 70%; those with co-
infection had higher bacterial loads and increased symptoms than those with bacteria 
alone.  Serum IL-6 was also greater in this group[334].  Finally another study 
identified COPD subjects who were colonised with bacteria and found that nasal IL-8 
and bacteria load were increased[335], in addition upper and lower airway IL-8 levels 
were positively correlated. 
 
4.22 Prophylactic antibiotic therapy in COPD 
There has been interest in using long term prophylactic antibiotics in stable COPD to 
reduce the incidence of exacerbations.  However early studies did not identify a 
benefit and this led to a Cochrane review[336] which concluded there was a small 
benefit but insufficient evidence to support their routine use in clinical practice.  A well 
conducted randomised study using erythromycin did find a reduction in exacerbations 
compared to the placebo group[337], but was underpowered.  The benefits of 
erythromycin in this study appeared to be through an anti-microbial effect rather than 
the class related anti-inflammatory effect.  As individuals were likely to have 
experienced an average of 2-3 common colds per year, the benefit of prophylactic 
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antibiotics may be through reducing the incidence of secondary bacterial infections, 
however to date no studies have investigated this mechanism.  Finally a recent 
randomised trial of azithromycin as prophylaxis for AECOPD over a one year period 
also identified a benefit over placebo with reduction in exacerbation frequency in the 
treatment group.  However there are several uncertainties about the study.  The 
incidence of AECOPD was lower than expected in the placebo group and there was 
an increase in side effects and minimal improvement in respiratory quality of life 
questionnaires in the treatment group.  Additionally there was a high dropout rate 
from both arms of the study and worse than expected compliance, again leading to 
doubts over the reliability and power of the study[338]. 
 
This data suggest that macrolide antibiotics may have a beneficial role in prophylaxis 
against exacerbations.  Whether the effects or macrolide therapy are anti-microbial or 
anti-inflammatory remain poorly understood whilst the role of viruses in these 
exacerbations have not been studied.   
 
4.23 Bacterial species detected in COPD group 
When the species of bacteria detected following the peak virus load was analysed 
there were significantly more pathogenic bacteria identified in the COPD group 
compared to controls.  This difference between the two groups raises interesting 
questions.  In the data presented in this chapter the three species identified in COPD 
subjects were H. influenza, S. aureus and S. pneumoniae and in published studies 
similar species have been identified.  In a study investigating the association 
between sputum purulence and bacterial infection during an AECOPD, species were 
found in the following frequencies: H. Influenza, M. catarrhalis and S. pneumoniae, 
additionally this was applicable across a range of COPD disease severities[325].  
Studies which have associated AECOPD with the acquisition of a new bacterial strain 
have isolated either H. influenza  M. catarrhalis and S. pneumoniae[258].  In other 
studies S. aureus has been reported as a cause of AECOPD, however less 
frequently than those described above[339, 340]. 
 
The identification of H. influenza and S. pneumoniae in this RV challenge study is 
therefore supported by evidence from published studies, however no M. catarrhalis 
was found in sputum samples following RV infection.  There are several possible 
explanations for this.  It is possible that RV infection does not predispose to infection 
with M. catarrhalis, particularly if M. catarrhalis associated exacerbations were due to 
acquisition of the bacteria rather than reactivation of a colonised agent.  An 
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alternative possibility is that the milder disease severity of the subjects in this study 
reduced their risk of M. catarrhalis infection, however data from Stockley et al would 
appear not to support this argument[325].  However the modest number of subjects 
with bacteria detected in my study is the most likely explanation. 
 
Although mechanisms of bacterial infection have not been investigated specifically in 
this study, it would be an important area of future work.  Given the modest 
differences in clinical, spirometric and inflammatory markers between COPD subjects 
and controls at baseline, the striking differences in bacterial species identified 
between the two groups appears to be of utmost importance in the pathogenesis of 
RV induced exacerbations.   
 
4.24 Relationship between virus load and symptom scores 
Studies that have specifically investigated the association between RV and LRT 
symptom scores have typically been in immunocompromised subjects[341, 342].  In 
these studies RVs have been detected during the stable state, and levels above 105 
virus copies/ml in nasal lavage were associated with symptoms of illness.  During 
AECOPD virus detection has been associated with fever[253] but studies of the 
correlation between increased virus load and symptom scores are lacking. 
 
The significant correlation between virus load and symptom scores presented in this 
chapter was not identified in previous RV challenge studies from COPD subjects[164, 
290].  This may reflect differences in the method of data analysis used.  In the study 
presented here all time points for either nasal lavage or sputum collection were 
correlated with upper or lower respiratory tract symptoms for the corresponding day.  
In the published study only the peak virus load was used or peak in LRT symptom 
scores, this results in significantly fewer correlating points and importantly does not 
take into account periods during the study when lower virus load is associated with a 
reduced symptom burden.  This illustrates the difficulty of comparing published 
studies with each other; in this case even though identical study protocols were used 
different methods of data analysis resulted in variations in results. 
 
4.25 Relationship between virus load and cytokines 
No studies with a direct relationship between sputum cytokines and virus load in 
COPD subjects have been published.  A study by Aaron et al identified increases in 
TNF-, IL-8 and MPO during AECOPD compared to stable state; but concluded that 
there were no differences in inflammatory mediators between exacerbations where 
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an infectious agent was or was not identified[343].  A cautious interpretation of these 
findings is required as virus was only detected in 3 subjects and so the reliability of 
this statement is not clear.   
 
An in vitro study of RV infection in cultured tracheobronchial tissue from COPD and 
control subjects demonstrated higher virus titre and copy numbers in COPD tissue, 
which was associated with increases in IL-6 and IL-8 concentrations[134].  
Additionally Schneider et al reported increased interferon beta (IFN-) mRNA 
production in ex vivo COPD tissue compared to control samples but was not able to 
detect IFN- protein in media following RV infection[134].  Interestingly other studies 
have suggested IFN- deficiency as a possible mechanism in RV induced COPD 
exacerbations[164].   
 
Although this data does not allow direct comparison with the positive correlation 
between sputum virus load and inflammatory cytokines reported in this chapter it 
offers in vitro evidence supporting this in vivo data.  The unique nature of an 
experimental challenge study allows collection of samples over the full time course of 
a virus infection and data presented in this chapter illustrates the power of relating 
this to changes in immunological and inflammatory markers. 
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4.26 Conclusion 
 
The results of virus and bacteria studies from nasal lavage and sputum in the study 
group have been presented in this chapter.  The virus load was found to be similar in 
upper airway samples between the three study groups, but COPD subjects had an 
elevated and prolonged virus burden in the lower respiratory tract compared to 
controls.  This is likely to explain the excess of lower respiratory symptoms in this 
group. 
 
A greater number of sputum samples grew bacteria in the COPD group during their 
exacerbation compared to control subjects.  The second striking factor was that all 
bacteria identified in the COPD group were recognised respiratory pathogens 
whereas the opposite was true in controls.  Although this data has not identified a 
causal link or investigated potential mechanisms between RV and bacterial infection, 
the results have provided strong supporting evidence for this hypothesis.  However 
this is an important field in which future work should focus. 
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Chapter 5: Measurement of immune mediators in 
sputum and BAL 
 
5.1 Introduction 
The Meso Scale Discovery platform was used to measure a range of cytokines and 
chemokines as described in chapter 2, Materials and Methods.  The results of 
selected proinflammatory cytokines and mediators of macrophage and virus related 
inflammation have been included in this chapter.  Only data from sputum and BAL 
supernatant of successfully RV infected study subjects are presented in this chapter.  
Differences between groups have been analysed using one-way ANOVA and 
changes from baseline with the paired t test. 
 
Results 
5.2 Sputum supernatant mediators 
All MSD assays in sputum supernatant were performed in duplicate wells and the 
mean concentration calculated, data displayed is corrected for the 9 fold dilution of 
the sputum sample during laboratory processing. 
 
5.3 Pro-inflammatory cytokines in sputum supernatant  
The proinflammatory cytokines IL-1, IL-6, IL-8 and TNF- have been included in this 
section, with mediator concentrations in each study group over the time course of the 
study shown and changes from baseline in the three study groups. 
 
5.4 IL-1in sputum supernatant 
The time course of IL-1 in individual study groups is shown in figure 5.1.  There 
were no differences between groups in sputum IL-1 levels at baseline prior to 
infection.  There was a significant difference between the mean concentration of IL-
1 between groups on day 9 (one way ANOVA, p=0.002: post hoc Tukey‟s analysis 
difference between COPD and non-smoking controls, p=0.002) and 15 (one way 
ANOVA, p=0.008; post hoc Tukey‟s analysis difference between COPD and non-
smoking controls, p=0.006).   
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Figure 5.1 Time course of IL-1 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups, (**p<0.01, **Day 9 COPD vs NS, **Day 15 COPD vs NS) 
 
Changes from baseline in individual study groups are shown in figure 5.2, with 
significant changes for non-smoking controls on day 5 and 21; smoking controls on 
days 5, 9 and 15 and 42; and COPD on days 9 to 42 inclusive. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2a Non-smoking controls 
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Figure 5.2b Smoking controls   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2c COPD subjects 
Figure 5.2 IL-1 changes from baseline for (a) non-smoking controls, (b) smoking controls 
and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001)  
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5.5 IL-6 in sputum supernatant 
The time course of IL-6 in individual study groups is shown in figure 5.3.  There was 
no difference in sputum IL-6 levels between groups at baseline (p=0.748).  There 
were significant differences in the mean concentrations of IL-6 between the three 
study groups on all study visits after infection.  This demonstrated significant 
differences between non-smoking controls and smoking controls in addition to 
differences between non-smoking controls and COPD subjects.   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Time course of IL-6 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, **p<0.01, ***p<0.001) 
 
 
Changes from baseline in individual study groups are shown in figure 5.4.  There 
were significant falls from baseline on days 3 (paired t test, p=0.024), 15 (p=0.044) 
and 42 (p=0.012) in non-smoking controls.  In COPD subjects there was a significant 
increase from baseline on day 9 alone (paired t test, p=0.010).  In smoking controls 
there were no significant increases from baseline at any time point. 
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Figure 5.4a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4b Smoking controls 
 
 
 
 
 
 
 
 
 
 
Figure 5.4c COPD subjects  
Figure 5.4 IL-6 changes from baseline for (a) non-smoking controls, (b) smoking controls and 
(c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01)  
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5.6 IL-8 in sputum supernatant 
The time course of IL-8 in individual study groups is shown in figure 5.5.  There was 
no difference in sputum IL-8 levels between groups at baseline (p=0.623).  There 
were significant differences in the mean concentrations of IL-8 between the three 
study groups on days 9 to 42 inclusive.  Tukey‟s analysis showed that on days 9 and 
12 this difference was between non-smoking controls and COPD subjects (p=0.001 
and p=0.017 respectively) and on days 15, 21 and 42 the difference was between 
non-smoking controls and smoking controls (p=0.048, p=0.041 and p=0.001 
respectively) in addition to non-smoking controls and COPD subjects (p<0.001, 
p=0.022 and p=0.010 respectively).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Time course of IL-8 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, ***p<0.001) 
 
Changes from baseline in individual study groups are shown in figure 5.6.  In 
smoking controls there were significant increases from baseline on days 5, 9, 15 and 
42 (paired t test, p=0.011, p=0.038, p=0.011 and p=0.012 respectively).  In COPD 
subjects there was a highly significant increases from baseline in sputum IL-8 levels 
from days 9 to 42 inclusive (paired t test, p<0.01).  In non-smoking controls there 
were no significant increases from baseline at any time point. 
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Figure 5.6a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6b Smoking controls 
 
 
 
 
 
 
 
 
 
 
Figure 5.6c COPD subjects 
Figure 5.6 IL-8 changes from baseline for (a) non-smoking controls, (b) smoking controls and 
(c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001) 
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5.7 TNF- in sputum supernatant 
The time course of TNF- in individual study groups is shown in figure 5.7.  There 
was no difference in sputum TNF- levels between groups at baseline (p=0.252).  
There were significant differences between the means of the three study groups on 
days 3 to 15 when analysed using a one way ANOVA.  Tukey‟s analysis 
demonstrated that at each of these time points this difference was between non-
smoking controls and COPD subjects and on day 9 there was also a difference 
between smoking controls and COPD subjects (p=0.037).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Time course of TNF- concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, ***p<0.001) 
 
Changes from baseline analysis using the paired t test for non-smoking controls 
showed significant reduction on days 3, 5, 15, 21 and 42.  No significant changes 
from baseline in smoking controls at any time points and significant increases in 
sputum TNF- from baseline at days 5 to 15 inclusive in COPD subjects, figure 5.8. 
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Figure 5.8a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
Figure 5.8b Smoking controls 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8c COPD subjects 
Figure 5.8 TNF- changes from baseline for (a) non-smoking controls, (b) smoking controls 
and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001) 
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Overall the pattern observed post RV infection was similar for IL-1, IL-6, IL-8 and 
TNF- in each study group over the time course of the study.  There were significant 
differences between the mean cytokine concentrations of all three study groups on 
days 9 and 15, with highest levels measured in COPD subjects.  Only the COPD 
group had a significant increase from baseline in all four pro-inflammatory cytokines 
on day 9. 
 
5.8 Pro-inflammatory chemokines in sputum supernatant  
The pro-inflammatory chemokines and mediators related to macrophage activity MIP-
1, GM-CSF and MCP-1 have been included in this section. 
 
5.9 MIP-1 in sputum supernatant  
The time course of study groups is shown in figure 5.9.  There was no difference in 
sputum MIP-1 levels between groups at baseline (p=0.238).  Only on day 9 was 
there a significant difference between the means of the three study groups when 
analysed using a one way ANOVA, p=0.007.  Tukey‟s analysis demonstrated 
differences between non-smoking controls and COPD subjects (p=0.014) and 
smoking controls and COPD subjects, (p=0.017).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Time course of MIP-1 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (**p<0.01) 
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Changes from baseline analysis using the paired t test for non-smoking controls 
showed no significant change at any time points.  In smoking controls MIP-1 
increased significantly from baseline on days 9, 15, 21 and 42 and in COPD on days 
3 and 9 to 21 inclusive, figure 5.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10b Smoking controls 
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Figure 5.10c COPD subjects 
Figure 5.10 MIP-1 changes from baseline for (a) non-smoking controls, (b) smoking controls 
and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001) 
 
 
5.10 GM-CSF in sputum supernatant  
 
GM-CSF levels were not significantly different at baseline between the three groups 
(p=0.871).  The time course of GM-CSF in individual study groups is shown in figure 
5.11.  On days 5 to 42 inclusive there were significant differences between the 
means of the three study groups.  Tukey‟s post hoc test showed differences between 
non-smoking controls and COPD subjects on all of these time points and between 
smoking controls and COPD on day 15 only (p=0.023).  On days 21 and 42 there 
were significant differences between the two control groups.  
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Figure 5.11 Time course of GM-CSF concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, **p<0.01, ***p<0.001) 
 
Changes from baseline using the paired t test showed significant increases in the 
COPD subjects on days 9 to 42 inclusive and in smoking controls on days 21 and 42, 
figure 5.12. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12a Non-smoking controls 
 
0 3 5 9 12 15 21 42
-0.8
-0.6
-0.4
-0.2
-0.0
0.2
0.4
Days post infection
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
L
o
g
1
0
 G
M
-C
S
F
 (
p
g
/m
l)
0 3 5 9 12 15 21 42
1.0
1.5
2.0
2.5
3.0
3.5
NS
Smk
COPD
*
** * *** **
**
Days post infection
L
o
g
1
0
 G
M
-C
S
F
 (
p
g
/m
l)
181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12b Smoking controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12c COPD subjects 
Figure 5.12 GM-CSF changes from baseline for (a) non-smoking controls, (b) smoking 
controls and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test 
analysis for comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001) 
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5.11 MCP-1 in sputum supernatant  
 
The time course of GM-CSF in individual study groups is shown in figure 5.13.  MCP-
1 levels were not significantly different at baseline between the three groups 
(p=0.108).  On days 9, 12 and 42 there were significant differences between the 
means of the three study groups.  Tukey‟s post hoc test showed day 9 differences 
between non-smoking controls and COPD subjects (p<0.001) and smoking controls 
and COPD subjects (p=0.014).  On day 12 the differences were between smoking 
controls and COPD subjects (p=0.028) and on day 42 the difference was between 
the two control groups (p=0.007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Time course of MCP-1 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, **p<0.01, ***p<0.001) 
 
 
 
Changes from baseline using the paired t test showed significant increases in the 
COPD subjects on days 9 to 15 inclusive and in smoking controls on days 5, 9, 15 
and 42, figure 5.14. 
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Figure 5.14a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
Figure 5.14b Smoking controls 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14c COPD subjects 
Figure 5.14 MCP-1 changes from baseline for (a) non-smoking controls, (b) smoking controls 
and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001) 
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5.12 MMP-9 in sputum supernatant 
The time course of the collagenase MMP-9 in individual study groups is shown in 
figure 5.15.  MMP-9 levels were not significantly different at baseline between the 
three groups (p=0.108).  On day 9 there were significant differences between non-
smoking controls and COPD subjects (Tukey‟s post hoc, p=0.013).  On day 15 there 
was a difference between non-smoking controls and COPD subjects in addition to 
smoking controls and COPD subjects (p=0.013 and 0.031 respectively).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 Time course of MMP-9 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, **p<0.01) 
 
 
 
A significant change from baseline using the paired t test was found in non-smoking 
controls on days 3, 5 and 42; in smoking controls on day 15 and in COPD subjects 
on days 9 to 21 inclusive, figure 5.16. 
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Figure 5.16a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
Figure 5.16b Smoking controls 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16c COPD subjects 
Figure 5.16 MMP-9 changes from baseline for (a) non-smoking controls, (b) smoking controls 
and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01) 
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In summary MMP-9, MIP-1, GM-CSF and MCP-1 were all found to change over the 
time course of the study in a similar pattern within each of the three study groups.  
There were trends to higher levels in COPD subjects at most time points throughout 
the study, with significantly higher levels on day 9 for all four mediators listed above.  
Only COPD subjects demonstrated a significant increase from baseline levels on 
days 9, 12 and 15. 
 
5.13 Virus related cytokines in sputum supernatant  
The results of IP-10 and IFN- concentrations in sputum supernatant have been 
selected to illustrate the differences between groups of virus related mediators. 
 
5.14 IP-10 in sputum supernatant 
Levels of IP-10 were not significantly different between the three groups at baseline 
(p=0.059).  The time course of IP-10 in individual study groups is shown in figure 
5.17.  On days 9, 15 and 42 there was a significant difference between the means of 
the three study groups when analysed with one way ANOVA (p<0.001, p=0.003 and 
p=0.013 respectively).  On days 9 and 15 there was a difference between the non-
smoking controls and COPD subjects and on days 15 and 42 there was a difference 
between the two control groups.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17 Time course of IP-10 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (**p<0.01, ***p<0.001) 
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IP-10 concentrations were significantly increased compared to baseline in all three 
study groups on days 5 to 15 inclusive.  Additionally in smoking controls, increases 
from baseline were identified on days 3, 21 and 42 and on day 21 in COPD subjects, 
figure 5.18.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18b Smoking controls 
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Figure 5.18c COPD subjects 
Figure 5.18 IP-10 changes from baseline for (a) non-smoking controls, (b) smoking controls 
and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001) 
 
5.15 IFN-in sputum supernatant 
The time course of IFN-in individual study groups is shown in figure 5.19.  Levels of 
IFN-were not significantly different between the three groups at baseline (p=0.203).  
There was a significant difference between the means of the three study groups on 
days 9, 12, 15 and 21 when analysed using one way ANOVA (p=0.002, p=0.012, 
p=0.012 and p=0.021 respectively).  Post hoc Tukey‟s analysis confirmed that on 
days 9, 12 and 15 the differences were between the two control groups and the non-
smoking and COPD groups.   
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Figure 5.19 Time course of IFN- concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, **p<0.01) 
 
There was no difference in IFN- concentrations between the smoking controls and 
COPD subjects on these time points.  Changes from baseline are shown in figure 
5.20.  This demonstrated reduction in IFN-concentrations in the control groups and 
increased levels compared to baseline in the COPD subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20a Non-smoking controls 
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Figure 5.20b Smoking controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 (a) non-smoking controls, (b) smoking controls and (c) COPD subjects 
Figure 5.20 IFN- changes from baseline for (a) non-smoking controls, (b) smoking controls 
and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test analysis for 
comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001) 
 
5.16 Eosinophil related mediator in sputum supernatant  
Eotaxin-3 in sputum supernatant 
Baseline levels of Eotaxin-3 were not significantly different between the three groups 
(p=0.914).  The time course of Eotaxin-3 in individual study groups is shown in figure 
5.21.  On days 5, 9, 15, 21 and 42 there was a significant difference between the 
means of the three study groups when analysed with one way ANOVA.  Differences 
0 3 5 9 12 15 21 42
-1.0
-0.8
-0.6
-0.4
-0.2
-0.0
0.2
0.4
0.6
0.8
1.0
* *
*
Days post infection
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
L
o
g
1
0
 I
F
N
- 
 (
p
g
/m
l)
0 3 5 9 12 15 21 42
-1.0
-0.8
-0.6
-0.4
-0.2
-0.0
0.2
Days post infection
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
L
o
g
1
0
 I
F
N
- 
 (
p
g
/m
l)
*
*
191 
 
were detected between the two control groups on days 5, 15, 21 and 42, and 
between non-smoking controls and COPD subjects on all these time points.  
Compared to baseline, Eotaxin-3 concentrations were significantly increased on day 
15 in non-smoking controls, days 5, 15, 21 and 42 in smoking controls and on all post 
infection time points in COPD subjects, figure 5.22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21 Time course of Eotaxin-3 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, **p<0.01, ***p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22a Non-smoking controls 
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Figure 5.22b Smoking controls 
 
 
 
 
 
 
 
 
 
 
Figure 5.22c COPD subjects 
Figure 5.22 Eotaxin-3 changes from baseline for (a) non-smoking controls, (b) smoking 
controls and (c) COPD subjects.  Data presented as mean +/- SEM, using paired t test 
analysis for comparison between baseline and study visit (*p<0.05, **p<0.01, ***p<0.001) 
 
5.17 BAL Supernatant Mediators 
All MSD assays in BAL supernatant were performed in duplicate wells and the mean 
concentration calculated.  Correcting for both dilution and variations in the volume of 
BAL samples recovered is controversial, with several methods recognised in the 
literature.  Here to maintain consistency throughout the study the same volume of 
saline was instilled during each bronchoscopy.  There was no significant difference in 
the total volume of BAL recovered either between or within groups, data presented in 
chapter 3.  No correction has been made for the BAL cell count.  Analysis of 
differences between groups at baseline and day 7 were performed using one way 
ANOVA.  Changes from baseline to day 7 in each of the three study groups was 
performed with a paired t test for each mediator presented. 
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5.18 Pro-inflammatory cytokines in BAL 
Results of the proinflammatory cytokines IL-1, IL-6, IL-8 and TNF- in BAL 
supernatant have been included in this section.  The pattern between groups and 
across the time course of the study was similar for each of those examined, however 
only IL-1 had significant differences between the three study groups.  
 
5.19 IL-1 in BAL 
BAL IL-1 levels were significantly different between groups at baseline (p=0.001) 
and day 7 (p=0.010) these differences were between the two control groups, figure 
5.23.  There was no significant increase from baseline to day 7 in any of the study 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23 Pre and post-infection IL-1 concentration in BAL supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (**p<0.01, ***p<0.001) 
 
5.20 IL-6 in BAL 
The concentrations of BAL IL-6 were not significantly different between the three 
study groups at baseline or day 7 and no changes from baseline were detected in 
individual study groups, figure 5.24. 
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Figure 5.24 Pre and post-infection IL-6 concentration in BAL supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups 
 
5.21 IL-8 in BAL 
The concentrations of BAL IL-8 were not significantly different between the three 
study groups at baseline or day 7 and no changes from baseline were detected in 
individual study groups, figure 5.25. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25 Pre and post-infection IL-8 concentration in BAL supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups 
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5.22 TNF- in BAL 
The BAL concentration of TNF- was not different between the three study groups at 
baseline or day 7.  There was a significant increase in TNF- concentrations from 
baseline in non-smoking controls (p=0.006) and COPD subjects (p=0.024), figure 
5.26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26 Pre and post-infection TNF- concentration in BAL supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups.  Paired t test for change from baseline: **p<0.01 non-smoking controls and •p<0.05 
COPD subjects 
 
5.23 Pro-inflammatory chemokines in BAL 
The macrophage related mediators MIP-1, GM-CSF and MCP-1 have been shown 
below. 
 
5.24 MIP-1 in BAL 
The concentrations of BAL MIP-1 were not significantly different between the three 
study groups at baseline or day 7 and no changes from baseline were detected in 
individual study groups, figure 5.27. 
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Figure 5.27 Pre and post-infection MIP-1 concentration in BAL supernatant of individual 
study groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three 
study groups 
 
5.25 GM-CSF in BAL 
The BAL concentration of GM-CSF was not different between the three study groups 
at baseline or day 7.  There was a significant increase in GM-CSF concentrations 
from baseline in COPD subjects (p=0.044), figure 5.28. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28 Pre and post-infection TNF- concentration in BAL supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups.  Paired t test for change from baseline: •p<0.05 COPD subjects 
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5.26 MCP-1 in BAL 
The concentrations of BAL MCP-1 were not significantly different between the three 
study groups at baseline or day 7 and no changes from baseline were detected in 
individual study groups, figure 5.29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.29 Pre and post-infection MCP-1 concentration in BAL supernatant of individual 
study groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three 
study groups 
 
 
5.27 MMP-9 in BAL 
There was no difference in MMP-9 levels between the study groups at either baseline 
or day 7.  From baseline MMP-9 levels increased significantly in all three study 
groups (paired t test, non-smoking controls p=0.008, smoking controls p=0.032 and 
COPD subjects p=0.005), figure 5.30. 
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Figure 5.30 Pre and post-infection MMP-9 concentration in BAL supernatant of individual 
study groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three 
study groups.  Paired t test for change from baseline: **p<0.01 non-smoking controls, 
■■
p<0.01 smoking controls and 
••
p<0.01 COPD subjects 
 
5.28 Virus related cytokines in BAL 
The results of IP-10 and IFN- concentrations in BAL supernatant are shown.  
5.29 IP-10 in BAL 
The concentrations of BAL IP-10 were not significantly different between the three 
study groups at baseline or day 7 and no changes from baseline were detected in 
individual study groups, figure 5.31. 
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Figure 5.31 Pre and post-infection IP-10 concentration in BAL supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups 
 
5.30 IFN- in BAL 
IFN- concentrations were not significantly different between the three study groups 
at baseline or day 7.  Only COPD subjects had a significant increase from baseline, 
p=0.038, figure 5.31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.32 Pre and post-infection IFN- concentration in BAL supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups.  Paired t test for change from baseline: 
•
p<0.05 COPD subjects 
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5.31 Eosinophil related mediators in BAL 
The results of Eotaxin and Eotaxin-3 concentrations in BAL supernatant are shown.  
5.32 Eotaxin in BAL 
BAL Eotaxin levels were significantly different between groups at baseline (p=0.023) 
but not at day 7.  The difference at baseline were between non-smoking controls and 
COPD subjects (p=0.043) and smoking controls and COPD subjects (p=0.033).  
There was no significant increase from baseline to day 7 in any of the study groups, 
figure 5.33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.33 Pre and post-infection Eotaxin concentration in BAL supernatant of individual 
study groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three 
study groups. 
 
5.33 Eotaxin-3 in BAL 
The concentrations of BAL Eotaxin-3 were not significantly different between the 
three study groups at baseline or day 7 and no changes from baseline were detected 
in individual study groups, figure 5.34. 
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Figure 5.34 Pre and post-infection Eotaxin-3 concentration in BAL supernatant of individual 
study groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three 
study groups 
 
5.34 Correlation of pro-inflammatory cytokines and LRT scores 
In chapter 4 it was shown that the virus load in nasal lavage and sputum correlated 
strongly with URT and LRT symptom scores in COPD subjects, (r=0.52, p<0.001) 
and (r=0.63, p<0.001) respectively.  To evaluate the association between 
inflammatory markers in sputum and their possible effect on clinical symptoms, the 
inflammatory cytokines and LRT scores has been correlated in this section. 
 
When all subjects were considered in combination IL-1 and the total LRT score 
were found to have a positive correlation (r=0.38, p<0.001), figure 5.35.  In individual 
groups the relationship was strongest in COPD subjects (r=0.44, p<0.001), followed 
by smoking controls (r=0.37, p=0.006); however the relationship was not maintained 
in non-smoking controls (r=0.03, p=0.788), figure 5.36.  This is likely to reflect 
minimal changes in LRT scores in non-smoking controls during the time course of the 
study. 
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Figure 5.35 Correlation of sputum IL-1 concentration and corrected LRT symptom scores in 
all subjects combined (r=0.38, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.36a Non-smoking controls (r=0.03, p=0.79) 
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Figure 5.36b Smoking controls (r=0.37, p=-0.006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.36c COPD subjects (r=0.44, p<0.001) 
Figure 5.36 Correlation of sputum IL-1 concentration and corrected LRT symptom scores in 
(a) non-smoking controls, (b) smoking controls and (c) COPD subjects 
 
 
A similar pattern was identified when the correlation between TNF- and LRT scores 
was examined.  In all subjects combined the relationship was shown to correlate 
positively (r=0.34, p<0.001), figure 5.37a but this is again driven mainly by COPD 
subjects (r=0.44, p<0.001), figure 5.37b.  Only in non-smoking controls was there no 
correlation between the two parameters (r=-0.08, p=0.525). 
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Figure 5.37a All subjects combined (r=0.34, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.37b COPD subjects (r=0.44, p<0.001) 
Figure 5.37 Correlation of sputum TNF- concentration and corrected LRT symptom scores in 
(a) all subjects combined and (b) COPD subjects 
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The mediators that were found to have the strongest correlation with LRT scores in 
COPD subjects were TNF- and IL-1.  These two markers were also found to 
correlate most strongly when the relationship between LRT scores and sputum viral 
load was examined.  Further evidence that increasing concentrations of inflammatory 
cytokines drives an increase in LRT symptoms is provided in table 5.1.  Here the 
correlation coefficient is found to be greater for all mediators measured in COPD  
subjects compared to the study population.  
 
 
 
 
Table 5.1 Pearson‟s correlation coefficient for LRT symptom scores and inflammatory 
cytokines in the three study groups 
 
 
5.35 Correlation of chemokines and LRT scores 
Calculation of the association between total LRT scores and sputum chemokines 
was performed to investigate the strength of the relationship; data for all chemokines 
measured in the MSD assay are presented in this section.  MCP-1 and IP-10 were 
found to have the greatest correlation coefficient with symptoms score.  
 
The correlation between MCP-1 and total LRT score is shown in for all subjects 
(r=0.32, p<0.001), figure 5.38a and for the COPD group (r=0.39, p<0.001), figure 
5.38b.   
 
 Non-smoking controls Smoking  controls COPD 
 Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value 
TNF- -0.08 0.525 0.33 0.017 0.44 0.001 
IL-1 0.03 0.788 0.37 0.006 0.44 0.001 
IL-10 -0.02 0.854 0.20 0.155 0.40 0.001 
IFN- -0.24 0.046 0.20 0.147 0.36 0.002 
IL-8 -0.10 0.410 0.38 0.005 0.35 0.003 
IL-2 -0.03 0.820 0.36 0.009 0.33 0.005 
IL-6 -0.05 0.671 0.23 0.096 0.29 0.016 
IL-12 -0.14 0.238 0.30 0.029 0.26 0.027 
GM-CSF -0.12 0.343 0.28 0.045 0.24 0.049 
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Figure 5.38a All subjects combined (r=0.32, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.38b COPD subjects (r=0.39, p<0.001) 
Figure 5.38 Correlation of sputum MCP-1 concentration and corrected LRT symptom scores 
in (a) all subjects combined and (b) COPD subjects 
 
When the correlation between IP-10 and LRT score was investigated the results 
were highly significant for all subjects combined, figure 5.39a.  The COPD group had 
the strongest association (r=0.38, p=0.001), figure 5.39b compared to non-smoking 
(r=0.16, p=0.186) and smoking (r=0.40, p=0.004) controls.  The data for all subjects 
combined and the COPD group are shown, figure 5.39. 
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Figure 5.39a All subjects combined (r=0.37, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.39b COPD subjects (r=0.38, p=0.001) 
Figure 5.39 Correlation of sputum IP-10 concentration and corrected LRT symptom scores in 
(a) all subjects combined and (b) COPD subjects 
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In addition to LRT symptom scores concentrations of sputum MCP-1 and IP-10 were 
found to correlate most strongly with sputum virus load, chapter 4.  The Pearson‟s 
coefficient for correlations between all measured chemokines and LRT symptom 
scores is shown in table 5.2.  The COPD group demonstrated the strongest 
association for all parameters measured when compared to controls.  
 
 
 
 
Table 5.2 Pearson‟s correlation coefficient for LRT symptom scores and chemokines in the 
three study groups 
 
 
5.36 Anti-inflammatory cytokine (IL-10) results 
IL-10 is regarded as an anti-inflammatory cytokine, sputum and BAL IL-10 results 
have been included in this final section of the chapter.  The results of mean sputum 
IL-10 concentration from individual study groups is shown in figure 5.40.  There were 
significant differences between the group means on days 5, 9, 12, 15, 21 and 42.  At 
baseline there was a trend to lower mean concentrations in the COPD group; 
following infection the levels increased in this group until a peak on day 9.  In control 
subjects the levels fall immediately following infection.  In non-smokers they remain 
significantly lower on days 3, 5 and 15 following infection.  However in smoking 
controls they increased again to a peak similar to COPD subjects on day 21. 
 
 Non-smoking controls Smoking  controls COPD 
 Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value 
MCP-1 0.00 0.968 0.27 0.053 0.39 0.001 
IP-10 0.16 0.186 0.40 0.004 0.38 0.001 
Eotaxin 0.14 0.255 0.35 0.012 0.37 0.002 
MCP-4 -0.09 0.478 0.32 0.019 0.30 0.010 
MDC 0.16 0.182 0.30 0.032 0.29 0.014 
MIP-1β -0.12 0.314 0.35 0.011 0.27 0.023 
Eotaxin-3 -0.20 0.099 0.33 0.016 0.23 0.056 
TARC 0.09 0.466 0.23 0.104 0.16 0.196 
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Figure 5.40 Time course of IL-10 concentration in sputum supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05, **p<0.01) 
 
5.37 IL-10 in BAL 
BAL IL-10 levels were significantly different between groups at baseline (p=0.034) 
but not at day 7.  The difference at baseline were between smoking controls and 
COPD subjects (p=0.027).  There was a significant increase from baseline to day 7 in 
COPD subjects (p=0.024), figure 5.41. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.41 Pre and post-infection IL-10 concentration in BAL supernatant of individual study 
groups.  Data presented mean +/- SEM, one-way ANOVA analysis between the three study 
groups (*p<0.05).  Paired t test for change from baseline: 
•
p<0.05 COPD subjects 
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5.38 Chapter discussion 
These results demonstrate that the MSD assay can be used to measure cytokines 
and chemokines in sputum and BAL supernatant from in vivo samples following RV 
challenge.  They also illustrate that a wide range of mediators can be measured with 
a minimal (25L) sample volume.  This utilised a new technique in our laboratory and 
to our knowledge is the first to measure samples from an RV challenge study.  There 
is however published data using the MSD technique in sputum supernatant from 
COPD subjects[303].   
 
The major strengths of this data come from its longitudinal nature, with repeated 
measures in sputum samples from the same subjects over time.  The quality of the 
data appeared technically accurate with small between well variations, biologically 
plausible findings and consistent patterns identified in different mediators. 
 
Exaggerated cytokine and chemokine response in COPD subjects 
5.39 Sputum pro-inflammatory cytokines 
In sputum, the pro-inflammatory cytokines IL-1, IL-8 and TNF- were elevated in 
COPD subjects compared to controls on at least two study time points (days 9 and 
15).  In smoking controls, the concentration of IL-1, IL-6 and IL-8 increased in post-
infection samples compared to baseline, however the absolute levels were lower 
than the COPD group.  In non-smokers the levels of inflammatory mediators 
remained static or even fell after RV exposure.  These findings are consistent with 
published studies and provide evidence of increased inflammation in COPD during 
an RV induced exacerbation.  This is the first data comparing inflammatory mediators 
during virus infection in COPD with smoking and non-smoking controls and also 
demonstrates that inflammatory responses to virus infection are enhanced in COPD. 
 
Factors controlling in vitro regulation of inflammatory cytokines may be responsible 
for the elevated levels identified in COPD subjects in this study, and the central 
hypothesis of this work is that reduced HDAC2 activity is a key factor responsible for 
this. 
 
5.40 Sputum pro-inflammatory chemokines 
The patterns of change in concentration seen following RV infection are similar in 
MMP-9, MIP-1, GM-CSF and MCP-1 for all groups over the time course of the 
study.  There was a trend to higher concentrations in the COPD subjects compared 
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to the controls throughout, and these were significantly higher on at least day 9 or 15.  
These findings also mirror those described in pro-inflammatory cytokines.  On days 
9, 12, and 15 only the COPD had a significant increase in post infection levels 
compared to baseline.  The significantly greater levels identified in COPD subjects 
suggests that these may be important mediators in RV induced exacerbations.  This 
data suggests that these mediators are involved in the pathogenesis of an 
exacerbation, as they reflect the clinical and inflammatory pattern with such a strong 
temporal correlation and the levels are greatest in the COPD subjects. 
 
5.41 Virus and eosinophil related mediators 
Eotaxin-3 and IP-10 were found to increase following RV infection, again these 
demonstrated a similar behaviour in COPD subjects, with significantly higher levels 
on days 9 (IP-10) and days 9, 12 and 15 (Eotaxin-3).  The results for IP-10 are 
consistent with those expected, as IP-10 has been found to increase in naturally 
occurring COPD exacerbations, and has been postulated as a possible biomarker 
specifically for RV induced exacerbations[195].  However there have been few 
studies that have examined the changes in Eotaxin and Eotaxin-3 during 
exacerbations of COPD, particularly as interest has focused on its role in asthma and 
allergic diseases.  However despite the selection of non-atopic subjects for inclusion 
into this study Eotaxin-3 levels rise in all groups after RV infection, and to a greater 
extent in COPD.  There is inconsistency in the nature of inflammation identified in 
COPD, but some studies have identified eosinophilia in 30% of exacerbations[228].  
This may therefore offer an explanation for the elevated levels of Eotaxin-3 found in 
COPD subjects. 
 
5.42 BAL samples 
Somewhat unexpectedly the pattern in BAL was different to that found in sputum and 
described above.  Although COPD subjects had the highest concentration of 
mediators in sputum; in BAL the concentration in smoking controls was greater than 
in COPD for all mediators described.  Only COPD subjects had an increase from 
baseline levels following RV16 infection in IL-10 and GM-CSF.  TNF- increased in 
both COPD and non-smoking controls whilst MMP-9 increased from baseline to day 
7 in all three study groups. 
 
Several possible mechanisms for differences between sputum and BAL exist.  
Samples reflect constituents of different airway compartments with induced sputum 
predominantly from large airways of the bronchial tree and BAL from alveolar and 
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small airway compartments.  Alveolar macrophages in COPD subjects may function 
less efficiently and therefore release lower levels of mediators whereas the cells 
upregulated as part of the inflammatory process (particularly neutrophils) produce 
excess mediators in the airways of COPD subjects.  Tissue destruction due to 
emphysema may result in lower levels of inflammatory cytokines found in BAL 
samples from COPD subjects, whereas smoking controls with no emphysematous 
change have increased alveolar inflammation. 
 
RV replication has been shown to occur in the lower respiratory tract, but low virus 
loads were found in BAL compared to sputum, suggesting that the larger airways are 
the main site of RV infection and hence chemo and cytokine production.  Although 
there is only one post infection time point for BAL sputum samples taken both before 
and after this demonstrate elevated mediators suggesting that it is not related to the 
sampling time point of the acute (day 7) BAL.  The data does not suggest that the 
procedure of bronchoscopy itself is leading to increased inflammation in sputum of 
COPD subjects as at time points prior to bronchoscopy (especially day 5) the 
mediators show a trend to higher levels than in smokers. 
 
5.43 Inflammatory mediators correlate with symptom scores 
To investigate which cytokines contribute to clinical illness, I examined the 
relationships between sputum mediators and LRT symptom scores.  It was found that 
IL-1 and TNF- had a strong positive correlation with symptoms only in the COPD 
subjects.  This suggests that these pro-inflammatory mediators have a role in driving 
RV infection and lower airway symptoms during an exacerbation.  The findings are 
surprisingly strong for many other mediators measured (IL-10, IFN-, IL-8 and IL-2) 
suggesting that they too either have a role in inducing or in responding to 
inflammation during an AECOPD. 
 
5.44 Anti-inflammatory cytokine (IL-10) increases in exacerbation 
The pattern of IL-10 following infection is different between the study groups.  In 
COPD subjects the concentration increases from a low baseline but in controls 
appears to fall.  This may be a response to exaggerated inflammation in the COPD 
subjects that is not seen in the other groups.  
 
 
 
213 
 
5.45 Limitations 
Spiking studies using known concentrations of mediators was not performed in 
sputum samples collected as part of this study.  However published data has shown 
that sputum samples processed with DTT using a similar method to the samples 
collected in this study is valid for most mediators[303].  The sensitivity of the MSD 
assay was reduced for Eotaxin, Eotaxin-3 and IFN- detection when DDT was 
present, however the data contains repeated measures with samples processed in 
the same way, so information over the time course of the study remains useful.  The 
final concentration of DTT in sputum samples used in this study were checked with 
MSD technical staff prior to performing the assay and their opinion was that these 
were too low to interfere with assay sensitivity.   
 
Sputum samples analysed in this study have produced rewarding data on time 
courses of change following RV infection, often with greatest between group 
differences on day 9.  However in general data in BAL samples did not demonstrate 
between group differences and this may reflect the sampling process.  Many 
mediators were close to the lower limit of detection in BAL and therefore its 
usefulness in the MSD assay may be questioned. 
 
5.46 Comparison with published studies 
The results described in this chapter cannot be compared directly with published 
literature as there are no studies which report a similar range of mediators over the 
time course of an exacerbation.  However many studies have reported on 
inflammatory cytokines in the sputum and BAL of stable COPD and at a single time 
point during an exacerbation. 
 
5.47 Pro-inflammatory cytokines 
Methods of obtaining samples from stable COPD subjects to compare with 
exacerbation state have varied between studies; some obtaining a pre-exacerbation 
and some a post-exacerbation sample.  Samples collected post-exacerbation risk 
bias if subjects have not returned to baseline levels or insufficient time has lapsed 
following the exacerbation or treatment has been administered.  Those obtaining 
samples pre-exacerbation require recruitment of a large defined population, who 
subsequently experience an exacerbation.  This can lead to over emphasis or 
investigation of a subject cohort, leading to bias from an unrepresentative population.   
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Studies employing both methods have found mediators that are increased in the 
stable state of COPD have all been shown to increase in sputum and BAL during an 
exacerbation particularly TNF-, IL-8, IL-6 and GM-CSF[145, 218, 343-345].  In the 
results presented in this chapter all of these mediators increased above baseline but 
only in the COPD subjects.  Few studies have investigated the time taken for 
inflammatory markers to return to baseline levels, but one study identified increased 
systemic inflammation and elevated symptoms scores 35 days after an exacerbation 
in 23% of their study cohort[346]. 
 
In a study designed to investigate the relationship between the upper and lower 
airway a study by Hurst et al identified a correlation between upper and lower airway 
concentrations of IL-8[335].  In the data reported in this chapter cytokines from nasal 
lavage have not been measured, but these may reveal interesting results if assayed 
in the future.  It is recognised that COPD patients have an excess of nasal symptoms 
and increased concentrations of inflammatory cytokines may be associated with this.  
The demonstration of a correlation between upper and lower inflammatory markers is 
of interest because sampling of the upper airway is likely to prove more practical in 
clinical practice.  However the study by Hurst et al did not demonstrate a correlation 
between upper and lower airway IL-6 levels, so further studies are required in this 
area to understand the reasons for this.   
 
A further study linking breathlessness and plasma cytokines showed that IL-6 and IL-
8 were increased during an AECOPD compared to samples collected during the 
recovery period[318].  This study failed to identify changes in TNF- concentrations 
between exacerbation and recovery sampling.  However comparisons with data 
presented in this chapter is limited because differences are likely to exist between 
plasma and sputum samples. 
 
5.48 Macrophage mediators 
It has been postulated that elevated concentrations of MMP-9 are a mechanism of 
damage in COPD.  An in vitro study using alveolar macrophages from COPD 
subjects and smoking and non-smoking controls supported this hypothesis[139].  The 
data from this RV challenge study demonstrating greater levels in COPD subjects 
appears to support this; however no published studies have yet identified increased 
sputum MMP-9 levels during an exacerbation in vivo.  A study using sputum samples 
collected during stable COPD did not identify differences in MMP-9 or IL-1 
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concentrations between COPD and control subjects, whereas IL-8 levels were 
elevated[347].  Again comparisons with published studies are limited by the lack of 
longitudinal studies during COPD exacerbations.  However the increase in MMP-9 
presented in this chapter suggests that these mediators are involved in the 
pathogenesis or are the sequelae of exacerbations.   
 
Induced sputum samples from COPD patients have been found to have significant 
increases in MPO and IL-8, and non-significant increases in GM-CSF and ECP 
during severe exacerbations[144].  This study by Tsoumakidou et al lacked a control 
group and the subject numbers were relatively small which may indicate why 
increases in GM-CSF were not significant.  Overall however these severe 
exacerbations appear to support the findings in the experimental exacerbation data 
presented here. 
 
5.49 Virus mediators 
In an in vitro and human challenge study of healthy volunteers investigating IP-10 
production by epithelial cells following RV infection, it was concluded that IP-10 was 
released in a RV dose dependent fashion[348].  The finding that IP-10 increased in 
the airway of healthy volunteers following RV infection led to the postulation that this 
may be an important mediator in RV induced exacerbations of airway disease.  The 
data presented in this chapter is the first to do so in COPD subjects and supports the 
findings by Spurrell et al[348]. 
 
5.50 Inflammatory mediators correlate with symptom scores 
No published studies have directly correlated sputum cytokines with respiratory tract 
symptoms.  Inherent in the definition of an exacerbation has been an increase in 
symptoms in those studies where inflammatory cytokines have been measured.  
Obtaining a direct correlation between specific markers and symptoms may lead to 
identification of those cytokines with greater importance in the pathogenesis of 
AECOPD or even identification of different phenotypes of exacerbation.  Many 
studies have attempted to identify a biomarker to confirm an exacerbation[349], 
define the aetiology[195] or grade severity[350] but these have not used sputum 
cytokines.  
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5.51 Conclusion 
 
The data presented in this chapter is novel and interesting.  No reports in the 
literature have included the number of inflammatory mediators measured over the 
time course of an exacerbation as documented here.  The picture of sputum 
inflammatory markers increasing above baseline levels in sputum, and in excess of 
control groups, is seen predominantly in the COPD group during the study time 
course.  This tended to peak between days 9 and 15 and correlated with the peak in 
symptoms, particularly in the COPD group.  The consistent finding of stronger 
correlations between cytokines and symptoms in the COPD group compared to the 
controls suggests that these mediators are driving features of exacerbations in 
COPD subjects. 
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Chapter 6: The role of histone deacetylase enzyme 
activity in rhinovirus induced COPD exacerbations 
 
6.1 Introduction 
 
Investigations of the inflammatory mechanisms responsible for COPD have led to 
interest in enzymes controlling gene expression, particularly the gene repressive 
effect of the histone deacetylase (HDAC) group.  These can act to obscure or expose 
transcriptionally active sites on DNA by controlling histone binding.  Their anti-
inflammatory effect is thought to be mediated through reducing DNA transcription 
and hence inflammatory gene expression.  It has been found that the activity HDAC 
enzymes is reduced in subjects with stable COPD and that this correlates with the 
severity of airflow obstruction[125].  This finding represents a potential mechanism 
for steroid resistance found in COPD[129].  Although little clinical data exists, 
particularly during exacerbations, a randomised study using treatment with 
theophylline, an HDAC activator,  identified reduced levels of TNF- and IL-8 in the 
sputum of the treatment group 3 months after an exacerbation[131].  There were no 
clinical outcomes measured. 
 
In this chapter longitudinal data of HDAC activity in both sputum and BAL over the 
time course of the study is presented.  The hypothesis to be tested is that HDAC 
activity is (i) reduced in both sputum and BAL macrophages from COPD subjects and 
that (ii) following rhinovirus infection this falls further when compared to non-
obstructed control subjects.   
 
Results 
 
HDAC2 isoenzyme activity was measured as described in the Materials and Methods 
chapter and all data shown is corrected for the volume of protein obtained in each 
sample.  This was measured using the Bradford protein assay.  In addition only data 
from successfully RV infected subjects is presented.  All data presented has been log 
transformed prior to analysis with parametric tests. 
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Sputum macrophage HDAC2 activity assays results 
6.2 Sputum HDAC2 activity at baseline in study groups 
To investigate differences between the study groups prior to RV infection the activity 
of HDAC2 at baseline in the three study groups are shown, figure 6.1.  This does not 
demonstrate a significant difference between the groups (one way ANOVA, p=0.095).  
The activity in the COPD group has a trend to the highest activity of the three groups.  
There was no difference in HDAC2 activity between the two control groups at 
baseline.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 HDAC2 activity in sputum macrophages at baseline in individual subject groups.  
Data presented mean +/- SEM, (one way ANOVA, p=0.095) 
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6.3 Time course in sputum HDAC2 activity in infected subjects 
To evaluate the effect of RV infection in the whole study population the level of 
HDAC2 activity in sputum supernatant on scheduled study visits is plotted in figure 
6.2.  When compared to baseline there is a significant and maximal fall in HDAC2 
activity on day 9 following RV infection, (paired t test, p=0.007).  There is a trend to 
increasing levels of HDAC2 activity from day 9 to day 15 when there is a return to 
baseline levels.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Time course of sputum macrophage HDAC2 activity in all RV infected subjects.  
Data presented mean +/- SEM, (paired t test, **p<0.01)  
 
6.4 Time course in sputum HDAC2 activity in study groups 
Sputum HDAC2 activity across the time course of the three study groups is shown in 
figure 6.3.  There was no statistical difference between the groups at any of the time 
points when analysed with one way ANOVA.  However there was a trend to lower 
absolute levels in the COPD group compared to controls following RV infection.  In 
control groups there was similar activity between the two groups, but a trend to 
reduced activity in smoking controls compared to non-smoking subjects following RV 
infection.  
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Figure 6.3 Time course of sputum macrophage HDAC2 activity in individual groups.  Data 
presented mean +/-SEM with no difference between groups demonstrated, (one way ANOVA) 
 
In order to further investigate the overall levels of HDAC2 activity in each group, the 
area under the curve (AUC) for each individual in the study over the whole time 
course was calculated and presented as mean (SEM) AUC for study groups in figure 
6.4.  This does not demonstrate a difference between the three study groups when 
analysed with one way ANOVA; but does confirm the trend to higher levels of 
HDAC2 activity in non-smoking subjects and lower levels in COPD subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Plot of area under the curve for sputum macrophage HDAC2 activity over total 
study time course in individual groups.  Data presented mean +/- SEM.  No difference 
between groups demonstrated, (one way ANOVA, p=0.798)  
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6.5 Change from baseline in sputum HDAC2 activity 
An important measurement of the impact RV infection had on HDAC2 activity is 
derived by calculating the change from baseline on subsequent study visits.  The 
results of baseline HDAC2 activity was therefore subtracted from measurements 
obtained on each study day.  Results of the change from baseline in HDAC2 activity 
from the three study groups is presented for the study time course, figure 6.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Time course of change of sputum macrophage HDAC2 activity from baseline in 
study groups.  Data presented mean +/-SEM, (one way ANOVA, *p<0.05, **p<0.01) 
 
The change from baseline was found to differ in the individual groups, with increased 
activity in non-smoking controls, no difference in smoking controls and a loss of 
activity in COPD subjects, from day 3 onwards.  There was a significant difference 
between the group means on days 3, 15, 21 and 42.  On day 3 this is driven by a fall 
in activity in the COPD group compared to controls and at the later time points by a 
fall in activity in the COPD group and an increase in the non-smoking controls. 
 
6.6 Change from baseline in individual study groups 
The changes in HDAC2 activity from baseline in individual groups have been plotted, 
figure 6.6.  It was found that in non-smoking controls (figure 6.6a) there was an 
increase in HDAC2 activity at early time points following infection; with significantly 
increased levels on day 5 (p<0.05).  Activity returns to baseline levels at day 9 and 
then there is a non-significant trend to increased levels with a second peak at day 15.  
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In smoking controls (figure 6.6b) there was no significant change from baseline at 
any time point following infection; there is a trend to lower HDAC2 activity on day 9.  
In COPD subjects (figure 6.6c), there is a significant fall in HDAC2 activity at all time 
points following infection, except on day 5.  The greatest fall from baseline occurs on 
day 12.  Activity increases after this time point but has still not returned to baseline 
levels by day 42.  This represents a complete reversal of the pattern seen in non-
smoking subjects and is an exaggeration of that seen in smoking controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6a Non-smoking controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6b Smoking controls 
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Figure 6.6c COPD subjects 
Figure 6.6 Change from baseline in sputum macrophage HDAC2 activity after infection in (a) 
non-smoking controls, (b) smoking controls and (c) COPD subjects.  Data presented mean +/- 
SEM. (Paired t test, *p<0.05, **p<0.01) 
 
BAL macrophage HDAC2 activity assays 
6.7 BAL HDAC2 activity at baseline in study groups 
The results of the HDAC2 activity assay from BAL macrophages at baseline have 
been presented for all subjects recruited into the study in figure 6.7a, and for those 
later found to have been successfully infected, figure 6.7b.  There is no difference in 
HDAC2 activity between the study groups at baseline, in either all subjects inoculated 
or in the smaller group of subjects that were successfully infected with RV16, p=0.81 
and p=0.49 respectively measured by one way ANOVA analyses.  These findings 
match those described in baseline sputum macrophages, although the magnitude of 
activity is approximately 2 fold higher in BAL samples. 
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Figure 6.7a All subjects recruited into study 
HDAC2 activity in baseline BAL macrophages from individual subject groups and all subjects 
combined.  Data presented mean +/- SEM, (one way ANOVA, p=0.81)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7b Successfully infected subjects only 
HDAC2 activity in baseline BAL macrophages from individual subject groups and all subjects 
combined.  Data presented mean +/- SEM, (one way ANOVA, p=0.499)   
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6.8 Pre and post-infection HDAC2 activity in BAL in all subjects 
The HDAC2 activity from BAL macrophages in all infected study subjects combined 
at baseline and day 7 is shown, figure 6.8.  There was a trend to reduced activity at 
day 7, but the standard error is large and this change is not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 BAL macrophage HDAC2 activity in all study subjects at baseline and day 7 
(paired t test, p=0.78) 
 
6.9 Pre and post-infection HDAC2 activity in BAL in study groups 
When the individual study groups were studied it was found that each group 
responded differently to RV infection, figure 6.9.  There was no change in activity in 
non-smoking controls.  In smoking controls there was a trend to increasing activity 
after infection, in COPD subjects however there was a trend to lower HDAC2 activity 
post infection.   The fold difference (95% CI) in HDAC2 activity in BAL macrophages 
following infection for non-smokers, smokers and COPD subjects was 1.02 (0.22 to 
4.80) p=0.982; 0.32 (0.04 to 2.30) p=0.294 and 4.52 (0.81 to 25.3) p=0.125 
respectively.   
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Figure 6.9 Time course of BAL macrophage HDAC2 activity in individual groups.  Data 
presented mean +/-SEM 
 
The time course of HDAC2 activity in BAL macrophages from individual study groups 
is shown, figure 6.10.  There is no significant difference between the time points in 
any group.  In non-smoking controls the levels are unchanged following infection, 
whereas in smoking controls there was a trend to higher levels of HDAC2 activity at 
day 7.  The absolute levels of activity on day 7 are the same in both control groups.  
In COPD subjects there was a trend to reduced levels of HDAC2 activity following RV 
infection, displaying the opposite pattern to that seen in smoking controls.  The post 
infection HDAC2 activity in COPD subjects has a trend to lower levels than in 
controls, (p=0.065, one way ANOVA). 
 
 
 
 
 
 
 
 
 
 
Figure 6.10a Non-smoking controls 
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Figure 6.10b Smoking controls 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10c COPD group 
Figure 6.10 Change from baseline in sputum HDAC2 activity after infection in (a) non-
smoking controls, (b) smoking controls and (c) COPD subjects.  Data presented mean +/- 
SEM 
 
6.10 Relationship between sputum HDAC2 activity and airway inflammatory 
cytokines 
To investigate the relationship between sputum macrophage HDAC2 activity and the 
concentration of inflammatory cytokines measured in corresponding sputum 
supernatant samples these parameters have been correlated.  There was 
consistently a strong negative correlation only in the COPD group; data for TNF-, 
GM-CSF and IL-8 are shown in the figures below to illustrate this followed by 
tabulation of correlation data for all cytokines measured using the MSD assay. 
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There was no significant correlation between sputum HDAC2 activity and TNF- 
levels in either control group.  However in COPD subjects there was a strong and 
highly significant negative correlation, (r= -0.53, p<0.001), illustrating that reduced 
HDAC2 activity was associated with increased sputum concentration of TNF- only 
in COPD subjects, figure 6.11. 
 
When sputum GM-CSF was correlated with HDAC2 activity there was again no 
significant relationship in control subjects, but in the COPD group there was a strong 
negative correlation, (r=-0.49, p<0.001), figure 6.12.  The same pattern of results was 
found in sputum IL-8 correlations, where the COPD subjects were found to have a 
negative correlation, (r=-0.49, p<0.001), in contrast to controls, in whom there was no 
significant relationship identified, figure 6.13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11a Non-smoking controls (r= -0.17, p=0.19) 
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Figure 6.11b Smoking controls (r=0.04, p=0.75) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11c COPD subjects (r= -0.53, p<0.001) 
Figure 6.11 Correlation of sputum macrophage HDAC2 activity and sputum TNF- 
concentration in (a) non-smoking controls, (b) smoking controls and (c) COPD subjects 
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Figure 6.12a Non-smoking controls (r=-0.16, p=0.21) 
 
 
 
 
 
 
 
 
 
 
Figure 6.12b Smoking controls (r=-0.003, p=0.98) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12c COPD subjects (r=-0.49, p<0.0001) 
Figure 6.12 Correlation of sputum macrophage HDAC2 activity and sputum GM-CSF 
concentration in (a) non-smoking controls, (b) smoking controls and (c) COPD subjects 
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Figure 6.13a Non-smoking controls(r=-0.09, p=0.48) 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13b Smoking controls(r=0.03, p=0.82) 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13c COPD subjects (r=-0.49, p<0.0001)Figure 6.13 Correlation of sputum 
macrophage HDAC2 activity and sputum IL-8 concentration in (a) non-smoking controls, (b) 
smoking controls and (c) COPD subjects 
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6.11 Relationship between sputum HDAC2 activity and airway anti-
inflammatory cytokine IL-10 
Concentration of the anti-inflammatory cytokine IL-10 in sputum also only correlated 
inversely with sputum HDAC2 activity in COPD subjects (r=-0.47, p<0.001), with no 
significant relationship between the two parameters in controls, figure 6.14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14 Correlation of sputum macrophage HDAC2 activity and sputum IL-10 
concentration in COPD subjects (r=-0.47, p<0.001) 
 
The results of the correlation between HDAC2 activity and cytokines measured in 
sputum using the MSD assay in the study is shown, table 6.1.  This illustrates the 
finding that the correlation coefficients were stronger and highly significant in the 
COPD group compared to the controls for all the mediators presented.  In both 
control groups the correlations were not statistically significant for any of the 
mediators measured. 
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Table 6.1 Pearson‟s correlation coefficient for sputum HDAC2 activity and cytokines in the 
three study groups 
 
 
6.12 Relationship between sputum HDAC2 activity and airway inflammatory 
chemokines 
The results of the correlation between sputum HDAC2 activity and chemokines 
measured in the sputum are displayed in this section.  Only the COPD group had 
significant correlations between the two parameters, and the coefficients were 
negative for all of these.  In COPD subjects the correlations were weaker for all 
chemokines compared with those observed with cytokines, described above.  These 
data suggest HDAC2 regulates pro-inflammatory cytokines more tightly than it does 
chemokines.   
 
The correlation between IP-10 and HDAC2 activity was not significant in the COPD 
group, (r=-0.15, p=0.25), figure 6.15.  This contrasts with the relationships observed 
between IP-10 and virus load and symptoms scores which both correlated strongly 
with IP-10.  These data suggest that HDAC2 does not play an important role in 
regulating increases in IP-10 following RV infection. 
 
 
 Non-smoking controls Smoking  controls COPD 
 Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value 
TNF- -0.17 0.195 0.04 0.750 -0.53 <0.001 
GM-CSF -0.16 0.213 -0.00 0.981 -0.49 <0.001 
IL-8 -0.09 0.480 0.03 0.820 -0.49 <0.001 
IL-6 -0.20 0.127 -0.24 0.069 -0.48 <0.001 
IL-10 -0.25 0.059 0.05 0.731 -0.47 <0.001 
IL-12 -0.15 0.259 -0.04 0.740 -0.45 <0.001 
IL-2 -0.06 0.653 0.04 0.761 -0.45 <0.001 
IL-1 -0.16 0.237 0.14 0.276 -0.41 <0.001 
IFN- -0.03 0.834 0.10 0.436 -0.35 0.005 
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Figure 6.15 Correlation of sputum macrophage HDAC2 activity and sputum IP-10 
concentration in COPD subjects (r=-0.15, p=0.25) 
 
Results of the correlation coefficient for all chemokines measured using the MSD 
assay and HDAC2 activity are shown, table 6.2.  There was no significant correlation 
between the two parameters in either control group.  In COPD subjects the 
correlation was only significant for MIP-1, eotaxin-3 and MCP-4. 
 
 
 
Table 6.2 Pearson‟s correlation coefficient for sputum HDAC2 activity and chemokines in the 
three study groups 
 
 Non-smoking controls Smoking  controls COPD 
 Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value 
MIP-1β 0.01 0.970 -0.20 0.125 -0.34 0.006 
Eotaxin-3 0.04 0.739 0.13 0.313 -0.34 0.007 
MCP-4 0.02 0.904 0.02 0.865 -0.33 0.008 
MCP-1 -0.02 0.879 -0.18 0.166 -0.23 0.066 
MDC -0.04 0.748 0.04 0.739 -0.16 0.206 
IP-10 -0.00 0.988 0.09 0.489 -0.15 0.250 
Eotaxin 0.17 0.195 0.09 0.517 -0.02 0.872 
TARC 0.10 0.476 0.17 0.203 0.17 0.181 
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6.13 Relationship between sputum HDAC2 activity and clinical measurements 
To investigate potential associations between HDAC2 activity and physiological and 
clinical measurements, sputum macrophage HDAC2 activity has been correlated with 
sputum virus load and total cell count; LRT symptom scores and clinic spirometry 
measurements in the three study groups, table 6.3.   
 
 
 
 
Table 6.3 Pearson‟s correlation coefficient for sputum HDAC2 activity and sputum virus load 
and total cell count, LRT symptom scores and clinic spirometry in the three study groups 
 
When all successfully infected subjects were analysed, the correlation of HDAC2 
activity with four spirometric measurements showed a weak positive correlation, 
these were % predicted FEV1 (r=0.22, p=0.004), % predicted FVC (r=0.17, p=0.024), 
PEF (r=0.16, p=0.037) and airflow obstruction, FEV1/FVC, (r=0.21, p=0.005).  In 
individual study groups; no parameters shown in table 6.3 correlated with HDAC2 
activity in smoking controls.  In non-smoking controls and COPD subjects sputum 
TCC demonstrated a significant negative correlated with HDAC2 activity.  In COPD 
subjects only there was a weak positive correlation between PEF and HDAC2 
activity. 
 
Chapter discussion 
6.14 Sputum macrophage HDAC2 activity 
The hypothesis tested in this chapter is that HDAC activity is reduced in COPD 
subjects compared to controls prior to RV infection and that this falls further following 
 Non-smoking controls Smoking  controls COPD 
 Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value Coefficient 
(r) 
p-value 
Virus Load 0.24 0.062 -0.00 0.986 -0.19 0.148 
Sputum TCC -0.29 0.020 -0.24 0.056 -0.42 0.001 
LRT scores -0.05 0.689 0.22 0.168 -0.22 0.075 
FEV1 0.01 0.942 -0.09 0.535 0.19 0.133 
% pred FEV1 0.23 0.077 -0.01 0.952 0.11 0.417 
FVC -0.04 0.745 -0.09 0.537 0.18 0.170 
% pred FVC 0.19 0.161 -0.15 0.296 0.14 0.291 
FEV1/FVC 0.23 0.077 -0.04 0.809 0.07 0.603 
PEF 0.06 0.628 0.01 0.940 0.26 0.044 
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successful experimental inoculation.  The data shown in this chapter did not 
demonstrate a difference in HDAC2 activity in sputum or BAL macrophages between 
the three study groups at baseline.  The trend to a small increase in HDAC2 activity 
in sputum macrophages from COPD subjects was the opposite finding to that 
expected.  The reasons for this result are not known.  It may reflect the relatively mild 
severity of COPD subjects enrolled in the study, in whom HDAC activity had 
increased appropriately in response to inflammation.  Although published studies 
have demonstrated reduced HDAC activity in GOLD stage II COPD subjects, the 
population in this study were not receiving any medications including steroids and 
had relatively mild baseline symptoms.  There are likely to be many disease 
phenotypes within the diagnostic umbrella of COPD and differences in HDAC activity 
within these groups may exist.  Within this study and published work the total number 
of COPD subjects and controls is relatively small, so the true differences in HDAC 
activity within COPD phenotypes may not be apparent.  Finally although subject 
numbers are greater in BAL when non-infected subjects are included, the total 
number of COPD subjects in this study is relatively small.  The comparison between 
this data and published literature is described below. 
 
Following RV challenge the activity of HDAC2 falls when the successfully infected 
study population in entirety is considered, with a peak and significant drop on day 9.  
When individual groups were considered the hypothesis was proved correct as only 
in COPD subjects did HDAC activity fall compared to baseline levels.  Interestingly 
the activity of HDAC was the opposite in non-smoking controls, with a significant 
increase from baseline levels, in smoking controls HDAC activity was largely 
unchanged following infection.  There was not a significant difference in absolute 
HDAC2 activity between the groups or the area under the curve for the entire study 
period, but this is likely to reflect (a) the small sample size, (b) the wide variation in 
results within groups and (c) the relatively mild severity of the COPD group.  
However a change in activity from baseline in the same subject group repeatedly 
sampled provided robust evidence for differences in HDAC activity between groups 
in response to RV infection. 
 
This data therefore provides interesting results, suggesting that the normal response 
to RV induced inflammation is to increase HDAC activity to counter act this.  In 
smoke exposed subjects the normal response is blunted and in COPD it is lost 
completely.  The data described in this chapter does not provide a mechanism for 
this, but the central hypothesis of the thesis is that cigarette exposure and additional 
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oxidative stress in COPD subjects drives, at least in part this loss of HDAC activity.  
Although the data provided here does not confirm this mechanism, it has been shown 
that COPD subjects experience greater symptoms, RV load and inflammatory 
cytokines compared to smoking non-obstructed control subjects.  In the following 
chapter, evidence is presented for increased oxidative and nitrative stress in the 
COPD population, further supporting this mechanism. 
 
6.15 BAL macrophage HDAC2 activity 
Although none of the changes in HDAC activity in BAL macrophages were 
significant, there was a trend to reduced activity after RV infection in the COPD 
group.  An unexpected finding was a trend to increased activity in the smoking 
control group following infection; this is the opposite finding to that seen in sputum 
macrophages, the reasons for this are not clear.  If subsequently shown to be a 
significant finding, HDAC activity in sputum and BAL macrophages may differ due to 
specific environmental variations in local lung compartments.  For example sputum 
macrophages from large airways are directly exposed to a greater burden of cigarette 
smoke and replicating RV than those in smaller airways and the alveolar 
compartment.  This could lead to abnormal activity in sputum macrophages while 
function is maintained in those from the lower airway. 
 
The alternative hypothesis is that retention of a normal response in BAL macrophage 
HDAC activity to RV infection is a factor in protecting this group from exaggerated 
inflammation and symptoms of an exacerbation identified in the COPD group.  
Finally, the development of airway obstruction is a dynamic process.  Smoking 
controls that presently have normal spirometry may progress to airway obstruction in 
association with worsening airway inflammation and a loss of HDAC activity in both 
BAL and sputum macrophages. 
 
6.16 Correlation of HDAC2 activity with cytokines and chemokines 
The known action of HDAC enzymes to reduce transcription of inflammatory genes 
lead to the hypothesis that reduced HDAC2 activity will correlate with increased 
concentrations of inflammatory cytokines[351].  Data has been published to support 
this hypothesis at a single time point[125], but not during the time course of a COPD 
exacerbation.  Although only demonstrating an association, the data displayed in this 
chapter supports the concept that reduced HDAC activity is associated with 
increased levels of inflammatory cytokines in sputum.  Interestingly only the COPD 
group demonstrate significant correlations, which were strong for several key 
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mediators recognised to be important in the pathogenesis of exacerbations, 
particularly TNF-, GM-CSF and IL-8.  The lack of association in the control groups 
suggests that only in COPD subjects is HDAC2 deficiency resulting in the production 
of cytokines and subsequent cellular inflammation.  Overall the data in this chapter 
strongly supports the rationale that a reduction in HDAC activity has a central role in 
the pathogenesis of RV induced COPD exacerbations.  Following RV infection only 
the COPD group were found to have a significant fall in HDAC2 activity, this was 
associated with statistically significant increases in inflammatory cytokine 
concentrations only in the sputum of COPD subjects, for example IL-1, IL-6, IL-8 
and TNF- results of which are presented in the previous chapter.  Additionally both 
virus load and clinical symptoms representative of an exacerbation have been shown 
to correlate with inflammatory cytokines only in the disease group.  Therefore 
although these correlations have not been able to attribute direct causation, they do 
support the hypothesis that exaggerated symptoms in COPD subjects following RV 
infection are related to reductions in HDAC activity.  Performing further studies to 
identify potential mechanisms for this process would also be desirable. 
 
A strong correlation between reduced HDAC2 activity and increasing concentrations 
of the anti-inflammatory cytokine IL-10 was also seen.  A mechanism for this 
association cannot be concluded from this data, but IL-10 may not be controlled 
directly by the activity of HDAC2.  Therefore the increase in inflammatory cytokines, 
particularly GM-CSF and TNF- which is mediated by reductions in HDAC2, may be 
responsible for the secondary increase in IL-10.  Many of the other mediators which 
have been measured in the study may not be influenced at a transcriptional level by 
HDAC2.  This may explain the weaker correlation seen between HDAC activity and 
the chemokines, for example if the transcriptional regions of DNA for these mediators 
were not tightly controlled by histone binding. 
 
6.17 Comparison with published studies 
No published study to date has provided longitudinal data on HDAC activity during an 
exacerbation of COPD; the particular strength of the information presented in this 
chapter is the presence of pre-exacerbation HDAC activity results.  This baseline 
data enables comparison of enzymatic activity in paired samples pre-, peri- and post 
exacerbation.  Studies of HDAC activity in COPD patients have also included both 
smoking and non-smoking subjects but all sampled at a single time point[125].  
Macrophages from COPD patients were shown to have reduced HDAC activity when 
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compared to smokers and non-smokers and this correlated with disease 
severity[125].  The data presented in this chapter however did not support these 
findings from the published literature.  Unexpectedly the HDAC2 activity was similar 
between subjects groups at baseline in both sputum and BAL macrophages in this 
study.  Previous reports of diminished HDAC activity in smokers compared to non-
smokers[352] were also not supported by data in this chapter.  A brief discussion of 
the possible explanations for this in sputum and BAL samples follows. 
 
6.18 Reduced HDAC activity in COPD subjects 
The only published study of HDAC activity in stable COPD has reported reduced 
activity when compared to controls[125].  However this finding was not reproduced in 
the data presented in this chapter, where baseline samples in sputum and BAL did 
not demonstrate between group differences.  When a greater number of subjects, 
including those who were not successfully infected, were considered a small trend to 
reduced activity in BAL macrophages from COPD subjects was observed, but this 
was not statistically significant.  Although the COPD subjects appear well matched 
with this and in the study by Ito et al (mean FEV1 69% and 65% predicted, age 60 
and 63 years respectively) the pack year history was greater in Ito‟s cohort compared 
to this study (58pyh vs 39pyh) and no comment on the severity of symptoms was 
made.  The subjects may therefore represent different extremes of COPD 
phenotypes, with greater cigarette exposure, symptoms and subsequent reduced 
HDAC activity.  It has been shown that HDAC2 activity is reduced in COPD subjects 
as a result of posttranslational and oxidative modifications[353, 354], and so burden 
of total cigarette exposure may contribute considerably to differences between the 
studies.  In both studies the subject numbers were small, and in a heterogeneous 
disease state this is likely to explain the differences identified.  Also differences in 
sample collection and laboratory analysis exist between the studies.  BAL samples 
were used by Ito et al compared to sputum in this study and different commercially 
available HDAC activity assays were also used. 
 
A study by Yasuo et al examined total HDAC2 protein expression, rather than 
activity, in lung samples from COPD subjects and controls undergoing surgical 
procedures.  In this study GOLD stage I & II COPD patients had the same expression 
of HDAC2 as patients with normal lung function, but significantly reduced protein 
expression was reported in GOLD stage III & IV patients[355].  This data supports 
the concept of a correlation between loss of HDAC and disease severity in COPD.  It 
also adds evidence to the proposal that subjects in the RV challenge study had 
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sufficiently mild disease that differences in HDAC activity between COPD subjects 
and controls might not be identifiable at baseline. 
 
6.19 Reduced HDAC activity in smoke exposed subjects 
Cigarette smoke has been shown to reduce HDAC activity both in vitro[356, 357] and 
in vivo[125, 131, 352].  A study of BAL macrophages from cigarette smoking subjects 
demonstrated reduced HDAC2 activity when compared to samples from non-
smokers.  This study also identified an inverse correlation between HDAC2 activity 
and IL-8 release[352].  The reduction of HDAC2 protein following cigarette exposure 
was subsequently found to be due to phosphorylation and ubiquitination of the HDAC 
enzyme[358].  In this chapter the data presented did not show significantly reduced 
HDAC activity in sputum or BAL macrophages in smoking controls compared to non-
smoking controls at baseline.  Although this does not support published work, there 
are methodological differences between the two studies.  Ito et al recruited subjects 
who were younger and may have had more intense cigarette exposure (mean age 29 
years, >20 pack year history) than the smoking controls in this study (mean age 53 
years, 32 pack year history).  Additionally radio-labelled histones were used to 
measure HDAC2 activity, utilising an alternative and potentially more sensitive 
method than the fluorometric assay used in this RV challenge study.  Finally in Ito‟s 
study subject numbers in whom BAL HDAC activity was measured were 
comparatively small with only 6 subjects in each of the smoking and non-smoking 
groups. 
 
Following RV infection HDAC2 activity was reduced in smoking controls compared to 
non-smoking controls in sputum macrophages but not in BAL.  There are no studies 
of HDAC2 activity in smoking subjects following RV infection, but as RV infection 
induces inflammation and oxidative stress it may impair HDAC activity in a similar 
way to that seen in COPD subjects in published studies. 
 
6.20 HDAC activity and inflammatory cytokines 
There are contradictions between published studies describing the effect of HDAC 
activity on inflammation, with some reporting an increase, and some a decrease, in 
inflammatory cytokine levels following inhibition of HDACs.  The majority of studies 
which have examined the relationship in the lungs suggest that HDAC inhibition or 
reductions in activity have a predominantly pro-inflammatory effect. 
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A correlation between TNF- release and reduced HDAC activity in human 
macrophages have been shown[352], additionally this effect was augmented by 
inhibition of HDAC activity using TSA.  Similarly enhanced expression of IL-8 and 
reduced HDAC activity was found to correlate.  Therefore data from my study is 
supported by others which have identified an association between increased 
inflammation and reductions in HDAC2 activity.  Yang et al reported an increase in 
NFB following TSA administration, and postulated that this was the mechanism of 
increased IL-8 release following cigarette exposure[356].  Several studies have 
identified a correlation between IL-8 release and histone acetylation[359-361].  
Moodie et al performed the study using an epithelial cell line which demonstrated 
reduced HDAC activity after exposure to both cigarette smoke and oxidative stress 
(H2O2), however the effect of these mediators was lost when cells were pre-treatment 
with the antioxidant NAC, reducing subsequent HDAC degradation and IL-8 
release[362].  Collectively these studies provide in vitro evidence that the loss of 
effectively function HDAC enzymes has a pro-inflammatory effect.  There is also 
evidence that provides a mechanism for oxidative stress induced inflammation. 
 
However the studies described above appear to contradict the findings of several 
reports in which HDAC inhibition leads to reduced cytokine release.  An in vivo 
rodent study demonstrated an anti-inflammatory effect following HDAC 
inhibition[133].  In this study LPS was used to stimulate the release of IL-6, TNF- 
and MIP-2, however pre-treatment with TSA significantly reduced induction of these 
cytokines by LPS.  Other experimental models have also demonstrated an anti-
inflammatory effect associated with a reduction in cytokine levels and HDAC 
inhibition.  Amongst these includes a rodent model of asthma in which TSA 
attenuated airway hyperresponsiveness in association with reductions in 
inflammatory cells and cytokines[363]; an experimental model of sepsis in which 
TNF- and IL-1 release from PBMC was reduced by HDAC inhibition[364] and an 
arthritis model in which IL-6 and IL-1 were reduced following administration of 
HDAC inhibitors to rodents[365]. 
 
The majority of studies performed in vitro using pulmonary cells identify HDAC as 
repressors of inflammation while whole organ or in vivo studies identify a pro-
inflammatory role for HDAC activity.  This concept is supported by data in the study 
by Dombrowsky et al in which a discrepancy between results obtained following TSA 
exposure was found, specifically an up regulation of inflammatory genes in tissue 
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culture studies and a repression of cytokine release following LPS stimulation in vivo 
and perfused lung studies.  Finally there is evidence that the degree of histone 
acetylation correlates poorly with gene expression[133]. 
 
The conflicting nature of this data illustrates the complexities of studies in this field.  It 
is likely that changes in gene transcription are dynamic, with the response to external 
stimuli modulated by the activity of HDAC.  A multitude of factors influence HDAC 
activity and it is likely that different responses will be seen in different disease states. 
 
Studies of HDAC activity following smoke exposure and in COPD have consistently 
identified an increase in inflammation associated with reduced HDAC2 activity.  The 
data presented in this chapter is supported by these studies; my data demonstrated a 
strong negative correlation between HDAC2 activity and inflammatory cytokines only 
in COPD subjects.  Importantly this is the first study in which RV infection modulates 
HDAC2 activity, and this is performed in human subjects, providing evidence that the 
discrepancy described above is not related to differences between in vitro and in vivo 
studies.  Although the data described here does not provide sufficient evidence to 
draw firm conclusions, it appears likely that the effects of HDAC activity are related to 
the specific tissue types or disease phenotypes.   
 
6.21 Bacterial induced HDAC suppression 
The finding of reduced HDAC2 activity only in COPD subjects in the study suggests 
an association with clinical features of an exacerbation.  However the mechanism of 
action following RV infection has not been studied specifically.  In addition to RV 
infection the COPD subjects had greater levels of bacterial detection in their sputum 
than control subjects.  An in vitro study using bacterial infection identified reduced 
HDAC activity in BEAS2B cell line[366].  This suggests that secondary bacterial 
infection could be causing or contributing to the reduction in HDAC activity seen in 
the COPD group.  It is possible that an infective process by either viruses or bacteria 
can lead to posttranslational reductions in HDAC activity, and both could contribute to 
this through induction of oxidative stress.  Additionally exacerbations of COPD where 
co-infection with both bacteria and viruses have been shown to result in excess 
inflammation and clinical illness compared to those in which only a single infective 
agent is identified[1].  Therefore greater reductions of HDAC activity in co-infection 
may be responsible for this and further studies with larger numbers of subjects are 
justified to examine this hypothesis.   
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Legionella pneumophila was found to cause histone acetylation and pro-inflammatory 
gene transcription following cellular infection in an in vitro study[367].  The study 
demonstrated that these changes were induced by L pneumophila flagellin 
specifically, as studies with flagellin deleted mutants did not induce IL-8 release or 
histone acetylation.  Interestingly the addition of TSA to L pneumophila infected cells 
further increased IL-8 protein expression, demonstrating that loss of HDAC activity 
contributes to excessive cytokine release in bacterial infection in vitro.  It was 
therefore postulated that in vivo inflammation induced by lung infections might be 
mediated through HDAC activity and that this is exaggerated in obstructive lung 
disease[367]. 
 
M catarrhalis has been associated with colonisation and exacerbations in COPD has 
been shown to decreased HDAC activity and expression following infection in 
vitro[366].  In this study using BEAS2B cells, M catarrhalis induced IL-8 and GM-CSF 
production and the release of these mediators was augmented by addition of TSA, 
suggesting that HDAC enzymes have a role in limiting inflammatory mediator 
release.  Following M catarrhalis infection the expression of HDAC1 and HDAC2 was 
found to be reduced by 25% and 50% respectively compared to pre-infection levels. 
 
Collectively these data suggest that bacterial infection can lead to increased 
inflammation through HDAC suppression.  The importance of this in COPD 
exacerbations has not been investigated, but this provides a possible mechanism for 
excessive inflammation associated with further reductions in HDAC activity in airways 
disease. 
 
6.22 Virus infection and HDAC activity 
It is possible that virus infection leads to changes in HDAC activity in a similar way to 
that described for bacteria.  However no published studies have investigated the 
relationship between respiratory virus, or specifically RV, infection and HDAC activity.   
 
The majority of studies it the literature focusing on HDACs and viruses have aimed to 
investigate either mechanisms of chronic virus infection or study the potential 
carcinogenic role of viruses.  A study intended to identify cellular causes of increased 
resistance to CMV infection showed an association with increased HDAC activity, 
particularly HDAC3 and inhibition of CMV infection[368].  Here the permissiveness of 
cells for CMV infection was linked to the degree of histone acetylation.  It is believed 
that part of the host response to virus infection is activation of HDACs to silence 
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transcription from the virus genome.  To counteract this defence, it is postulated that 
viruses may directly inhibit HDACs.  Data supporting this was shown in an in vitro 
study of varicella zoster infection, which identified virus related phosphorylation of 
HDAC1 & 2 following infection[369].  Finally a study using simian virus supported this 
concept, as it was demonstrated that inhibition of HDAC enzymes resulted in 
increased virus infection[370]. 
 
As virus infection is a major cause of respiratory tract illness and chronic airway 
diseases are typically associated with increased inflammation, further studies on the 
role of HDACs in this disease area are important.   
 
6.23 HDAC activity and immune responses 
The interaction between immunological mediators and the activity of HDACs have 
recently become an area of research interest.  The potential ability of this class of 
enzymes to modulate immune responses may have an impact on airway diseases.  
This includes COPD which has been regarded by some authors as an autoimmune 
disease[371, 372].  Aberrant host defence mechanisms therefore may have a role in 
airway inflammation.  In a study designed to investigate potential mechanisms of 
immune tolerance, IL-10, which has an anti-inflammatory role, was shown to be 
suppressed by overexpression of HDAC11[373].  However this finding appeared to 
be contradicted by a study using a malignant cell line, in which HDACi which are 
already in clinical use they were found to suppress IL-10 production[374]. 
 
A study on HDACi in cell lines and mice identified increased susceptibility to infection 
and failure in host defence mechanisms.  There was a reduced host response to 
microbial pathogens and impairment of innate immune responses[135].  A recent 
review of the role of HDAC enzymes in innate and adaptive immune pathways 
suggested that they act as regulators of immunity as well as inflammation.  
Furthermore it was stated that their inhibition can compromise host defence[375].  
This data hints at a potential mechanism of increased infections in COPD in the 
setting of reduced HDAC activity.  Therefore although specific studies and data are 
not yet available, the potential impact of abnormal HDAC activity in COPD may 
extend beyond airway inflammation and into direct impairments of host immune 
function. 
 
Of relevance to the data presented in this study; it might be postulated that RV 
infection leads to reductions in HDAC activity, which in turn impairs host defence 
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mechanisms as illustrated by studies discussed here and leading to increased rates 
of secondary bacterial infection identified in the COPD subjects in this study. 
 
6.24 Mechanisms of HDAC reduction in COPD 
The precise role of impaired HDAC performance in COPD is not known.  Although 
disease severity is associated with a progressive reduction in HDAC activity, it is 
unclear if this is a consequence or a mechanism of the disease process.  Evidence 
supporting both concepts exists and in vivo it is possible that the two situations 
coexist, leading to positive feedback and disease progression.  A recent study in rats 
and a human pulmonary vascular cell line investigated the relationship between 
reduced HDAC activity and induction of emphysema.  The data demonstrated an 
association between HDAC inhibition (using TSA and siRNA) and lung tissue 
destruction[376].  This provides intriguing evidence that fully functioning HDAC is 
required for the maintenance of normal lung structure, and that at least part of the 
inflammation and tissue destruction seen in COPD is driven by reduced HDAC 
expression and activity.  However, the pulmonary environment in COPD is 
characterised by inflammation and excess oxidative stress.  This leads to a loss of 
HDAC enzymes through a variety of mechanism.  There is evidence of 
posttranslational modifications[353] and subsequent breakdown by ubiquitination of 
HDAC protein[358, 377].  Reductions in HDAC expression and activity as a result of 
oxidative and nitrative stress have also been demonstrated in cell culture and human 
ex vivo samples[377]. 
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6.25 Conclusion 
 
The data presented in both sputum and BAL supports the hypothesis that increased 
inflammation found in RV induced exacerbations is mediated by a fall in HDAC2 
activity.   
 
No other published studies have collected longitudinal data on HDAC2 activity both 
before and after RV infection in COPD and control populations.  Published data of 
HDAC activity in COPD has focused on the stable state or at a single time point post 
exacerbation.  The pattern of change in HDAC activity during the acute phase of an 
exacerbation has therefore not been examined until now.   
 
The changes from baseline in individual study groups represent the most intriguing 
findings, particularly as HDAC2 activity behaves differently in the three study groups 
following RV infection.  The significant falls from baseline only in COPD subjects 
offers the strongest evidence to support the hypothesis.   
 
Within this chapter there are many interesting findings presented, particularly the 
correlation with HDAC2 activity and cytokines.  However cautious interpretation of 
this data is required, due to limited sensitivity of the HDAC2 assay in sputum 
macrophages and detection levels close to the lower limit.  Further work is required 
to investigate fully the associations with inflammatory and clinical markers and the 
findings of reduced HDAC2 activity in COPD subjects. 
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Chapter 7: Oxidative and nitrative Stress 
7.1 Introduction 
 
The importance of oxidative and nitrative stress in the pathogenesis of COPD is 
becoming increasingly evident despite the difficulties in accurate measurement of 
these parameters.  Patients with COPD have been shown to have an excess of 
oxidative and nitrative stress which is compounded by a diminished antioxidant 
capacity; this in turn leads to tissue damage from an excess burden of harmful 
radicals.  It is known that RV infection leads to induction of both oxidative and 
nitrative stress following infection in both healthy and diseased individuals.  Here I 
measure nitrative stress and antioxidant potential following RV infection using the 
Griess assay and the Potential of Antioxidant (PAO) assay to explore the hypothesis 
that COPD subjects experience a greater burden of reactive oxygen species 
following RV infection when compared to non-obstructed controls and that this, in 
turn is associated with adverse inflammatory and clinical parameters. 
 
Results 
7.2 Oxidative and nitrative stress assays 
The Griess assay was used to measure levels of organic nitrite and hence indirectly 
measure nitrative stress in BAL, EBC and sputum supernatant.  However BAL and 
EBC samples were found to be too dilute for reliable measurement, with the majority 
of values falling below the lower detection limit of the standard curve.  No attempts 
were made to concentrate BAL or EBC owing to concerns over the reliability of nitrite 
levels obtained this way; these results are therefore not discussed further in this 
chapter. 
 
7.3 Nitrative stress at baseline 
To investigate differences in nitrative stress between the three study groups prior to 
RV infection the results of the Griess assay from baseline sputum samples is 
presented, figure 7.1.  At baseline there was a trend to lower levels of nitrite detected 
in the sputum supernatant of smoking controls.  The highest level was detected in 
non-smoking controls.  However there was no significant difference in the mean 
nitrite levels measured between the three study groups; log10 mean (SEM) 
concentrations in non-smoking controls, smoking controls and COPD was 0.7 (0.1), 
0.5 (0.2) and 0.6 (0.1) respectively, (p=0.281, one way ANOVA). 
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Figure 7.1 Baseline sputum nitrite levels in individual study groups, Data presented mean +/- 
SEM, (one way ANOVA, p=0.281) 
 
7.4 Nitrative stress following RV infection 
To assess the effect of RV infection on the whole study population the level of nitrite 
in sputum supernatant from all subjects who were successfully infected is shown 
over the time course of the study in figure 7.2.  When compared to baseline using the 
paired t test and each time point there was a significant increase in nitrite levels on all 
days following infection, with a peak on day 9.  The levels had still not returned to 
pre-infection concentrations by day 42. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Time course of sputum nitrite levels in all RV infected subjects.  Data presented 
mean +/- SEM, (paired t test, *p<0.05, **p<0.01, ***p<0.001) 
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To investigate differences between the study groups, the results of sputum nitrite 
concentrations are shown over the time course of the study in figure 7.3.  This 
demonstrated that COPD subjects had statistically higher nitrite levels when 
compared to both control groups on day 15 (p=0.008, one way ANOVA) and on day 
12 there was a higher level in COPD and non-smoking subjects when compared to 
smoking controls (p=0.003, one way ANOVA).  In addition the mean nitrite level was 
non-significantly higher in COPD subjects during the study.  The mean (SEM) total 
sputum nitrite levels for non-smokers, smokers and COPD subjects over the time 
course measured using the area under the curve (AUC) was 55.6 (5.7), 72.8 (19.0) 
and 102.1 (15.8) respectively.  There was a significant difference in AUC between 
the non-smokers and COPD groups (mean difference 46.4, 95% CI 12.3 to 80.6, p= 
0.010, one way ANOVA) with no difference between any other groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 Time course of sputum nitrite levels in individual groups.  Data presented mean +/-
SEM, (one way ANOVA, *p<0.05; Tukey analysis, **Day 12 COPD vs Smk and **Day 15 
COPD vs NS and **COPD vs Smk) 
 
When the change from baseline in sputum nitrite concentration in individual groups 
was analysed using the paired t test from study time points, the increase following 
infection was found to be significant only in the non-smoking controls and COPD 
subjects, figure 7.4.  In non-smoking controls there was a significant increase from 
baseline on days 3 and 15 with a peak on day 12.  In smoking controls there was a 
0 3 5 9 12 15 21 42
0.0
0.5
1.0
1.5
NS
Smk
COPD
*
*
Days post infection
L
o
g
1
0
 N
it
ri
te
 (
u
M
)
250 
 
trend to increased nitrite levels but this was not significant on any day post infection.  
The peak change occurred on day 9 and a trend to increasing levels was seen from 
day 12 to day 42.  Only the COPD group had a significant increase from baseline at 
all time points following infection with the peak increase identified on day 15.  The 
magnitude of the increase in nitrite from baseline was greatest in the COPD subjects 
and least in the non-smoking control group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4a Non-smoking group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4b Smoking group 
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Figure 7.4c COPD group 
Figure 7.4 Change from baseline in sputum nitrite levels after infection in (a) non-smoking 
controls, (b) smoking controls and (c) COPD subjects.  Data presented mean +/-SEM, (paired 
t test from baseline at study time points, *p<0.05, **p<0.01) 
 
7.5 Assay of antioxidant potential at baseline 
The PAO assay was performed in BAL and sputum supernatant.  However levels in 
BAL fell below the lower limit of detection for the assay, and so this will not be 
discussed further in this chapter.  At baseline there was no significant difference 
between the PAO levels in sputum supernatant in the three study groups; mean 
(SEM) non-smoking controls 125.1 (9.4), smoking controls 180.2 (33.2) and COPD 
subjects 101.9 (27.7) p=0.097, one way ANOVA.  Although not significant; this data 
illustrates a trend to higher levels in smoking controls and reduced levels in COPD 
subjects, figure 7.5. 
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Figure 7.5 Results of PAO assay at baseline from sputum supernatant in study groups.  Data 
presented mean +/-SEM, (p=0.097, one way ANOVA) 
 
7.6 Assay of antioxidant potential in study groups 
Investigation of the effects of RV16 infection on antioxidant potential in all study 
subjects is presented in figure 7.6.  The pattern was of a decline in PAO activity from 
baseline at all post infection time points until day 42.  However the variance of the 
data was large and this was not statistically significant when compared to baseline 
and analysed with a paired t test at any time point.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 Time course of sputum PAO levels in RV infected subjects.  Data presented mean 
+/-SEM, (paired t test, p>0.05) 
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When the results from the PAO assay in individual study groups was analysed 
across the whole time course of the study a complex pattern was identified, figure 
7.7.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7 Time course of PAO level in sputum supernatant by study group.  Data presented 
mean +/-SEM (*p<0.05, one way ANOVA) 
 
Initially PAO levels increased in COPD subjects until day 5, with a fall at day 9, then 
a consistent rise until day 42.  The overall trend was to lower levels in COPD 
subjects when compared to control groups across the whole study. 
 
In smoking controls the concentration fell until day 5, increased on day 9 and then 
consistently fell until day 42.  The overall trend in smokers was to higher levels 
compared to the other two groups across the whole study time course.  In non-
smoking controls there was little variation in PAO levels following RV16 infection. 
 
There was a statistically significant difference between the means of the three study 
groups on day 9 and day 42, (one way ANOVA p=0.042 and p=0.036 respectively).  
Tukey‟s analysis demonstrated that the difference on day 9 between smoking 
controls and COPD subjects was significant, p=0.033.  In summary the results of the 
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PAO assay following RV16 infection in COPD subjects has an inverse trend to that 
found in smoking controls, with significant differences between these two groups on 
day 9. 
 
Because of the complex pattern in changes over time within each group an analysis 
of the area under the curve (AUC) for total antioxidant potential in each group over all 
study visits was performed.  Overall the AUC values for the PAO time course 
demonstrated no significant difference between the groups with mean (SEM) results 
of 785.2 (50.1), 938.4 (81.5) and 690.3 (102.7) in non-smoking controls, smoking 
controls and COPD subjects respectively, (p=0.102, one way ANOVA).  Despite the 
non-significant p value, this illustrates that there was a trend to a higher levels of 
PAO activity in control groups, with smoking subjects exceeding those of non-
smokers, when compared to COPD subjects across the whole time course of the 
study. 
 
7.7 Assay of antioxidant potential change from baseline 
To evaluate the effect of RV infection on oxidant levels in each group, the change 
from baseline in PAO assay activity was calculated, figure 7.8.  In non-smoking 
controls the antioxidant potential remained constant during the study time course with 
no change from baseline at any time point, (paired t test from study time points and 
baseline, p>0.05).  In smoking controls there was a trend to falling levels of 
antioxidant activity compared to baseline following infection.  This was greatest and 
significant on day 42, (paired t test, p=0.039).  In contrast, in COPD subjects there 
was no significant change from baseline at any time point measured, p>0.05, paired t 
test.  There was a small trend to increasing activity from day 15 until the final study 
time point. 
 
The magnitude of the peak change from baseline was fivefold greater in smoking 
controls compared to the non-smoking and COPD groups, mean peak change from 
baseline for non-smoking controls, smoking controls and COPD subjects was 19.3, -
99.3 and 26.5 respectively.  The peak change from baseline occurred on day 21 in 
non-smokers and day 42 in smoking and COPD groups, figure 7.8.  
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Figure 7.8a Non-smoking group 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8b Smoking group 
 
 
 
 
 
 
 
 
 
 
Figure 7.8c COPD group 
Figure 7.8 Change in sputum PAO levels from baseline after infection in (a) non-smoking 
controls, (b) smoking controls and (c) COPD subjects.  Data presented mean +/-SEM, (paired 
t test, *p<0.05) 
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7.8 Correlation of nitrative stress and antioxidant potential 
The trend in all successfully infected subjects was an increase in nitrite concentration 
and reduction in the antioxidant potential over the whole study time course.  However 
the mean changes in individual study groups for the results of the PAO assay did not 
follow this pattern.  Therefore to investigate the relationship between the nitrite and 
PAO level in all subjects combined the two parameters have been correlated, figure 
7.9.  This identified a significant negative correlation suggesting that increased 
nitrative stress was associated with a reduction in antioxidant potential, (Spearman‟s 
coefficient rs=-0.31, p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9 Correlation of sputum supernatant nitrite and antioxidant levels in all infected 
subjects, (rs= -0.31, p=<0.001) 
 
The association between sputum nitrite concentration and PAO results was then 
investigated in individual study groups, figure 7.10.  There was a significant negative 
correlation only in smoking controls and COPD subjects, (rs=-0.44, p<0.001 and r=-
0.36, p=0.002 respectively).  In non-smoking controls there was no relationship, 
(rs=0.17, p=0.162).   
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Figure 7.10a Non-smoking group, (rs=0.17, p=0.162) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10b Smoking group, (rs= -0.44, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10c COPD group, (rs= -0.36, p=0.002) 
Figure 7.10 Correlation of sputum nitrite and antioxidant levels in RV infected (a) non-smoking 
controls (b) smoking controls (c) COPD subjects 
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7.9 Ratio of Griess to PAO assay 
To further investigate the degree of redox stress in the three study groups the ratio of 
the Griess to PAO assay has been calculated.  At baseline there were no differences 
between the three study groups when this nonparametric data was analysed using 
the Kruskal-Wallis test, (p=0.235), figure 7.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11 Baseline ratio of Griess to PAO assay in individual study groups, data presented 
as median (interquartile range).  Kruskal-Wallis, p=0.235  
 
To investigate the effect of RV16 infection on the Griess to PAO ratio the time course 
from each study group is plotted in figure 7.12.  When the median values between 
the three study groups were analysed on each time point using the Kruskal-Wallis 
analysis, there was found to be significant differences on days 9, 12 and 15 
(p=0.008, p=0.015 and p=0.011 respectively).  This was due to differences between 
smoking controls and COPD subjects, figure 7.12. 
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Figure 7.12 Time course of ratio of Griess to PAO assay in individual study groups, data 
presented as median.  Kruskal-Wallis, *p<0.05 **p<0.01 between study groups 
 
7.10 Correlation of virus load and nitrative stress 
To investigate the relationship between RV infection and nitrative stress the sputum 
virus load and nitrite concentration have been correlated, figure 7.13.  In all subjects 
there was a positive correlation between the two parameters, r=0.32 (p<0.001), 
demonstrating that subjects with a greater virus load had higher nitrative stress 
levels. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.13 Correlation of sputum virus load with nitrite concentration in all successfully 
infected subjects, (r=0.32, p<0.001) 
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When the relationship between sputum nitrite and virus load in study groups was 
analysed, a positive correlation was found in smoking controls and COPD subjects, 
figure 7.14.  In non-smoking controls there was no association demonstrated, r=0.08 
(p=0.548).  The correlation was stronger in COPD subjects r=0.39 (p=0.004) 
compared to smoking controls, r=0.28 (p=0.03). 
 
Neither of the control groups had a significant increase in both nitrite and virus load 
on the same day following infection.  However the COPD group had a significant 
increase in both parameters on days 3, 5, 9 and 12.  The stronger positive correlation 
in this group suggests that the increase in virus load may be responsible for the rise 
in nitrite concentration to a greater extent than in control groups. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.14a Non-smoking group, (r=0.08, p=0.548) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.14b Smoking group, (r=0.28, p=0.035) 
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Figure 7.14c COPD group, (r=0.39, p=0.004) 
Figure 7.14 Correlation of sputum nitrite and virus load in (a) non-smoking controls (b) 
smoking controls (c) COPD subjects 
 
7.11 Correlation of virus load and antioxidant potential 
The sputum virus load and PAO assay results from all subjects was correlated to 
investigate their relationship, figure 7.15.  There was a significant but weak negative 
association with a Spearman‟s correlation of rs=-0.15, (p=0.048) identified.  This 
suggests that an increased virus load was associated with reduced antioxidant 
potential. 
 
However when the results of the PAO assay and virus load in individual groups was 
studied, no significant correlation was identified for any group.  Non-smoking controls  
rs=0.06 (p=0.672), smoking controls -0.11 (p=0.404) and COPD subjects -0.08 
(p=0.581). 
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Figure 7.15 Correlation of sputum virus load with antioxidant potential in all successfully 
infected subjects, (rs=-0.15, p=0.048) 
 
 
7.12 Association of nitrative stress and antioxidant potential with airway 
inflammation 
 
To study the relationship between markers of redox stress and airway inflammation, 
the sputum total cell count (TCC) and sputum supernatant level of IL-8 were 
correlated with the results of the Griess and PAO assay.  The sputum TCC had a 
strong correlation with nitrite concentration when all subjects were considered in 
combination, r=0.65 (p<0.001), figure 7.16.  There was a weaker but significant 
negative correlation between the TCC and antioxidant capacity, r=-0.18 (p=0.008), 
figure 7.17.   
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Figure 7.16 Correlation of sputum TCC with nitrite concentration, (r=0.65, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.17 Correlation of sputum TCC with antioxidant potential, (r= -0.18, p=0.008) 
 
There was a strong positive correlation between sputum nitrite and IL-8 levels in all 
infected subjects r=0.70 (p<0.001), figure 7.18, and a significant but weak negative 
correlation between the PAO assay and sputum IL-8 levels in all subjects r=-0.15 
(p=0.036), figure 7.19.   
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Figure 7.18 Correlation of sputum nitrite with IL-8 concentration in all infected subjects, 
(r=0.70, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.19 Correlation of sputum antioxidant capacity with IL-8 concentration in all subjects, 
(r=-0.15, p=0.036) 
 
When individual study groups were examined there was a significant positive 
correlation between sputum nitrite and IL-8 in all groups, figure 7.20.   
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Figure 7.20a Non-smoking controls, (r=0.70, p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.20b Smoking controls, (r=0.78, p<0.001) 
 
 
 
 
 
 
 
 
 
 
Figure 7.20c COPD group, (r=0.72, p<0.001) 
Figure 7.20 Correlation of sputum nitrite with IL-8 concentration in (a) non-smoking, (b) 
smoking and (c) COPD subjects 
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Figure 7.21a Non-smoking controls, (r=0.30, p=0.018) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.21b Smoking controls, (r=-0.27, p=0.021) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.21c COPD group, (r=-0.25, p=0.038) 
Figure 7.21 Correlation of sputum antioxidant capacity with IL-8 concentrations in (a) non-
smoking, (b) smoking and (c) COPD subjects 
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The correlations between the antioxidant potential measured using the PAO assay 
and IL-8 concentrations in individual subject groups have been shown, figure 7.21.  
There was a significant negative correlation seen in smoking controls and the COPD 
group, r=-0.27 (p=0.021) and r=-0.25 (p=0.038) respectively.  However in non-
smoking controls there was a positive correlation r=0.30 (p=0.018). 
 
7.13 Correlation of nitrative stress and antioxidant potential with HDAC2 
activity 
To investigate possible mechanisms for the relationships described above between 
IL-8 and oxidative and nitrative stress; the results of the HDAC2 activity assay have 
been correlated with the PAO and Griess assays.  When all infected subjects were 
considered, figure 7.22, there was a weak but highly significant negative correlation 
between HDAC2 activity and nitrite concentration.  This suggests that increased 
nitrative stress is associated with reductions in HDAC2 activity.  When the three 
study groups were examined, figure 7.23, this relationship was found only to remain 
significant in COPD subjects, figure 7.23c with a negative correlation, (r=-0.47, 
p<0.001).  In control groups there was no association, non-smoking controls, figure 
7.23a, (r=-0.12, p=0.336) and smoking controls, figure 7.23b, (r=-0.11, p=0.396). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.22 Correlation of sputum nitrite with HDAC2 activity in all successfully infected 
subjects, (r=-0.26, p<0.001) 
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Figure 7.23a Non-smoking controls, (r=-0.12, p=0.336) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.23b Smoking controls, (r=-0.11, p=0.396) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.23c COPD group, (r=-0.47, p<0.001) 
Figure 7.23 Correlation of sputum nitrite concentration with HDAC2 activity in (a) non-
smoking, (b) smoking and (c) COPD subjects 
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When the relationship between HDAC2 activity and the PAO assay was examined, 
there was no correlation in all subjects, or in any of the three study groups 
individually figure 7.24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.24 Correlation of sputum antioxidant capacity with HDAC2 activity (rs=0.03, p=0.706) 
 
Chapter discussion 
 
7.14 Baseline observations of nitrative stress 
Data presented in this chapter examined the concentration of sputum nitrite levels in 
baseline samples from individual study groups prior to RV infection.  No significant 
difference in nitrite levels was identified between the three study groups.  There was 
a trend to lower levels in smoking controls and greatest in non-smoking controls.  
Published work on nitrative stress in COPD have been equivocal with some studies 
reporting elevated levels of nitrative stress while others have shown no differences 
between COPD and healthy subjects.  These are discussed below. 
 
7.15 Excess nitrative stress in COPD 
A study by Ichinose et al compared three markers of reactive nitrogen species; 
exhaled NO and nitrotyrosine and iNOS levels from induced sputum, in healthy 
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COPD subjects compared to both other groups, correlated with airway obstruction 
and iNOS was detected at higher levels in COPD.  However there was no difference 
between COPD and healthy subjects in exhaled NO concentrations[378].  The 10 
COPD subjects studied by Ichinose et al were all ex-smokers with a mean FEV1 of 
58% predicted[378].  Direct comparison between data presented in this chapter and 
the study by Ichinose et al is difficult because of the different methods of measuring 
nitrative stress.  Although the COPD subjects are both GOLD stage II, those in my 
RV challenge study had a higher mean FEV1 % predicted and the majority were 
current smokers.  The potential influence of these factors on measured nitrative 
stress is not known. 
 
A further study of nitrative stress in GOLD stage II COPD subjects measured 
peroxynitrite derivatives, nitrosothiols and exhaled NO in stable disease.  Greater 
levels of nitrosothiols were found in induced sputum from COPD subjects but not 
exhaled NO when compared to healthy controls[379].  However the control subjects 
in this study were significantly younger than those with COPD (38 years versus 61 
years) making the reliability of these results uncertain.  Comparison between these 
results and those presented in this chapter is difficult because although the COPD 
subjects appear well matched nitrative stress was measured using different assays.  
 
Finally, in an investigation of bronchial biopsies from stable patients Ricciardolo et al 
demonstrated increased markers of nitrative stress in severe COPD patients 
compared to moderate COPD subjects, healthy smokers and non-smokers.  Here 
nitrotyrosine and MPO cell numbers were significantly greater in severe COPD; 
however there was no difference between these markers in moderate COPD 
subjects and non-obstructed controls.  The concentration of iNOS was greater in both 
smoking controls and moderate COPD subjects when compared to non-
smokers[380].  This data suggests that nitrative stress worsens with increasing 
severity of COPD.  Although the results in this chapter cannot be compared directly 
with those reported by Ricciardolo et al, the moderate COPD group appeared well 
matched, and did not show markers of increased nitrative stress compared to 
smoking controls. 
 
7.16 No difference in nitrative stress between COPD and controls 
As described previously there are contradictory reports in the literature, regarding the 
role of nitrative stress in COPD compared to controls, where no differences in 
markers of nitrative stress were found between COPD subjects and healthy controls. 
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Rutgers et al measured exhaled NO, iNOS in cells and nitrite and nitrate in 
supernatant from induced sputum to evaluate the degree of nitrative stress in stable 
COPD[107].  In this study, the mean FEV1 was 63% predicted in the COPD group 
and half the subjects were active smokers.  No difference was identified in exhaled 
NO between COPD and non-obstructed subjects.  Interestingly in healthy controls 
NO was lower in smoking compared to non- or ex-smoking subjects but in the COPD 
group active smoking did not affect NO levels.  Nitrite levels were measured using 
the Griess assay and the pattern of results in study groups matched that described 
for exhaled NO.  Finally the number of iNOS positive staining cells was also not 
different between COPD and control subjects.  The data from Rutgers et al supports 
the results presented in this chapter.  Both studies used similar methods for 
measuring nitrite in induced sputum and although not statistically significant there 
was a trend to lower levels in smoking controls in the RV challenge study.  The 
severity and age of COPD subjects was also similar allowing for accurate 
comparisons to be made. 
 
A study designed to identify biomarkers in COPD measured NO in serum samples 
during the stable and exacerbated state.  When compared to controls the stable 
COPD group did not have a significant difference in NO concentrations[381].  
Interestingly the NO concentration showed a positive correlation with pack year 
history in COPD subjects, these subjects had a mean FEV1 of 46% predicted.  
Although not the primary aim of the study by Karadag et al, this data provides further 
evidence that stable COPD subjects do not have increased nitrative stress compared 
to control subjects. 
 
Another study has been published which reports the use of the Griess assay in 
COPD patients[382].  However in this Italian study nitrite levels were lower in the 
plasma of COPD patients compared to controls, which the authors suggested might 
be related to pulmonary hypertension.  It is not possible to compare these results 
with those obtained in this study. 
 
Collectively these studies illustrate the complexities of measuring nitrative stress in 
stable COPD.  Overall the published literature supports the results presented in this 
chapter as the only study to use the Griess assay did not identify significant 
differences between stable COPD and healthy controls.  The contradictions between 
studies are likely to represent differences in methods of measuring nitrative stress 
and the severity of COPD subjects included. 
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7.17 Baseline observations of oxidative stress 
At baseline there was no significant difference in the results of the PAO assay 
between the three study groups.  There was a trend to higher levels in smoking 
controls with the lowest detected in COPD subjects.  The interpretation of these 
results raises interesting questions.  There is evidence from previous studies of 
increased oxidative stress and reduced antioxidant levels in COPD subjects. 
 
7.18 Increased oxidative stress in stable COPD 
In an early study to investigate the relationship between oxidative stress and airflow 
obstruction the in vivo measurement of O2
- was found to correlate with bronchial 
hyperactivity in patients with airflow obstruction[383].  Subsequently the 
Thiobarbituric acid reactive substances (TBARS) assay was used to measure 
markers of lipid peroxidation by several studies.  In a study primarily designed to 
investigate lipid peroxidation in lung cancer, it was also found that the degree of 
airway obstruction was associated with markers of oxidative stress measured using 
the TBARS assay and that recent cigarette smoke exposure also increased these 
markers[384].  Greater levels of both H2O2 and TBARS mediators were measured in 
EBC from COPD subjects compared to non-smoking controls[100].  Active smoking 
had a trend to increase markers of lipid peroxidation but this was not significant.  
Although results from this study are of interest, 13 of the 44 COPD subjects had 
never smoked raising uncertainty about the aetiology of their lung disease. 
 
An alternative measure of lipid peroxidation was studied by assessing cellular 
staining for the aldehyde 4-hydroxy-2-nonenal (4-HNE) which is a stable and specific 
end product of oxidation[385].  COPD subjects were found to have higher levels than 
smoking controls in bronchial and alveolar cells and this was inversely correlated with 
FEV1.  The mean FEV1 % predicted in the COPD group was 66%, and although the 
control group was well matched, the majority of both groups were ex-smokers 
making comparison with active smokers less reliable.  Additionally all tissue samples 
were obtained from subjects undergoing lung resection for malignancy, introducing a 
confounding factor. 
 
Several studies have examined EBC for markers of oxidative stress in COPD.  An 
early study identified increased levels of H2O2 in EBC from stable COPD subjects 
compared to non-smoking controls[101].  The COPD group had a mean FEV1 of 51% 
predicted and age of 70 years.  A further study measured both H2O2 and 8-
isoprostane in EBC from stable COPD subjects and found increased levels of both 
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parameters compared to smoking controls[82].  In addition the concentration of H2O2 
correlated significantly with FEV1, neutrophil count and dyspnoea score in COPD 
subjects, however this correlation was not observed with 8-isoprostane.  The study 
included three COPD groups; mild, moderate and severe, in whom H2O2 
concentration was found to increase with disease severity.  Individually mild, 
moderate and severe subjects were not reported to have significantly higher levels 
than controls.  Finally a study investigating clinical features and their association with 
oxidative stress, identified increased EBC 8-isoprostane in stable COPD was 
associated with an increased BODE index, hypoxia and increased dynamic 
hyperinflation[386]. 
 
Collectively these reports provide significant evidence for increased oxidative stress 
in stable COPD, which worsens with disease severity.  However there are several 
factors which make comparing these studies with the data presented in this chapter 
problematic; the severity of COPD subjects is similar but control groups typically 
haven‟t included non-smoking subjects.  Additionally assay methods are different and 
none of these studies report results in sputum supernatant. 
 
7.19 Antioxidant capacity in COPD 
Excessive oxidative stress occurs either when antioxidant capacity is reduced or 
when redox burden is increased and several studies have identified reduced 
antioxidants as a possible disease mechanism in COPD.  However research in this 
area is complicated by difficulties in defining a „normal range‟ for antioxidant 
parameters and the considerable number of environmental and genetic interactions 
which exist, particularly in a dynamic system in which antioxidants respond to oxidant 
burden.  Several studies have also reported increased antioxidant levels in COPD. 
 
Rahman et al measured plasma antioxidant capacity using the Trolox equivalent 
antioxidant capacity (TEAC) assay which equates substrate antioxidant capacity to 
the vitamin E analogue Trolox.  This study identified greater antioxidant levels in the 
serum of non-smokers compared to non-obstructed smokers and COPD subjects, 
but there was no difference in levels between these last two groups[387].  Studies in 
smokers have reported reduced antioxidants in plasma[388] and BAL despite dietary 
supplementation[389] compared to non-smokers.  Additionally an epidemiological 
study reported reduced lung function in association with decreased dietary intake of 
antioxidant vitamins C and E[390]. 
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However other studies have discovered increased levels of antioxidants in COPD.  
Beeh et al reported increased concentrations of the antioxidant glutathione in 
induced sputum samples[379], a finding that was associated with increases in other 
markers of both oxidative and nitrative stress.  A study of antioxidants in skeletal 
muscle found that biopsy samples contained greater levels of several antioxidants in 
COPD subjects compared to controls[391]. 
 
It has been postulated that low antioxidant capacity in blood reflects excessive 
oxidant burden, but in sputum the opposite hypothesis has been suggested.  Studies 
in this field contain contradictions or have limitations which indicate that further work 
is required.  Direct comparison with the data presented in this chapter is problematic, 
particularly as different assays have been used.  However where studies have been 
performed in sputum a reduction of antioxidants has been reported and a trend to 
this was seen in my COPD subjects prior to RV infection.     
 
7.20 Does RV infection increase oxidative and nitrative stress? 
Data presented in this chapter supports the hypothesis that nitrative stress is 
increased following RV infection and that this is elevated in COPD subjects 
compared to controls.  When all subjects were combined nitrative stress significantly 
increased on all days post infection.  This was greater in COPD subjects compared 
to controls and was significantly higher by day 15.  The delay of two weeks from 
nasal inoculation is likely to reflect the initial virus incubation period and then the time 
taken before inflammation develops in the lower airway.  The increase from baseline 
in nitrative stress in COPD subjects was greater compared to controls. 
 
When all subjects were combined the antioxidant levels fell following RV infection, 
although this was not found to be statistically significant compared to baseline.  The 
fall in antioxidant capacity is likely to occur as a result of RV induced oxidative stress; 
however the data presented in this chapter cannot refute or confirm this.  When the 
three individual subjects groups were analysed, only the smoking controls had a 
significant change from baseline at any time point, day 42.  The range of inter and 
intra subject results obtained using the PAO assay was large making detecting 
significant changes difficult to identify.  This may have been due to wide variations in 
antioxidants levels in the samples tested, or could reflect poor sensitivity or reliability 
in the assay.  Measuring oxidants directly is difficult due to their short lived state and 
reactive nature; therefore surrogate markers are often used.  However the results of 
275 
 
the PAO assay presented in this chapter are likely to have been limited by the small 
subject numbers, particularly in the COPD group.   
 
The interpretation of the results of the PAO assay following RV infection is complex.  
The trend in smoking controls is a fall from relatively high baseline levels following 
RV inoculation.  A possible interpretation of this data is that non-obstructed smokers 
are able to mount an appropriate antioxidant response to chronic cigarette smoke 
exposure, however following RV infection the additional oxidative stress results in 
falls of antioxidants.  COPD subjects have a trend to lower antioxidant levels at 
baseline and following RV infection these remain unchanged or fall further until day 
21.  This may reflect higher levels of oxidative stress in COPD subjects prior to 
infection, with an additional ROS burden following RV infection, resulting in a further 
non-significant drop in antioxidants on day 9.  At this time point there was 
significantly higher antioxidant levels in smoking controls compared to COPD 
subjects.  The results of the PAO assay are relatively unchanged following RV 
infection in non-smoking controls, with no significant changes from baseline. 
 
There are both in vitro[279, 280] and ex vivo[134] studies which have demonstrated 
induction of oxidative stress by RV infection.  However no longitudinal studies have 
investigated oxidative stress as a result of RV infection in humans.  The data 
presented in this chapter therefore illustrates novel data. 
 
7.21 Increased nitrative stress in AECOPD 
There are reports of increased nitrative stress identified during exacerbations 
compared to stable state in COPD[144, 381].  The study by Tsoumakidou et al 
recruited 12 COPD subjects and found increased nitrotyrosine positive inflammatory 
cells in induced sputum samples and work by Karadag et al identified serum nitric 
oxide as a candidate biomarkers in AECOPD. 
 
Increased H2O2 has also been reported in EBC in AECOPD[101].  However this 
study excluded patients with a clinically suspected upper airway infection because of 
concern over contamination of EBC with H2O2 derived from the upper airways.  This 
limits comparisons with the data presented in this chapter, but does provide 
interesting evidence that acute exacerbations due to aetiologies other than 
respiratory viruses are associated with increased oxidants.  A further study in 
AECOPD identified an increase in superoxide anion from blood[93]. 
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Finally at least four studies have measured antioxidants during an AECOPD.  
However none have used the PAO assay or presented longitudinal data similar to 
that in this chapter.  A study measuring markers in serum identified reductions in 
antioxidants during an AECOPD[93], furthermore this was found to return to normal 
levels with treatment[392]. 
 
A study which collected serum samples from COPD subjects during an exacerbation, 
with repeat samples during the stable state, was designed to investigate the activity 
of the antioxidant vitamins A, C and E[393].  Lower levels of vitamin A and E were 
identified during the acute illness, suggesting that oxidative stress was significantly 
involved in this.  The authors suggest that supplementation with vitamin A and E may 
be beneficial to the treatment of acute exacerbations. 
 
7.22 Is there an association between oxidative and nitrative stress? 
There was a highly significant inverse correlation between the Griess and PAO assay 
when all subjects were studied.  The link between oxidative and nitrative stress was 
stronger and consistent when smokers and COPD subjects were examined 
individually but non-smokers did not demonstrate any correlation.  This data 
demonstrate that lower levels of nitrative stress are associated with higher levels of 
antioxidant in cigarette exposed subjects.  It also supports the use of the PAO assay 
as an indirect measure of oxidative stress.  The ratio between the Griess and PAO 
assay was also helpful in providing additional information in redox stress in the study.  
 
7.23 Is there a correlation between oxidative and nitrative burden and 
inflammation? 
The total non squamous cell count in sputum and IL-8 concentrations were found to 
correlate strongly with increasing nitrite concentrations, supporting an association 
between RV infection, nitrative stress and airway inflammation.  COPD subjects were 
found to have a similar strength of correlation to control groups although their 
absolute markers of inflammation and nitrative stress were elevated compared to 
controls.  A negative correlation was identified between the PAO assay and 
inflammatory markers in all subjects combined; providing supporting evidence for a 
role of oxidative stress in inflammation.  When subjects were examined individually 
this pattern was repeated in smokers and COPD subjects with lower PAO levels 
associated with increased IL-8 but was reversed in non-smokers. 
 
277 
 
Several published studies have investigated the relationship between oxidative and 
nitrative stress and modifications to HDACs.  There is evidence that inflammation 
induced by nitrative stress may act though loss of HDAC activity, specifically by 
nitration of tyrosine residues[377].  An in vitro study investigating mechanisms of 
renal disease, in which nitrative stress was measured using the Griess assay, 
identified a relationship between HDAC2 and activation of the iNOS gene[394].  The 
data presented in this chapter identified a significant negative correlation between 
HDAC2 activity and nitrite concentrations in COPD subjects only.  This data suggests 
that this relationship is involved in the excess inflammation and symptoms identified 
in the RV induced COPD exacerbation.  However the data presented here does not 
provide information of the mechanisms involved in this process, it cannot be 
determined if nitrative stress in impairing HDAC2 activity or if falls in HDAC2 activity 
are inducing nitrative stress. 
 
A study by Rhaman et al illustrated a mechanism of oxidative induced inflammation 
which was exaggerated by inhibition of HDAC enzymes, illustrating a possible 
mechanism for exaggerated inflammation induced by oxidative stress in COPD 
(where HDACs have been shown to be deficient)[360].  Other studies have also 
demonstrated that oxidative stress reduces HDAC and this results in an increases in 
IL-8 levels[395].  Finally a possible mechanism for this was proposed by Marwick et 
al, in this study it was shown that oxidative modifications are responsible for the 
posttranslational destruction of HDAC2[353, 354]. 
 
7.24 Correlation of oxidative and nitrative stress with HDAC2 activity 
There was found to be a significant negative correlation between HDAC2 activity and 
nitrite concentration only in the COPD subjects.  There was no association 
demonstrated between the PAO assay and HDAC2 activity in any of the study 
groups. 
 
It is not possible to identify a causative relationship for the correlation between nitrite 
and HDAC2 activity from the data presented in this chapter.  However it is interesting 
to note that only in the COPD group are the two parameters significantly related.  It 
has been demonstrated in vitro, that oxidative and nitrative stress may be 
responsible for inactivating HDAC enzymes[126, 395].  It is therefore postulated that 
increased nitrative stress is responsible for the reduction of HDAC2 activity 
demonstrated by this correlation.  This supports the central hypothesis of the work 
presented in this chapter and provides a possible mechanism for the increased 
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inflammatory cytokines seen with increases in nitrite.  This is the first study to identify 
a correlation in inflammation and nitrative stress in vivo following a RV induced 
COPD exacerbation.  It was anticipated that increases in oxidative stress would be 
associated with reductions in HDAC2 activity.  It is not known if there is a direct 
relationship between antioxidants and HDAC activity; no published studies have 
specifically addressed this question.  However the data presented in this chapter did 
not demonstrate any correlation between antioxidants and HDAC2 activity.  The 
reasons for this are not known.  The PAO assay is not a direct measurement of 
oxidative stress and so it is not possible to comment on the role of oxidants 
specifically, but oxidative changes are mirrored in vivo by those in nitrative stress, 
suggesting that the correlation between the Griess assay and HDAC2 activity may be 
mirrored by oxidants.  It could be postulated that changes in antioxidants are too slow 
to respond to RV infection and so are not detected in the two to three week period 
following infection when the changes in HDAC2 activity are most dynamic.  
Additionally if there is a lag period between changes in antioxidants and oxidative 
stress, then the former measure will not demonstrate a correlation with HDAC activity 
in corresponding sputum samples.  An alternative method of analysing this data 
would therefore be to relate samples collected a different time points, for example 
day 5 HDAC activities with day 9 antioxidants or peak changes in each mediator.  
However this has not been performed on the data from this chapter as the changes 
from baseline in the PAO assay were not significant following RV infection. 
 
In summary there are no published longitudinal studies in AECOPD which have 
examined HDAC activity with oxidative and nitrative stress.  Therefore the data 
presented in this chapter is novel and interesting.  The increase in nitrite in the COPD 
group following RV infection and the correlation between this and reduced HDAC2 
activity and increased cytokine concentrations supports the hypothesis that this is a 
mechanism which induces inflammation specifically in an exacerbation. 
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7.25 Conclusion 
 
The data shown has provided evidence of increases in oxidative and nitrative stress 
following RV infection and that these are exaggerated in COPD subjects compared to 
controls.  There are also strong correlations between these and clinically relevant 
markers of inflammation.  However although interesting trends have been identified 
many results were not significant.  The wide range of variation in assay results and 
the small sample size are likely to be the major factors responsible.  Further work 
with an increased sample size and possibly the use of more sensitive oxidative stress 
assays are likely to be helpful. 
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Chapter 8: Summary of results and future work 
8.1 Introduction 
This chapter includes a summary of the results presented and discussed in each of 
the proceeding results chapters and a comparison of these with the stated 
hypothesis for the thesis.  Following this is a brief discussion of proposed future work 
which has arisen from the findings presented in this thesis. 
 
8.2 Clinical findings 
The results of clinical data presented in chapter 3 demonstrated that COPD subjects 
had greater symptomatic and spirometric changes when compared to controls and 
that these findings were consistent with those identified during naturally occurring 
exacerbations.  Specifically the LRT symptoms scores were higher and took longer to 
return to baseline in COPD subjects, who were the only group in the study to have a 
significant fall in FEV1 when compared to baseline following RV infection, therefore 
this data supports the hypothesis that experimental RV16 infection leads to features 
consistent with naturally occurring exacerbations. 
 
This was the first RV challenge study in COPD subjects to include non-smoking 
controls.  It was hypothesised that this group would experience the least LRT 
symptoms and changes in lung function compared to smoking controls and COPD 
subjects following experimental inoculation.  The results showed in non-smoking 
controls there was a minimal reduction in FEV1 compared to the two other study 
groups.  In addition to this, non-smoking controls demonstrated lower LRT symptom 
scores compared to the COPD and smoking controls following RV infection.  My 
findings are thus consistent with this hypothesis. 
 
8.3 Virus load 
Following RV infection there were increases in the virus load from nasal lavage, 
sputum and BAL samples in all successfully infected subjects.  There was no 
difference in the virus load in nasal lavage between the three study groups, but in the 
sputum of COPD subjects it was determined that on days 12 and 15 to be elevated 
compared to the control groups.  I have shown that the URT symptom scores 
correlated with virus load in nasal lavage and LRT symptom scores with sputum virus 
load in all infected subjects supporting the clinical findings described above.  I have 
also found that there was an increased rate of bacteria detection following RV 
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infection.  This was more common in COPD subjects where pathogenic bacteria 
were frequently isolated compared to controls. 
 
8.4 Pro-inflammatory cytokines and chemokines 
Following RV infection sputum inflammatory mediators were found to be increased in 
all subjects.  There were higher levels in the COPD group compared to non-smoking 
and smoking controls for several of the mediators measured.  In BAL the 
concentrations were higher in smoking controls whilst the COPD group were more 
likely to have had significant increases from baseline after RV infection.  Interestingly 
correlations with symptoms and inflammatory mediators were only found in COPD 
subjects.  This data demonstrated that the exaggerated inflammatory response 
following RV infection is only associated with increased symptoms in COPD subjects. 
 
8.5 HDAC2 activity  
The central aim of this study was to examine the role of HDAC2 activity in COPD and 
control subjects following RV infection.  I have shown at baseline that there was no 
difference in HDAC2 activity between the three study groups.  HDAC2 activity in 
sputum and BAL macrophages was found to fall only in COPD subjects following RV 
infection.  In non-smoking control subjects there was an increase in sputum HDAC2 
activity following RV infection, with little change in smoking controls.  Only in the 
COPD subjects was there a significant negative correlation between HDAC2 activity 
and acute mediators of inflammation.  This data demonstrates that HDAC2 activity is 
reduced following RV infection only in COPD subjects and supports the hypothesis 
that HDAC2 deficiency plays a central role in RV induced exacerbations.   
 
8.6 Oxidative and nitrative stress 
Measurements of nitrative stress were shown to increase following RV infection and 
there was evidence of a trend to reduced antioxidant capacity.  Nitrite concentration 
was higher in COPD subjects at time points following RV infection and had greater 
increases from baseline compared to the control groups..  The results of the PAO 
assay suggested antioxidant capacity fell in COPD subjects compared to smoking 
controls.  The Griess and PAO ratio as a surrogate marker of redox stress was 
elevated in COPD subjects compared to controls reflecting an overall increase in 
redox stress exclusive to COPD subjects.  There was no difference between the 
groups at baseline, demonstrating that these changes in oxidative stress occurred as 
a result of RV infection. 
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My results have shown that mediators of inflammation correlated with nitrative stress.  
Reduced HDAC2 activity in COPD subjects was also negatively associated with 
markers of nitrative stress.  These findings substantiate the hypothesis of my study. 
 
8.7 Conclusion 
My data supports the previous work performed with RV challenge in COPD, but it is 
strengthened significantly by the addition of a non-smoking control group.  Many 
parameters have been measured in this work which demonstrates increased 
symptoms, inflammation and markers of disease burden in COPD subjects which are 
consistent with an exacerbation and were not identified in controls.   
 
The incorporation of a non-smoking control group has enabled identification of 
modest increase in symptoms and airway inflammation compared to smoking 
controls.  Cigarette smoke exposure is known to increase oxidative stress and airway 
inflammation.  Although the smoking control group in this study have normal 
spirometry the extent of their future risk of developing COPD is unknown.  It is 
possible that smoking subjects with a propensity to developing COPD also display 
features of airway obstruction following RV infection.  In addition absolute falls in 
some measures of lung function were greatest in the smoking control subjects.   
 
The overall conclusions from this work are that the results presented here support 
the study hypothesis.  COPD subjects experienced features of an exacerbation, 
higher virus loads and greater airway inflammation compared to controls.  This was 
associated with an excess of redox stress and falls in HDAC2 activity.  Although 
specific mechanisms have not been studied, all of these parameters correlated more 
strongly in COPD subjects and were temporally augmented following RV infection. 
 
Future work 
Further assessment in this study group 
8.8 Oxidative and nitrative stress 
Further measurements of oxidative and nitrative stress could be performed to 
strengthen the findings of the assays described here.  Specifically this would include 
measurement of 8-isoprostane in EBC, sputum and BAL supernatant.  Assessment 
of protein damage due to oxidative stress, for example assessment of reactive 
carbonyl groups by mass spectrometry, would also provide further evidence of the 
role of oxidants in the pathogenesis of exacerbations.  Measurement of samples 
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already collected and stored using the TBARS and TEAC assays may also prove 
interesting. 
 
8.9 Antioxidants 
Recent interest in the systemic manifestation of COPD has led to recognition of 
malnutrition and weight loss, predominantly due to reduced muscle mass.  This 
relationship reflects a complex interaction of increased energy demand due to 
elevated metabolic rate and work of respiratory muscles, alongside a decreased 
intake of energy due to breathlessness and depression.  Poor nutritional status may 
impact disease progression.  One area of particular interest is vitamin B6 
metabolism.  Interest in COPD has been stimulated by the link between B6 status 
and cardiovascular disease.  A recent study compared vitamin B6 status in a group 
of COPD outpatients to non-obstructed controls and found plasma levels of vitamin 
B6 to be significantly reduced in the COPD group[396].  This provides evidence for 
future work in this field both to assess their role as antioxidants and co-factors for 
effective immune function.  
 
8.10 HDAC studies 
Measurement of HDAC2 and other HDAC isoenzymes gene expression in mRNA 
from stored macrophages pellets would also support the data presently obtained.  In 
addition immunohistochemistry staining for HDAC could be performed in bronchial 
biopsies, although this will not provide evidence of changes in HDACs functional 
activity. 
 
8.11 Future RV challenge studies 
Further RV challenge studies should be performed with several aims.  Firstly to 
increase the numbers of successfully infected COPD subjects, as although this study 
demonstrates interesting results these could be statistically strengthen by increasing 
the subject numbers.  Secondly future studies should include an ex-smoking non-
obstructed control group to investigate the cofounding feature of active cigarette 
smoking.  Although not specifically documented in the inclusion and exclusion criteria 
of my study, all subjects in the smoking control group and the majority of COPD 
subjects were active smokers during participation in the study.  The extent to which 
results are due to active smoking during the study cannot be investigated without this 
additional control group in future studies.   
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Detailed studies of bacteria should be included in any future RV challenge study as 
this relationship with RV in exacerbations is important.  These would include 
molecular phenotyping of samples at baseline in order to identify acquisition of new 
strains during an experimental exacerbation or overgrowth of a previous commensal 
species.  Some work on immune mediators has already been performed in sputum 
supernatant from this study, and investigations of defensins and similar molecules 
may prove helpful.  Additionally RV challenge could be performed with the addition of 
prophylactic antibiotics and using biomarkers of bacterial infection, including 
procalcitonin guided treatment[319]. 
 
Given the huge global disease burden resulting from COPD it is important that 
excellent future clinical studies are performed in collaboration with translational 
research which leads to greater understanding of disease mechanisms and potential 
new therapies.  
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Chapter 9: Appendix 
9.1 List of abbreviations used in this thesis 
 
6MWT    Six minute walk test 
1-AT     Alpha-1 antitrypsin 
AECOPD    Acute exacerbation of COPD 
AM     Alveolar macrophages 
AM3     Immunomodulatory research drug (see reference 161) 
ANOVA    Analysis of variance analysis 
ARTP     Association for Respiratory Technology and Physiology 
ATS     American Thoracic Society 
AUC    Area under curve 
BAL     Bronchoalveolar lavage 
BCA    Bicinchoninic acid assay 
BEAS2B    Bronchial epithelium and adenovirus SV40 cell line 
BLF     British Lung Foundation 
BMI Body mass index 
BODE  Body mass index, airflow obstruction, dyspnoea and 
exercise capacity score 
BTS     British Thoracic Society 
CC     Chemokine Cysteine-Cysteine (beta) chemokine 
CCR2     CC motif receptor 2 
CD4+     T helper cells 
CD8+     Cytotoxic T cells 
CFU     Colony forming units 
ChIP     Chromatin immunoprecipitation 
CLED agar    Cystine lactose electrolyte deficient medium 
CMV    Cytomegalovirus 
CO2     Carbon dioxide 
COPD     Chronic Obstructive Pulmonary Disease 
CPE     Cytopathic effect 
CRP     C reactive protein 
CSE     Cigarette smoke extract 
CT     Computed tomography scan 
Ct     Cycle number 
Cu+     Copper (1) ion 
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Cu++     Cupric ion 
DLCO    Diffusing capacity 
DMSO    Dimethyl sulfoxide 
DNA     Deoxyribonucleic acid  
dsRNA    Double stranded ribonucleic acid 
DTT     Dithiothreitol 
DUOX     Dual oxidase enzymes 
EBC     Exhaled breath condensate 
ECP     Eosinophilic cationic protein 
EDN     Eosinophil derived neurotoxin 
ELISA     Enzyme-linked immunosorbent assay 
ENA-78    Epithelial neutrophil activating protein 78 
EPO     Eosinophil peroxidase 
ERS     European Respiratory Society 
FBC     Full blood count 
FCS     Fetal calf serum 
FEV1     Forced expiratory volume in 1 second 
FEV1/FVC Forced expiratory volume in 1 second and forced vital 
capacity ratio 
FOB     Fibre optic bronchoscopy 
FRC    Functional residual capacity 
FRV     Filtered rhinovirus 
FVC     Forced vital capacity 
GM-CSF    Granulocyte macrophage-colony stimulating factor  
GOLD     Global initiative for chronic obstructive lung disease 
GRO-    Growth related oncogene alpha 
GSH     Glutathione 
H2O2     Hydrogen peroxide 
H3PO4     Phosphoric acid 
HAT     Histone acetyltransferase 
HDAC     Histone deacetylase enzymes 
HDAC2    Histone deacetylase enzyme 2 
HDACi    Histone deacetylase enzyme inhibitor 
HeLa     Henrietta Lacks cell line 
HIV     Human immunodeficiency virus 
HMGB1    High mobility group box 1 protein 
HOCl     Hypochlorous acid 
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ICAM     Intercellular adhesion molecule 1 
IFN-     Interferon gamma 
IL-10     Interleukin 10 
IL-12     Interleukin 12 
IL-1    Interleukin 1 beta 
IL-2     Interleukin 2 
IL-27     Interleukin 27 
IL-6     Interleukin 6 
IL-8     Interleukin 8 
iNOS     Inducible nitric oxide synthase 
IP     Immunoprecipitation 
IP-10    Interferon gamma-induced protein 10 
IRF     Interferon regulatory transcription factor 
IS     Induced sputum 
KCO    Lung diffusion capacity corrected for alveolar ventilation 
LABA    Long acting beta agonist 
LPS     Lipopolysaccharide 
LRT     Lower respiratory tract 
LTB4     Leukotriene B4 
MAPK    Mitogen-activated protein kinase 
MBP     Major basic protein 
MCP-1    Monocyte chemotactic protein 1 
MCP-4    Monocyte chemotactic protein 4 
MDC     Macrophage derived chemokine 
MDI    Metered dose inhaler 
MDM     Monocyte derived macrophages 
MIP-1    Macrophage inflammatory protein alpha 
MIP-1    Macrophage inflammatory protein beta 
MMP-9    Matrix metalloproteinase-9 
mRNA    Messenger ribonucleic acid 
MSD     Meso scale discovery platform® 
MUC5AC    Mucin 5AC gene/protein 
MUC5B    Mucin 5B gene/protein 
NAC     N-acetylcysteine 
NADPH    Nicotinamide adenine dinucleotide phosphate oxidase 
NE     Neutrophil elastase 
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NFB Nuclear factor kappa light chain enhancer of activated 
B cells 
NHS    National Health Service 
NK     Natural killer cells 
NL     Nasal lavage 
NO     Nitric oxide 
NOS     Nitric oxide synthase 
NS     Non smoker 
O2
-     Superoxide 
OH-     Hydroxyl 
O-O2-     Peroxide 
PAMP     Pathogen-associated molecular patterns 
PAO     Potential of antioxidant assay 
PBMC     Peripheral blood mononuclear cells 
PBS     Phosphate buffered saline 
PCR     Polymerase chain reaction 
PDI    Phosphodiesterase 4 inhibitor 
PEF     Peak expiratory flow 
PEFR     Peak expiratory flow rate 
PHA    Phytohaemagglutinin 
PiZZ     Homozygous deficiency of 1-AT 
PKC     Protein kinase C 
PU.1     Transcription factor PU.1 
PYH    Pack year history 
qPCR     Quantitative PCR 
r Pearson‟s correlation coefficient 
RANTES Regulated upon activation, normal T cell expressed and 
secreted 
ResV    Residual volume 
RIPA     Radioimmunoprecipitation assay 
RLT     Ribonucleic acid lysis buffer 
RNA     Ribonucleic acid 
RNS     Reactive nitrogen species 
ROS     Reactive oxygen species 
RPM     Revolutions per minute 
rs    Spearman‟s correlation coefficient 
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RSV     Respiratory syncytial virus 
RT     Room temperature 
RV     Rhinovirus 
RV16     Rhinovirus 16 
SEM     Standard error of mean 
SIRT1     Silent information regulators (sirtuins) (1) 
Smk     Smoker 
SOB     Shortness of breath 
SOD     Super oxide dismutase 
SpO2    Peripheral oxygen saturation 
TARC     Thymus and activation regulated chemokine 
TBARS    Thiobarbituric acid reactive substances 
TCC     Total cell count 
TCID50    Tissue infective dose 50% 
TEAC     Trolox equivalent antioxidant capacity 
Th1     T-helper cell type 1 
Th2     T-helper cell type 2 
TIMP     Tissue inhibitors of matrix metalloproteinases 
TLC    Total lung capacity 
TNF-   Tumour necrosis factor alpha 
TSA     Trichostatin-a 
UK     United Kingdom 
URT     Upper respiratory tract 
USA     United States of America 
V/Q     Ventilation perfusion 
VEGF    Vascular endothelial growth factor 
WHO     World Health Organisation 
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9.2 Patient information sheet 
PARTICIPANT INFORMATION SHEET 
 
 
MECHANISM OF EXACERBATION IN COPD FOLLOWING 
VIRAL INFECTION 
 
 
We are inviting you to take part in a research study.  We have put together some information 
here to tell you more about the research; why we are doing in and what is involved.  You may 
take as much time as you would like to decide if you would like to take part in this study, 
please consider the information carefully and discuss with other people if you wish. 
 
 
WHAT IS THE PURPOSE OF THE STUDY? 
 
 
This research study is designed to find out about inflammation in the lungs after an infection 
with the common cold virus, called the human rhinovirus. 
 
We want to try to find out why there is a different response to infection in normal healthy 
people, those who smoke and those with chronic bronchitis and emphysema (called Chronic 
Obstructive Pulmonary Disease – COPD). 
 
It is not known why infection makes people with COPD more breathless and we aim to see if 
better treatments for this condition can be developed.  There are many millions of people in 
the world who suffer from COPD.  However there will not be an immediate benefit to your 
health from taking part in this study. 
 
 
WHY HAVE I BEEN INVITED and DO I HAVE TO TAKE PART? 
 
 
We would like to study a wide range of individuals.  This means involving both people who 
smoke and those who do not.  We also want to study people with and without lung disease.  
You do not have to take part in the study if you do not want to and can withdraw at any time. 
 
 
WHAT WILL HAPPEN IF I TAKE PART? 
 
 
The study will involve attending St Mary’s Hospital for a screening visit, involving a brief 
medical examination and questions to find out if you are suitable to take part.  You should not 
have had a cold in the last six weeks.  We will perform some routine breathing tests, a skin 
test for allergy and a blood test.  These are all done in the Outpatient Clinic.  If these tests 
show no evidence of infection, or any other problems with your health, you can continue to 
the main part of the study.  We ask you to have a Chest X-ray and an ECG – heart tracing test.  
No-one in previous studies like this developed any adverse events, but we will monitor you 
closely to ensure that any serious adverse events are detected.  We will arrange for you to 
have prompt treatment at St Mary’s Hospital in the unlikely event that this did occur.  In the 
previous study around half of people with COPD developed mild bacterial bronchitis but they 
all improved with no additional treatment.  The serious adverse events which are monitored 
include difficulty in breathing, wheeze, change in breathing tests or if you or the study doctor 
think that treatment is required. 
291 
 
 
 
 
MAIN STUDY 
 
 
For the main part of the study you will need to attend the hospital ten times.  On the second 
visit we will perform more breathing tests, washings from your nose and a sputum test.  These 
are all common tests in a Chest Clinic.  On the next visit we will perform a bronchoscopy; 
this is a telescope test into the lungs.  This is repeated a second time when you come back to 
the hospital in 21 days.  There are further details about bronchoscopy below. 
 
On the visit following the first bronchoscopy (Day -14) we will infect volunteers with the 
human rhinovirus, common cold, to measure how this affects the lungs.  Although this may 
sound alarming it has been done at St Mary’s in other volunteers who have both asthma and 
COPD.  You are given the cold by breathing in a fine mist containing the virus.  We perform 
the sputum & breathing tests, nose washings and blood tests on subsequent visits.  
Specifically blood is taken on days 0, 7, 9, 12, 15 and 42.  On each occasion about 15mls 
(three teaspoons) of blood are taken.  Timings of each test are on the timetable given to 
volunteers when they join the main study. 
 
 
WHERE DID THE VIRUS COME FROM? 
 
 
The virus has been used in many previous studies, where it has been shown to be safe.  It was 
prepared especially for research and has been stored carefully in our laboratory since that 
time.  Unlike medicines there are no special rules for preparing viruses in this country, but it 
was made by experts following previously established procedures. 
 
Typical symptoms of the common cold include a sore throat and runny nose which usually 
lasts for 3-4 days.  Those with COPD may also notice a worsening of usual symptoms with 
increased sputum production, cough and possible bronchitis and wheeze.  Symptoms may last 
for up to five weeks, but this does not occur in everyone. 
 
We then ask you to return to the hospital for frequent visits.  These are so we can sample your 
sputum, blood, washings from your nose, breath and breathing tests.  We will not do every 
test on every visit.  The fourth and consecutive visits will be three days later, five days, seven 
days, nine days, twelve days, fifteen days, twenty-one days and a final visit forty-two days 
later.  Each visit will last about an hour.  Although this may sound like a lot of trips to the 
hospital we will make sure you do not have to wait or make more trips than necessary.  To 
collect your sputum we will ask you to inhale salty water, this is done with a nebuliser 
machine which makes a fine mist for you to breath.  Rarely this can cause narrowing of the 
airways, but this will be monitored closely.  We will telephone you frequently during the 
study to answer any questions and to follow your progress. 
 
WHAT IS A BRONCHOSCOPY? 
 
 
This is a test performed frequently in chest departments.  It is usually done as an Outpatient 
and involves passing a small telescope tube (about the width of a biro) into the lungs.  There 
is no need for a general anaesthetic but we use mild sedation and local anaesthetic.  You are 
able to breath normally around the tube.  This enables us to look into the lungs and take 
samples.  We wash the airways and take small samples of cells and tissue.  Specifically we 
collect six small tissue samples (biopsies) using forceps, four sets of cell samples using a 
brush and finally lung washings using up to 8 tubes of sterile salty water  These are 30ml 
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tubes (about the size of a perfume bottle) and the water is sucked back into the telescope.  
These are all routine parts of many bronchoscopy tests. 
 
You will need to come to the Endoscopy Unit with an empty stomach.  We ask you to have 
nothing to eat for six hours before the test.  We will put a small needle in your arm to give 
you medications.  The test usually takes about twenty minutes.  We ask you to stay in the 
department until the sedation has worn off.  HOWEVER YOU SHOULD NOT DRIVE A 
CAR AFTER SEDATION.  The test is performed with nursing staff and another research 
doctor or nurse present. 
 
 
ARE THERE ANY SIDE EFFECTS FROM BRONCHOSCOPY? 
 
 
There may be some discomfort during the test but this is reduced with local anaesthetic.  The 
test may make you cough.  This is a safe procedure but on rare occasions the airways can 
narrow, if this occurs medication can be given to open the airways.  Some people have mild 
fever, and rarely infection, after the test but this can usually be treated with paracetamol, other 
treatments are not normally required.  Occasionally after taking the tissue sample (biopsy) 
people can cough up small amounts of blood, this stops without further treatment.  The test 
can be stopped at any time if you wish.  In the unlikely event that you experienced any 
problems, again we would arrange for you to have prompt and appropriate treatment at St 
Mary’s Hospital. 
 
 
WHAT IF SOMETHING GOES WRONG? 
 
 
Imperial College London holds insurance policies which apply to this study.  If you 
experience harm or injury as a result of taking part in this study, you may be eligible to claim 
compensation without having to prove that Imperial College is at fault.  This does not affect 
your legal rights to seek compensation. 
 
If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you have been treated during the course of this study then you should immediately 
inform the Investigator Professor Sebastian Johnston or Dr Joseph Footitt.  The normal 
National Health Service complaint complaints mechanisms are also available to you.  If you 
are still not satisfied with the response, you may contact the Imperial College Clinical 
Research Office. 
 
 
 
AM I PAID FOR TAKING PART IN THIS STUDY? 
 
 
We do not pay people specifically for taking part in the study.  However we will cover any 
costs for your travel and make a donation to you to compensate you for your time and 
inconvenience while involved in the study. 
 
 
IS EVERYTHING KEPT CONFIDENTIAL? 
 
 
Yes.  No personal information is taken out of the hospital.  We use a code in the laboratory so 
you cannot be identified.  We will write to your GP to let them know that you are taking part 
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in the study.  The anonymous samples obtained in the study will be stored in a freezer in our 
laboratory. 
 
CAN I WITHDRAW PERMSSION TO TAKE PART IN THIS STUDY? 
 
 
Your participation in this study is voluntary.  You are free to withdraw at any time and do not 
have to give a reason for this, even after you have agreed to take part.  Being part of this study 
will not affect your normal medical care, either now or in the future. 
 
The investigator may also withdraw you from the study at any time if considered appropriate.  
The investigator will have access to your hospital records but your confidentiality will be 
maintained.  All records from the study are stored in the strictest confidence.  Results from the 
study may be published in medical journals but you will not be identified.  We will inform 
your GP that you have taken part in this study.  Samples will be stored anonymously for 
future research, you can ask for these to be destroyed at any time in the next 10 years. 
 
FURTHER INFORMATION 
 
If you require further information about the study, please contact: 
 
Dr Joseph Footitt    Telephone: 020 7594 3751 
Clinical Research Fellow   Mobile: 075 0452 7128 
Department of Respiratory Medicine Email: j.footitt@imperial.ac.uk 
Imperial College School of Medicine 
Norfolk Place, London 
W2 1PG 
 
Or 
 
Professor Sebastian Johnston  Telephone: 020 7594 3764 
Professor Respiratory Medicine  Email: s.johnston@imperial.ac.uk 
 
This study has been approved by the St Mary’s Research Ethics Committee (REC Ref 07/H0712/138) 
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9.3 REC confirmation letter 
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9.4 Telephone participant screening sheet 
Telephone Participant Screening Sheet 
 
Date:       Address: 
 
 
Name: 
 
 
 
Age (40-75 years): 
        DoB: 
 
Contact Number: 
 
 
Smoking History (Yes - over 20pyh): 
 
 
Treatments: 
 
 
 
Illnesses:        GP: 
 
 
Allergies: 
 
Suitable for screening visit:   YES   NO 
 
Screening Visit Arranged: 
 
 
Map & Reminder: 
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